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Abstract 
 
Introduction: Mammalian circadian rhythms form an integral physiological system 
allowing for the synchronisation of all metabolic processes to daily light/dark cycles, 
thereby optimising their efficacy.  Circadian disruptions have been implicated in the 
onset and progression of different types of cancers, including those arising in the breast. 
Several links between the circadian protein Per2 and DNA damage responses exist. 
Aberrant Per2 expression results in potent downstream effects to both cell cycle and 
apoptotic targets, suggestive of a tumour suppressive role for Per2. Due to the severe 
dose limiting side effects associated with current chemotherapeutic strategies, including 
the use of doxorubicin, a need for more effective adjuvant therapies to increase cancer 
cell susceptibility has arisen. We therefore hypothesize, that the manipulation of the 
circadian Per2 protein in conjunction with doxorubicin may provide a more effective 
chemotherapeutic strategy for the treatment of breast cancer. The aims of this project 
were thus to: (i) Characterize the role of Per2 in normal breast epithelial cells as well as 
in ER+ and ER- breast cancer cells; (ii) to determine the role of Per2 in doxorubicin-
induced cell death, (iii) to determine the role of Per2 in autophagy and finally (iv) to 
assess whether the pharmacological inhibition of Per2 with metformin, can sensitize 
chemo-resistant MDA-MB-231 breast cancer cells to doxorubicin-induced cell death. 
Methods: An in vitro model of breast cancer was employed using the normal MCF-12A 
breast epithelial, estrogen receptor positive (ER
+
) MCF-7 and estrogen receptor negative 
(ER
-
) MDA-MB-231 breast adenocarcinoma cell lines.  Circadian rhythmicity of Per2 
protein expression was determined using western blotting, and Per2 cellular localization 
was assessed using fluorescent confocal microscopy. Per2 was then silenced by means 
of an endoribonuclease-prepared siRNA, and silencing efficiency was determined with 
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the use of western blotting. The roles of Per2 in doxorubicin-induced cell death and 
autophagy were assessed by treating MDA-MB-231 breast cancer cells under the 
following conditions (1) Control, (2) 2.5 µM doxorubicin or 10 nM bafilomycin A1 (3) 30 
nM esiPer2 and (4) 30 nM esiPer2 in combination with 2.5 µM doxorubicin or 10 nM 
bafilomycin A1. Following treatments cell viability was assessed using the MTT assay, 
western blotting for markers of apoptosis including p-MDM2 (Ser
166
), p-p53 (Ser
15
), 
cleaved caspase-3 and –PARP as well as markers of autophagy (AMPKα, mTOR and 
LC3). Furthermore, cell cycle analysis, G2/M transition and cell death (Hoechst 33342 
and propidium iodide staining) were assessed by means of flow cytometry. The 
pharmacological inhibition of Per2 was achieved by treating MDA-MB-231 cells with 40 
mM metformin as well as in combination with 2.5 µM doxorubicin. MTT cell viability 
assays, cell cycle analysis (flow cytometry) and western blotting for apoptosis (Per2, p-
AMPKα (Thr172), p53, caspase-3 and PARP) were assessed. 
Results and discussion: A circadian pattern of Per2 protein expression was observed 
in the normal MCF-12A and MDA-MB-231 cancer cells with protein levels peaking at 
±700% and ±500% of baseline was observed. However, no rhythmic expression was 
observed in the MCF-7 cancer cells. Immunostaining for Per2 showed localization OF 
Per2 in the cytoplasm as well as in the nucleus of both the MCF-12A and MDA-MB-231 
cells. Concentration curves showed a significant reduction in cell viability following 2.5 
µM doxorubicin treatment for 24 hours. Per2 protein expression was significantly 
reduced with both esiPer2 and metformin treatment. Silencing of Per2 in combination 
with doxorubicin treatment resulted in cell cycle arrest with a significant increase in 
apoptosis, indicating that Per2 silencing effectively sensitized the MDA-MB-231 cancer 
cells to the anti-carcinogenic properties of doxorubicin. Modulation of Per2 protein 
expression was effectively achieved with the use metformin although this decrease 
occurred independently of AMPKα phosphorylation. A significant increase in apoptosis 
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was observed following treatment with metformin in combination with doxorubicin 
treatment. However, no changes in cell cycle regulation were observed. Per2 appears to 
be involved in the regulation of autophagy as a significant increase in autophagy flux 
was observed when Per2 was silenced. Additionally, this increase in autophagic flux 
resulted in a significant increase in MDA-MB-231 cancer cell death which was enhanced 
further when autophagy was inhibited with bafilomycin A1 subsequent to Per2 silencing.   
Conclusions: Per2 protein expression was shown to display a 24 hour circadian 
rhythm in the MCF-12A cells, and to a lesser extent in the MDA-MB-231 cells. However, 
the MCF-7 cells failed to show rhythmic changes in Per2 protein expression. Per2 was 
shown to be located predominantly in the cytoplasm, with nuclear localization observed 
when cytoplasmic fluorescent intensity was lower. Per2 silencing effectively sensitized 
the chemo-resistant MDA-MB-231 breast cancer cells to both doxorubicin-induced cell 
death and autophagic inhibition.  
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Uittreksel 
 
Inleiding: Sirkadiese ritmes vorm ‘n integrale fisiologiese sisteem wat die sinkronisasie 
van alle metaboliese prosesse asook lig/donker siklusse se effektiwiteit optimaliseer.  
Onderbreking van hierdie sirkadiese ritmes word geïmpliseer in die ontstaan en 
bevordering van verskillende kankertipes, insluitend borskanker. Verskeie raakpunte 
bestaan tussen die sirkadiese proteïen, Per2, en die DNA skade-respons. Abnormale 
Per2 uitdrukking veroorsaak afstroom effekte op beide die selsiklus en apoptotiese 
teikens wat moontlik aanduidend van ‘n tumor-onderdrukkende rol vir Per2 kan wees. 
Daar bestaan ‘n groot nood vir meer effektiewe adjuvante terapieë om kankersel 
vatbaarheid vir chemoterapie te verhoog as gevolg van dosis-beperkende newe-effekte 
wat geassosieer word met huidige chemoterapeutiese strategieë, insluitende dié van 
doxorubicin. Ons hipotese is dus dat die manipulering van die sirkadiese Per2 proteïen 
tesame met doxorubicin ‘n meer effektiewe chemoterapeutiese strategie vir die 
behandeling van borskanker sal wees. Die doelwitte van hierdie projek was dus om: (i) 
Die rol van Per2 in normale borsepiteelselle sowel as in ER
+
 en ER
-
 borsepiteel 
kankerselle te karakteriseer; (ii) die rol van Per2 in doxorubicin-geïnduseerde seldood te 
bepaal; (iii) te bepaal of Per2 ‘n rol in autofagie speel en laastens (iv) te bepaal of die 
farmakologiese inhibisie van Per2 met metformin chemo-weerstandbiedende MDA-MB-
231 kankerselle kan sensitiseer vir doxorubicin-geïnduseerde seldood. 
Metodes: ‘n In vitro model vir borskanker is gebruik wat normale MCF-12A 
borsepiteelselle, estrogeen reseptor positiewe (ER
+
) MCF-7 en estrogeen reseptor 
negatiewe (ER
-
) MDA-MB-231 bors adenokarsenoomselle insluit.  Sirkadiese ritmisiteit 
van Per2 proteïen uitdrukking is deur middel van die westelike kladtegniek bepaal en die 
sellulêre ligging van Per2 deur middel van fluoresensie mikroskopie.  siPer2 is voorberei 
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deur middel van endoribonuklease-siRNA  en die effektiwiteit daarvan is deur middel 
van westelike kladtegniek getoon. Die rol van Per2 in doxorubicin-geinduseerde seldood 
en autofagie is bepaal deur MDA-MB-231 borskankerselle onder die volgende 
omstandighede te toets: (1) Kontrole, (2) 2.5 µM doxorubicin of 10 nM bafilomycin A1 (3) 
30 nM esiPer2 en (4) 30 nM esiPer2 in kombinasie met 2.5 µM doxorubicin of 10 nM 
bafilomycin A1. Na die behandeling, is sellewensvatbaarheid bepaal deur gebruik te 
maak van ‘n MTT toets; westelike kladtegniek is gebruik om vir merkers van apoptose 
soos p-MDM2 (Ser
166
), p-p53 (Ser
15
), gekliefde caspase-3 en -PARP asook vir merkers 
van autofagie (AMPKα, mTOR en LC3) te toets. Die selsiklus, G2/M oorgang en seldood 
(Hoechst 33342 en propidium iodide kleuring) is deur middel van vloeisitometrie bepaal. 
Per2 is ook farmakologies geïnhibeer deur MDA-MB-231 selle met 40 mM metformin 
asook in kombinasie met 2.5 µM doxorubicin te behandel. Daarna is 
sellewensvatbaarheid (MTT) sowel as die selsiklus (vloeisitometrie) en apoptose 
(westelike kladtegniek vir Per2, p-AMPKα (Thr172), p53, caspase-3 and PARP) gemeet. 
Resultate en bespreking: ‘n Sirkadiese patroon vir Per2 proteïen uitdrukking is in die  
normale MCF-12A selle asook in die MDA-MB-231 kankerselle waargeneem met 
proteïenvlakke wat hul piek by ±700% and ±500% onderskeidelik in vergelyking met 
basislyn bereik het. Geen ritmiese patroon van Per2 proteïen uitdrukking is egter in die 
MCF-7 kankerselle waargeneem nie. Immunokleuring om Per2 ligging te bepaal het 
getoon dat Per2 in the sitoplasma sowel as in die nukleus in beide MCF-12A en MDA-
MB-231 selle voorgekom het. Konsentrasie kurwes het aangetoon dat daar ‘n 
insiggewende vermindering in sellewensvatbaarheid voorgekom het na die behandeling 
van die selle met 2.5 µM doxorubicin vir 24 uur. Per2 proteïen uitdrukking is 
insiggewend verlaag met beide esiPer2 en metformin behandeling van die selle. esiPer2 
aleen of in kombinasie met doxorubicin behandeling het selsiklus staking tot gevolg 
gehad asook ‘n beduidende toename in apoptose veroorsaak wat dus aangedui het dat 
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esiPer2 effektief was om MDA-MB-231 kankerselle te sensitiseer vir die  anti-
karsinogeniese doxorubicin behandeling. Modulering van Per2 proteïen uitdrukking was 
effektief met metformin behandeling, alhoewel die afname onafhanklik van AMPKα 
fosforilasie plaasgevind het. ‘n Insiggewende toename in apoptose is waargeneem na 
metformin behandeling in kombinasie met doxorubicin. Geen veranderinge in die 
selsiklus is egter onder hierdie omstandighede waargeneem nie. Per2 blyk betrokke te 
wees in die regulering van autofagie aangesien ‘n insiggewende verhoging in autofagie 
omsetting waargeneem is na esiPer2 behandeling. Die toename in autofagie omsetting 
is geassosieer met ‘n insiggewende toename in seldood in MDA-MB-231 kankerselle 
wat verder verhoog is wanneer autofagie met bafilomycin A1 (autofagie inhibitor) in 
kombinasie met esiPer2 behandel is.   
Gevolgtrekkings: Per2 proteïen uitdrukking het ‘n 24 uur sirkadiese ritme in die MCF-
12A normale selle, en tot ‘n mindere mate in die MDA-MB-231 selle getoon. Die MCF-7 
selle het egter geen ritmiese patroon van Per2 proteïen uitdrukking getoon nie. Per2 
kom hoofsaaklik in die sitoplasma voor en het slegs in die nukleus voorgekom wanneer 
die sitoplasmiese fluoresensie intensiteit laer was. esiPer2 was dus effektief om die 
chemo-weerstandbiedende MDA-MB-231 borskankerselle te sensitiseer vir doxorubicin-
geïnduseerde seldood.  
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Chapter 1: Literature Review 
 
1.1. Introduction 
 
In the early 18
th
 century many people lived a predominantly rural lifestyle, with the rising 
and setting of the sun governing their activity and rest periods. However, due to 
increased urbanization as well as the perfection of the light bulb by Thomas Edison in 
1879, more and more people have become exposed to increasing lengths and 
intensities of light deep into the night time period. As a result of this rapid urbanization, 
our intrinsic biological clocks, which rely on consistent light/dark cycles, are unable to 
keep up. Thus increased exposure to wavelength appropriate light at night has resulted 
in a wide range of physiological disturbances, including that of sleep deprivation, nightly 
melatonin suppression as well as circadian rhythm disruption (Reiter et al., 2009). It is 
therefore reasonable to assume that constant perturbations in these intrinsic biological 
rhythms will result in the onset of pathophysiological diseases, such as that of coronary 
heart disease, Alzheimer’s and cancer.  
 
1.2. Breast Cancer 
 
Cancer has become a global concern as both the prevalence and burden of this disease 
is rapidly on the rise in both developed and developing countries. According to the latest 
world health organization (WHO) press release, the global cancer burden has risen to an 
alarming 14.1 million new cases with 8.2 million cancer associated deaths compared to 
the estimated 12.7 million and 7.6 million respective cases occurring in 2008 (Jemal et 
al., 2011). The most commonly diagnosed cancers are reported to be those of the lung 
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(13%) and breast (11.9%). This rapid increase in the prevalence of cancer in developing 
countries, including South Africa is largely attributed to an increase in population age 
and size. However, increasing evidence suggests that the adoption of more 
“westernized” cancer associated lifestyles play a critical role in the prevalence of cancer.  
 
A sharp increase in the global prevalence of breast cancer is seen with the incidence 
rate increasing by an alarming 20% and mortality rates rising by 14%, since 2008 
estimates. Currently an estimated 6.3 million women, diagnosed within the last 5 years, 
and an additional 1.7 million women diagnosed in 2012, are living with this disease. 
According to the South African National Cancer Registry (NCR) an estimated average of 
1 in 29 women were newly diagnosed with breast cancer, in 2004 alone (National 
Cancer Registry., 2004). More recently, Globocan, a WHO project used to assess the 
prevalence and morality of major cancer types in 184 countries, reported that breast 
cancer in South Africa has escalated to an incidence rate of 41.53 per 100 000 with a 
mortality rate of 16.51 per 100 000 women (Figure 1.1) (Globocan, 2012). 
 
According to the WHOs’ International Agency for Research on Cancer (IARC) a wide 
range of human epidemiologic evidence suggests that circadian disruption brought on by 
shift work is most likely carcinogenic to humans (IARC classification – Group 2A) (Straif 
et al., 2007). In fact, various epidemiological studies have demonstrated a significant 
increase in the prevalence of breast cancer in women working night shift (Sahar et al., 
2009, Wang et al., 2011). A cohort study looking at breast cancer incidence in 121 701 
female nurses between the ages of 30 – 55 at the start of the study demonstrated a 36% 
increased breast cancer risk as well as an astonishing 79% increase in lifetime risk with 
prolonged periods of rotating night shift (Schernhammer et al., 2001 and Innominato et 
al., 2010). Additionally, patients who slept ≤6 hours per night had an increased risk for 
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the development of breast cancer compared to those who slept 9 hours, indicative of an 
inverse correlation existing between sleep deprivation and increased risk / progression 
of breast cancer (Stevens, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.1: Age standardised rates (ASR) of global female breast cancer incidence and 
mortality (2012). Breast cancer has become a global concern and in South Africa the burden of 
this disease is rapidly on the rise. In 2012 an incidence rate of 41.53 per 100 000 with a mortality 
rate of 16.51 per 100 000 women was reported to have occurred. Adapted from: Globocan 2012. 
Incidence Age Standardised Rate 
Female 
Mortality Age Standardised Rate 
Female 
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The carcinogenic process is fundamentally complex and highly variable, with no single 
genetic alteration giving rise to cancer. However, the initiation of cancer development 
encompasses a series of stages beginning with an initial driver mutation responsible for 
tumourigenesis where they accumulate additional genetic mutations that confer 
proliferative and survival advantages (Fernald et al., 2013). Cancer cells have thus 
developed a variety of exquisite mechanisms to evade cell death (Hanahan et al, 2000). 
 
As such, current anticancer strategies involve the use of either radiation or 
chemotherapeutic agents, like doxorubicin, for the treatment of various solid tumours. 
However, severe side effects, ranging from kidney and bladder damage to neuro- and 
cardio-toxicity, are associated with both therapeutic strategies. Thus, a critical need for 
new treatment approaches, that increase cancer cell susceptibility whilst minimizing 
damage to normal tissue, has arisen. 
 
1.3. Doxorubicin 
 
Since its isolation from the fungus Streptomyces peucetius var. caesius in the early 
1970’s (Keizer et al., 1990), doxorubicin (Dox) a potent anthracycline antibiotic (Figure 
1.2), has been extensively used for the treatment of several cancer types, including 
those arising in the breast, due to its potent anti-neoplastic nature (Octavia et al., 2012). 
Pharmacological interest in the use of quinone antibiotics, specifically the anthracycline 
class has increased due to the finding that they exhibit potent anti-tumour effects in 
various animal neoplasm models. 
The highly effective nature of quinone antibiotics is predominantly due to the fact that 
they possess a wide range of molecular mechanisms as well as multiple modes of 
action. Naturally occurring quinone moieties are extensively abundant in nature, and are 
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seen in various derivatives of both vitamin K (naphthoquinone) and coenzyme Q 
(ubiquitous benzoquinone). Quinones are intimately associated with one electron and 
two-electron sequences in cell membrane electron transport chains due to their 
superficial redox reactions. Quinones thus act as mobile shuttles between cytochrome 
and flavoprotein membrane proteins, as such these bioreactive moieties are found 
abundantly in a range of quinone antibiotics (Lown, 1983). Due to the promising results 
obtained, anthracyclines are extensively used in clinical settings as effective 
chemotherapeutic agents as they target cellular DNA due to their high cellular sensitivity 
towards chemical-induced alterations (Lown, 1983).  
 
 
The clinical efficacy of Dox therapy is thought to be largely attributable to the fact that 
Dox has the ability to intercalate between DNA base pairs (Aubel-Sadron et al., 1984) 
thereby inhibiting the function of DNA topoisomerase II (TOP2A), thus leading to DNA 
strand breakage (Gewirtz, 1999). Additionally, with its intercalation into DNA, Dox has 
been shown to inhibit DNA and RNA polymerase, thus also inhibiting DNA replication 
and RNA transcription (Tacar et al., 2013). A wide variety of other molecular 
Figure 1.2: The molecular structure of doxorubicin (Dox). Detailed X-ray crystallographic analysis establishing 
the structure and conformation of doxorubicin has shown the molecule to be a glycoside consisting of a planar 
four-ring quinone encompassing chromophore attached at its 7-position to either one, two or three sugar moieties. 
The quinone ring adopts a half-chair conformation with the sugar moieties extending perpendicularly towards the 
plane of the chromophore. 
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mechanisms behind the cytotoxic effects of Dox have been proposed, including the 
inhibition of macromolecule biosynthesis, as well as free radical generation thereby 
resulting in cell death through mitochondrial permeability transition (MPT) and its 
subsequent activation of apoptosis (Thorn et al., 2011). 
 
Dox displays a high binding affinity for the cytoplasmic proteasome therefore it enters 
the cell via diffusion across the plasma membrane. Once inside the cytoplasm, Dox 
binds to the 20S subunit of the proteasome where after it translocates into the nucleus. 
Due to its higher binding affinity for nuclear DNA, Dox dissociates from the proteasome 
and binds to DNA (Tacar et al., 2013). Additionally, the cellular uptake of Dox also 
involves its initial oxidation to a semiquinone free radical, which is only stable under 
anoxic conditions. However, in normal oxygen rich conditions, Dox is converted back to 
its stable state via the donation of its unpaired electron to oxygen, which results in the 
release of superoxide and hydrogen peroxide (Keizer et al., 1990), a process known as 
“redox-cycling” (Figure 1.3).  As an iron chelator doxorubicin binds to form a complex 
which results in the conversion of hydrogen peroxide to reactive hydroxyl radicals, 
adding to the effect of doxorubicin-induced oxidative stress which may result in DNA 
damage and cell death (Yang et al., 2014).  
Dox has also been shown to rapidly increase intracellular ceramide concentrations 
(Yang et al., 2014). Ceramide, a lipid molecule, mediates a range of cellular effects, 
including that of apoptosis and cell cycle arrest (Senchenkov et al., 2001), through the 
down-regulation of c-myc expression (Liu et al., 2008). Cancer cells have been shown to 
be sensitized to Dox induced cell death by exogenous ceramide administration (Yang et 
al., 2014).  
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Much research has gone into ways of minimizing anthracycline dosages given to 
patients due to the severe cumulative dose dependent side effects associated with Dox, 
the most disturbing of these side effects is that of cardiotoxicity. Cardiotoxicity can be 
brought on either within the initial treatment period (acute) or it may present years after 
(chronic). 
Aside from the severe cumulative dose-dependent side effects associated with the use 
of anthracycline antibiotics like Dox, resistance of cancer cells to chemotherapeutic 
strategies (chemo-resistance) has become an ongoing complex issue faced by many 
cancer patients. Currently it is believed that chemo-resistance accounts for over 90% of 
the failure rate seen with the treatment of metastatic breast cancer (MBC) (Coley, 2008). 
 
Figure 1.3: Mechanism of action of doxorubicin-induced cell death.  Redox cycling of Dox by the mitochondria 
leads to an accumulation of superoxide, resulting in the generation of other reactive oxygen species (ROS). 
Accumulation of intracellular ROS leads to the increased expression of NO via the activation of NF-κB. The 
formation of peroxynitrite (ONOO
-
) results in the activation of intracellular stress pathways e.g. mitogen activated 
protein kinases (MAPK). Intracellular ROS accumulation leads to the phosphorylation of p53 (Ser
15
) which 
eventually causes the release of cytochrome c from the mitochondria, the activation of caspase-3 and ultimately 
results in apoptosis. The absence of p53 in certain cancers further exacerbates apoptosis induction as the 
negative feedback regulation of p53 on ROS production is lost. Abbreviations: Dox = Doxorubicin. Dox• = 
Doxorubicin semiquinone. O2
-
 = superoxide. OH• = hydroxyl radical. H2O2 = hydrogen peroxide. Adapted from: 
Feridooni et al., 2011. 
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1.4. Chemo-Resistance  
 
Unlike normal cells, which all respond in the same manner to drugs, cancer cells each 
respond differently. For example a treatment regime that works effectively for one cancer 
cell type may not work as effectively in another; similarly tumour cell populations are 
comprised of a range of heterogeneous cancer cells each with their own unique 
response to chemotherapeutic drugs. To date, various cellular mechanisms behind 
cancer cell resistance have been proposed which include (i) pharmacodynamic 
resistance pathways, including DNA repair processes, or (ii) pharmacokinetic resistance 
pathways, e.g. increased drug efflux mechanisms. 
Cancer cells respond to DNA damage caused by chemotherapeutic drugs via a range of 
intrinsic DNA repair processes, the exact pathway chosen depends largely on the DNA 
adduct formed by the drug. As mentioned previously, Dox forms a covalent Dox-DNA 
adduct as Dox preferentially intercalates between adjacent GC base pairs stabilized by a 
covalent bond (Yang et al., 2014), where it results in both single and double DNA strand 
breakages. Chemoresistance to Dox would therefore require DNA repair mechanisms 
specifically targeted to (i) base excision repair (BER), where base damages occur as a 
result of Dox induced ROS. The damaged base is removed by human 
apurinic/apyrimidinic (AP) endonuclease (APE1) and DNA glycosylases, the resultant 
site is trimmed by poly (ADP-ribose) polymerase (PARP) and polynucleotide kinase, and 
(ii) double strand breakage (DSB) repair, caused directly by Dox or as a result of 
replication from single strand breaks (Houtgraaf et al., 2006). Double strand breakages 
(DSB) are regarded as the most severe (genotoxic) form of DNA damage and rapid 
repair is essential. Two main pathways exist for the repair of DSBs, which are dependent 
on the stage of the cell cycle. Non-homologous end joining (NHEJ) is essential in 
quiescent (Go) cells or cells in G1, as ligation of the two broken strands occurs directly in 
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the absence of homology, whereas, homologous recombination (HR), occurs 
predominantly in dividing cells (cells in S-phase or G2) as HR requires absolute DNA 
homology of the sister chromatid, where missing information can be copied in without a 
loss of genetic information (Houtgraaf et al., 2006). 
Certain cancer cell types have developed mechanisms whereby they effectively 
circumvent the toxicity of chemotherapeutic drugs through the expression of the energy-
dependent drug efflux pump, P-glycoprotein (P-gp), alternatively known as the multidrug 
transporter. In humans P-gp, a product of the MDR1 gene, belongs to a family of ATP-
binding cassette (ABC), not only responsible for the efflux of drugs but also for nutrient 
transportation across the plasma membrane (Gottesman, 2002). A large variety of 
chemotherapeutic drugs including Dox are detected and bound to P-gp as it enters the 
plasma membrane. The binding of Dox to P-gp results in the activation of an ATP-
binding domain, and the subsequent hydrolysis of ATP. This results in a conformational 
change in P-gp and the release of Dox into the extracellular space. The transporter 
returns back to its original state upon the hydrolysis of a second ATP molecule, allowing 
for the cycle to be repeated (Sauna et al., 2000). 
As mentioned previously, Dox increases intracellular ceramide levels, which in turn 
results in an increase in glycosylceramide synthase (GCS) expression. Increased 
glycosylation of ceramide by GCS forms a positive feedback loop that is known to be 
anti-apoptotic. Thus, helping to confer cancer cell resistance to Dox (Tacar et al., 2013). 
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1.5. Apoptosis 
 
 
 
 
 
Apoptosis, adopted from the Greek word which means “falling leaves”, is a pervasive 
form of programmed cell death, which involves the genetic-controlled removal of cells. 
Apoptosis, is an essential process for the maintenance of cell populations in normal 
development and aging, and also acts as a defensive mechanism against damaged or 
infected cells.   
Apoptotic cell death is an important process for a range of physiological processes 
including that of embryonic development, normal cell turnover, chemical induced cell 
death, the immune system and hormone-dependent atrophy. The inappropriate 
induction of apoptosis has been implicated in a wide range of human diseases, including 
that of autoimmune disorders, ischaemic damage, neurodegenerative diseases and 
several cancer types  
A variety of both pathological and physiological stimuli can lead to the activation of 
apoptosis. However, not all cells respond to these stimuli in the same way. A classic 
example of this occurs in response to therapeutic strategies aimed at the eradication of 
cancer, where some cells react to DNA damage through the activation of a p53-
dependent apoptotic cell death pathway (Elmore, 2007).   
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The onset of apoptosis occurs via a two-step process, whereby the initial commitment to 
cell death is followed by an execution phase, involving distinct morphological changes in 
cell structure (Cohen, 1997). The initial commitment to cell death involves a highly 
complex and sophisticated mechanism, whereby an energy-dependent cascade of 
molecular events are elicited. Currently two main pathways have been described: the 
intrinsic mitochondrial pathway, and the extrinsic death receptor pathway. Although 
distinct from each other, these pathways are not mutually exclusive and are intertwined 
as molecules from one pathway may affect the other. Both the extrinsic and intrinsic 
pathways converge at the same executioner pathway, which occurs via the cleavage of 
caspase-3 resulting in DNA damage, nuclear condensation (pyknosis) and 
fragmentation (karyorhexis), cytoplasmic organelle compaction, cell shrinkage, the 
formation of apoptotic bodies and finally phagocytosis (Figure 1.4) (Elmore, 2007).  
Figure 1.4:  Schematic representation of the morphological changes occurring during the process of 
apoptotic cell death. Once a cell is committed to die via the process of apoptotic cell death, nuclear 
condensation (pyknosis) and fragmentation (karyorhexis) ensues, leading to cell shrinkage and the formation of 
apoptotic bodies. Adapted from: Kerr et al., 1994. 
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Apoptosis fundamentally differs from other modes of cell death, such as necrotic cell 
death, in that it is morphologically defined with the entire apoptotic process being 
contained within an intact plasma membrane. Thus, apoptosis does not elicit an immune 
response as apoptotic bodies are rapidly recognized and silently phagocytosed 
(Casares et al., 2005).  
 
1.5.1. The Caspases 
 
Central to the activation of apoptosis are a family of cysteine-dependent aspartate 
specific proteases known as the caspases (Mehmet et al., 2000). Caspases are 
responsible for the cleavage of over 400 different proteins (Thorburn, 2008). However, 
they are highly specific proteases in that they only cleave after aspartic acid residues 
(Thornberry et al., 1998). 
Like many of the proteases, caspases regulate their own activation via an amplification 
loop, whereby an active caspase activates its own precursor either directly or indirectly. 
This amplification loop allows for rapid exponential activation of the caspase cascade, 
allowing for the rapid execution of cell death. As a result of their highly reactive nature, 
directly upon their synthesis, caspases are stored as inactive pro-enzymes (± 50 kDa) 
which are activated during the proteolytic process (Bremer et al., 2006). These pro-
enzymes are made up of three domains; a large subunit (± 20 kDa), a small subunit (± 
10 kDa) and a NH2 – terminal domain. Their activation involves proteolytic re-
organization between domains and the formation of a tetramer between the small and 
large subunits with two independent catalytic sites (Thornberry et al., 1998). 
To date 14 mammalian caspase homologs with similarities in structure, amino acid 
sequences and substrate specificity have been identified (Porter et al., 1999). Their 
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predominant function in apoptosis appears to be to cleave apoptotic substrates thereby 
facilitating the organized disassembly of the dying cell as well as to disable cellular 
repair processes. The caspase family of enzymes can be classified broadly into two 
main subfamilies, namely: those predominantly involved in inflammation (caspases -1, -4 
and -5) and those involved in apoptosis (caspase -2, -3, -6, -7, -8, -9 and -10). The 
apoptotic subfamily of caspases is then further subdivided into two main groups: the 
initiators (caspase -2, -8, -9 and -10) and the effectors (caspase -3, -6 and -7) (Nicholson 
et al., 1997).   
 
1.5.2. The executioner pathway   
 
Both the extrinsic and intrinsic apoptotic pathways converge at the same point, with the 
activation of caspase-3, at the start of the executioner pathway (Figure 1.5). Considered 
the most important of the executioner caspases, caspase-3 is activated by the initiator 
caspases (caspase-8, caspase-9 or caspase-10), and results in the activation of 
caspase-activated deoxyribonuclease (CAD), an endonuclease. CAD is responsible for 
the degradation of chromosomal DNA (Robertson et al., 2000). Additionally, caspase-3 
directly induces the reorganisation of the cytoskeleton and the formation of apoptotic 
bodies (Thornberry, 1998).  
Poly (ADP-ribose) Polymerase (PARP) is a 116 kDa nuclear protein that plays a critical 
role in DNA damage repair mechanisms (Grasso et al., 2012). PARP is synthesized 
upon the fragmentation of DNA in the presence of nuclear poly-ADP ribosylated 
proteins. Its activation then occurs when PARP binds to broken DNA strands. Through 
the poly (ADP-ribosyl)ation of various nuclear proteins, PARP utilizes nicotinamide 
adenine dinucleotide (NAD
+
)
 
as a substrate. Therefore, it was originally thought that 
PARP contributes to apoptotic cell death via cellular depletion of NAD
+
 and ATP. 
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However, PARP has been shown to be cleaved by caspase-3 during the initial stages of 
apoptosis into 24- and 89 kDa fragments respectively containing the enzymatic DNA –
binding domains and active sites (Boulares et al, 1999). Once cleaved the smaller 24 
kDa fragment binds to fragmented DNA ends, inhibiting the access of DNA repair 
enzymes, and thus ensuring the cells commitment to apoptosis (Grasso et al., 2012).  
 
1.5.3. The extrinsic / death receptor pathway   
 
The initiation of apoptosis via the extrinsic signalling pathway involves death receptors 
(DR) from the tumour necrosis factor (TNF) superfamily (Sainz et al., 2003). TNF 
receptors all share a similar “death domain” composed of a cytoplasmic domain of 
approximately 80 amino acids as well as cysteine-rich extracellular domains. The death 
domain is critical for the transmission of death signals from the cell surface to the 
intracellular signalling pathways. 
Currently the best described mechanism for the induction of the extrinsic pathway are 
the Fatty acid synthase Ligand/ Fatty acid synthase Receptor (FasL/FasR) and tumour 
necrosis factor alpha/ tumour necrosis factor receptor 1 (TNF-α/TNFR1) models. These 
models involve the clustering of receptors and subsequent trimeric ligand binding. Upon 
the binding of ligands, cytosolic adapter proteins with corresponding death domains are 
recruited eliciting a cascade of responses. Binding of the Fas ligand to the Fas receptor 
leads to the binding of the Fas associated death domain (FADD) adapter protein. The 
binding of the TNF ligand to the TNF receptor leads to the binding of the adapter protein 
TNFR-associated death domain (TRADD) where after recruitment of FADD and receptor 
interacting protein (RIP) kinase occurs. Dimerization of the death effector domain (DED) 
occurs upon the association of FADD with procaspase-8. At this point, a death-inducing 
signalling complex (DISC) is formed, resulting in caspase-8s’ auto-catalytic activation, 
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which results in the cleavage of BH3 interacting domain death agonist (Bid) and the 
triggering of the executioner pathway of apoptosis. The inhibition of this death receptor-
mediated pathway occurs by the binding of c-FLIP to FADD and caspase-8 resulting in a 
loss of function (Figure 1.5) (Elmore, 2007). 
 
1.5.4. The intrinsic / mitochondrial pathway   
 
 
The intrinsic apoptotic pathway is initiated in response to a range of non-receptor 
mediated stressors, acting directly on intracellular targets that result in a cascade of 
mitochondrial driven responses. These stressors can be divided into two main groups, 
namely; positive signals, which include toxins, radiation and free radicals, or negative 
Figure 1.5: Schematic representation of the intrinsic and extrinsic pathways involved in the induction of 
apoptotic cell death. Adapted from: Fulda et al., 2006 
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signals, such as the withdrawal of specific hormones and growth factors that suppress 
apoptosis.  
Mitochondria respond to these stressors through the opening of the mitochondrial 
permeability transition (MPT) pore, resulting in the loss of membrane potential and the 
subsequent release of the pro-apoptotic mediators, cytochrome c and second 
mitochondrial activator of caspase or direct IAP binding protein with low pI 
(Smac/DIABLO), into the cytosol. Smac/DIABLO inhibits a class of proteins known as 
the inhibitors of apoptosis (IAP), and thus relieves their inhibitory effect on caspase-3. 
Cytochrome c facilitates the activation of apoptosis, through its activation and 
association with apoptotic protease-activating factor-1 (Apaf-1) and procaspase-9 
resulting in the formation an “apoptosome” and the subsequent activation of caspase-3 
(Figure 1.5) (Elmore, 2007).  
Like most physiological pathways, the extrinsic and intrinsic pathways of apoptosis 
cannot be mutually excluded from each other. Instead they function in concert whereby 
effective cell death execution occurs through the crosstalk between these two key 
pathways. Bid mediates this interaction, as its activation by caspase-8 results in MPT 
and the release of cytochrome c from the mitochondria (Grasso et al., 2012). 
 
1.6. Apoptosis and Cancer 
 
As mentioned previously, cancer cells have the exquisite ability to effectively circumvent 
apoptosis (Fernald et al., 2013). This is predominantly due to the fact that within these 
cells, the homeostatic balance between cell death and proliferation is skewed, and as 
such genetic abnormalities multiply as these cells survive (Sjöström et al., 2001). 
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One of the more common genetic aberrations associated with cancer is a loss or 
inactivation of the tumour suppressor p53. p53 plays an instrumental role in cellular 
regulatory signals, specifically those involved in cell proliferation, DNA repair and 
angiogenesis (Haupt et al., 2003). Under normal cellular conditions p53 remains 
inactive, a state predominantly controlled by the p53 inhibitor mouse double minute 2 
(Mdm2). Mdm2 not only inhibits p53s’ transcriptional activity it also promotes its 
degradation via the ubiquitin proteasome system (Ashcroft et al., 1999).  
 
The activation of p53 occurs when it is stabilized though co-factor protein-protein 
interactions and various post-translational modifications. Once activated, p53 responds 
to intracellular stress such as that of hypoxia, nutrient depletion and DNA damage (Horn 
et al., 2007), by inducing apoptosis or cell cycle arrest (at G1 and/or G2 phases) 
(Vousden et al., 2007). In this way, p53 directly prevents uncontrolled cell growth and 
tumour development (Bremer et al., 2006).The loss or dysfunction of p53 signalling is 
not only associated with the onset of the tumorigenic process but also with poor 
prognosis of patients suffering from certain cancer types (Whibley et al., 2009). 
 
Alternatively, certain cancer cell types have up-regulated expression of anti-apoptotic 
proteins, like BCL-2 and members of the IAP family. This ability of cancer cells to evade 
apoptosis makes them not only reliant on these aberrations for their survival but also for 
their resistance to certain chemotherapeutic drugs (Bremer et al., 2006). 
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1.7. Chemotherapeutic Drugs and Circadian Rhythms  
 
Recent evidence suggests that synchronization of circadian rhythms may influence anti-
tumour tolerability and the pharmacological efficacy of chemotherapeutic drugs (Filipski 
et al., 2002). 
Biological time is a measure of cycles ranging from milliseconds to years. The most well-
known circadian rhythm in mammals is that of the sleep/wake cycle. Circadian rhythms 
are external manifestations of intrinsic biological time measuring cycles on a 24 hour 
scale (Reppert et al., 2002). To date, all mammalian cell types have been shown to 
possess an intrinsic circadian clock, made up of self-sustained and self-perpetuating 
transcriptional feedback loops, responsible for keeping time within the cell (Sachdeva et 
al., 2008).  
Although the internal circadian rhythms of mammals have been known for centuries 
(Clairambault, 2010), the molecular nature behind these oscillations has only recently 
been understood (Hastings et al., 2003). The crucial point of this timing system, the 
master clock, lies within the suprachiasmatic nuclei (SCN) of the anterior hypothalamus 
and is solely responsible for coordinating the circadian programme within mammalian 
cells (Reppert et al., 2002). The SCN plays a critical role in controlling endocrine cycles 
and to a lesser extent metabolic rhythms. This occurs predominantly through anatomical 
connections that exist between the SCN and centres for sleep and wakefulness, thus 
controlling the timing of sleep as well as the timing of nocturnal hormonal secretion such 
as that of growth hormone and prolactin. Alternatively, SCN clocks are able to drive 
sleep-independent hormonal rhythms such as that of melatonin through connections to 
neuroendocrine and autonomic systems. This is evident in the continued cycling of 
melatonin in subjects who are prevented from sleeping (Hastings et al., 2007).  
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Circadian clocks have been shown to play a role in cell metabolism and tissue 
proliferation (Clairambault, 2010). Within mammalian tissue, nutrient and energy 
metabolism is temporally organized in order to synchronize energy storage and 
utilization to daily light/dark cycles. Circulating hormones and metabolites display distinct 
diurnal rhythms as they peak and subside throughout the course of the day. It has been 
shown that the expression of various metabolic genes is limited to specific tissue types, 
indicating that these metabolic pathways are not only tissue specific but also limited to 
specific periods during the day (Ma et al., 2012). This suggests that both nutrient and 
energy metabolism are tightly coupled to timing cues in mammalian tissue. As a result of 
the continuous cycling of this intrinsic circadian rhythm, rhythmic aspects of both cell 
proliferation and metabolism can be predicted (Mormont et al., 2003).  
 
1.8. Circadian clock genes 
 
Similar to the negative feedback loops that are prominent in the rhythmic regulation of 
hormonal release, the circadian system also consists of a delayed negative feedback 
loop where protein products of clock genes negatively regulate their own transcription. 
The only difference exists in the time scale of the circadian system where events are 
drawn out to produce a stable cycle over a period of more or less 24 hours (Hastings et 
al., 2007). Central to the correct functioning of the circadian rhythm are the basic helix-
loop-helix PER-ARNT-SIM (PAS) domain proteins Bmal1 and CLOCK, which 
heterodimerize (Xiang et al., 2008),  and ultimately lead to the expression of their 
repressors: Period (Per1, Per2, and Per3) and Cryptochrome (Cry1, and Cry2) (Figure 
1.6) (Curtis et al., 2014). Upon translation Per and Cry proteins heterodimerize and 
associate with human casein kinase 1 ε (CK1ε). This complex translocates into the 
Stellenbosch University  http://scholar.sun.ac.za
20 
 
nucleus resulting in the inhibition of CLOCK:Bmal1 mediated transcription (Sahar et al., 
2009).  
 
 
CLOCK is important for transactivation as it contains a glutamine rich region in its C-
terminus and intrinsic histone acetyl-transferase (HAT) activity. Upon transcription of 
these genes SCN Per and Cry mRNA levels increase over the course of a circadian day, 
levels of their proteins also increase, however, they lag behind by several hours. At the 
end of circadian daytime the levels of Per and Cry proteins peak in the nuclei of the SCN 
and levels of mRNA begin to decline as a result of the negative feedback loop that 
Figure 1.6: Schematic representation of the intrinsic circadian clock present in all mammalian cell types. 
The circadian clock system is comprised of core CLOCK and BMAL1 genes, the transcription and translation of 
which leads to the expression of Period and Cryptochrome genes. At the beginning of a circadian day Period and 
Cryptochrome proteins accumulate, dimerize to form a complex which translocates into the nucleus repressing 
their own transcription. This 24 hour feedback cycle is additionally stabilized through the activation of CKIε by 
AMPK which results in the phosphorylation and degradation of Per2, leading to a resetting of the clock system. 
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exists, specifically that of Cry proteins. Transcriptional activation and repression of Cry 
proteins, by the C-terminus of Bmal1, is critical for the switch mechanism between 
mRNA and protein synthesis.  
Additionally, CLOCK and Bmal1 proteins have been shown to activate the expression of 
certain “clock-controlled genes” (CCGs) (Figure 1.6), thus allowing for circadian 
regulated output of cellular, metabolic and physiological processes, for example the 
sensitivity of cells to genotoxic stress is regulated by the functionally active 
CLOCK:Bmal1 complex (Sahar et al., 2009).  
This negative feedback loop of the circadian rhythm is additionally stabilized and 
enhanced through accessory pathways; the main pathway involves the two orphan 
nuclear hormone receptor (NHR) proteins, RevErbα and Rorα, both of which are 
activated in phase with Per and Cry genes via CLOCK and Bmal1 (Figure 1.6) (Yang et 
al., 2006). Rorα has a positive effect on Bmal1 resulting in its increased expression, 
whereas RevErbα is a potent suppressor of Bmal1 (Curtis et al., 2014).  
As RevErbα levels decline at night, its suppression of Bmal1 is lifted, resulting in Bmal1 
activation. At the start of a new circadian day when the negative feedback begins to 
diminish; anti-phase oscillations of Bmal1 and Per mRNA’s, coupled to a surge in Bmal1 
expression,  results in an extra boost to initiate the new cycle of Per and Cry gene 
expression (Hastings et al., 2007). 
Single gene knockouts of either Per, Cry, RevErbα or Clock do not disable the circadian 
clock; it may however result in alterations in the length of the circadian period. In order to 
stop circadian cycling entirely the deletion of both Per1 and Per2 or both Cry1 and Cry2 
is essential. The only factor that appears to be indispensable in this network is Bmal1, 
however, mutations affecting the trans-activational role of Clock ultimately destabilize 
and prolong circadian periods.  
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The generation of this 24 hour period cycle is dependent on certain key factors; the first 
and most obvious is the rate at which transcription of both Per and Cry genes occurs, as 
they dominate within the circadian cycle. The second is the stability of the proteins that 
are synthesized; studies have shown that a mutation occurring in human casein kinase 1 
δ (CK1δ), closely related to CK1ε, is linked to an accelerated circadian period and 
advanced sleep. However, a mutation affecting the phosphorylation state of human Per2 
results in the manifestation of familial advanced sleep phase syndrome (FASPS) an 
extreme sleep disorder resulting from a similar accelerated circadian period (Hastings et 
al., 2007). 
Several molecular similarities are seen to exist between the circadian clock system and 
the cell cycle.  Both have been shown to be inherent in a wide range of cells running 
with a periodicity of more or less 24 hours - additionally both are reliant on chronological 
periods of gene transcription, translation, modifications and subsequent protein 
degradation (Hunt et al., 2007). It is therefore feasible that CCG’s involve genes 
dedicated to cell cycle regulation. 
 
1.9. Cell Cycle Regulation 
 
The human body is composed of ± 10
13
 cells, each arising from numerous cell divisions 
beginning from a single fertilized egg cell. Therefore, during the process of normal 
development the tightly controlled regulation of cell division is essential (Noatynska et 
al., 2013). As such, the cell cycle consists of a variety of intricate mechanisms each 
governing specific regions in order to ensure correct cell division (Vermeulen et al., 
2003).   
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Classically cell division is characterized by the replication of DNA and its subsequent 
nuclear and cytoplasmic division giving rise to two daughter cells (Massague, 2004). Cell 
division was originally thought to consist of two main stages, namely; mitosis (M), 
wherein nuclear material is divided, and interphase, the period where cell growth occurs. 
However, due to the development of more advanced molecular techniques, interphase 
was shown to consist of more phases (Figure 1.7) characterized by a gap (G1) where 
the cell prepares for DNA synthesis, DNA replication (S-phase), followed by another gap 
(G2) which allows the cell to prepare for mitosis (Vermeulen et al., 2003). 
G1 appears to be one of the more critical phases as a variety of signals, including 
environmental and metabolic stress signals are integrated, influencing both cell division 
and development. Based on these inputs cells then decide to either proceed through to 
the S-phase, enter the G0 an additional gap phase, where they become quiescent, or to 
exit the cycle completely and die (cell cycle arrest) (Massague, 2004). Additional 
Cyclin B 
CDK1 
Cyclin A 
CDK1 
Cyclin A 
Cyclin E 
Cyclin D 
CDK4 / CDK6 
CDK2 
CDK2 
Figure 1.7: Schematic representation of the stages and regulators involved in 
the cell cycle. Adapted from: Vermeulen et al., 2003. 
Stellenbosch University  http://scholar.sun.ac.za
24 
 
checkpoints found in the G2/M phase prevent the transition of cells with DNA damage 
into mitotic cell division. 
Key to the highly regulated transition from one phase to another phase of the cell cycle 
is a family of serine-threonine protein kinases known as the cyclin-dependent kinases 
(CDK).  Currently, five CDK proteins have been identified to play a role in the cell cycle, 
CDK4, CDK6 and CDK2 play a role in G1, CDKs also plays a role in the S-phase and 
CDK1 plays a role in G2 and M phases (Vermeulen et al., 2003). Upon their activation 
CDK elicit their responses through the phosphorylation of specific downstream proteins.  
CDK proteins are activated by their upstream activating proteins, the cyclins. Cyclins, 
like CDK are required during different phases of the cell cycle. Cyclin protein levels cycle 
in accordance with the cell cycle, where they intermittently activate CDKs, thus ensuring 
their constant protein levels (Morgan, 1995). Currently three cyclins (cyclin D1, cyclin D2 
and cyclin D3) are essential for the entry into G1 as they bind to CDK4. Cyclin E 
associates with CDK2 and is critical for G1 to S transition, whereas cyclin A binds to 
CDK2 during the S phase. During the late stages of G2 and early mitosis, CDK1 and 
cyclin A form a complex that is essential for cell progression into mitosis (Figure 1.7) 
(Vermeulen et al., 2003). 
Evidence reveals that cell cycle genes are under the regulation of circadian clocks 
(Kelleher et al., 2014). However, circadian clocks operate accurately independent of cell 
cycle regulation. Additional cell cycle genes, such as Wee1, c-myc and Cyclin D1 are 
thought to be directly regulated through the heterodimerization of CLOCK:BMAL1 (Rana 
et al., 2010).  
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1.10. Circadian Rhythms and Malignancy   
 
WEE1, a cell cycle kinase responsible for G2-M cell cycle transition, expression 
increases in response to the binding of CLOCK:BMAL1 to E-boxes of the WEE1 
promoter region (Masri et al., 2013). Cry1 mutant mice, lacking the inhibitory effect of 
Cry on the CLOCK:BMAL1 heterodimer, results in the accumulation of WEE1 (Rana et 
al., 2010). Activation of WEE1 in times of continuous DNA damage and DNA replication 
leads to the phosphorylation of the cell division cycle 2 (CDC2)/Cyclin B1 complex; this 
activation results in mitotic delay or cell cycle arrest (Hunt et al., 2007). Transition 
between G1 and S phases of the cell cycle is governed by c-myc (King et al., 1998), the 
transcription of which plays a critical role in apoptosis and cell proliferation (Sancar et al., 
2010). Mutant Per2 mice exhibit up-regulated c-myc and concomitantly down-regulated 
p53 transcription, an essential regulator of the G1-S checkpoint (Figure 1.8) (Rana et 
al., 2010).   
Under normal physiological conditions transcription of c-myc is inhibited by the binding of 
CLOCK:BMAL1 to E-boxes of c-myc promoter regions (Rana et al., 2010). However, the 
up-regulation of c-myc transcription associated with mutations of Per2 may be attributed 
to the decrease seen in BMAL1 levels, as Per2 is also a potent regulator of BMAL1 gene 
transcription (Sancar et al., 2010).  
Modulation of p53-mediated apoptosis plays a critical role in c-myc mediated oncogenic 
transformation, as pro-apoptotic activity needs to be overcome. Impaired p53 functioning 
occurs as a result of c-myc induced DNA damage, and is thought to occur via a reactive 
oxygen species (ROS) mediated mechanism.  In a recent study, γ-radiation was shown 
to result in less proficient G1 arrest in cells overexpressing c-myc compared to that of 
normal cells, suggesting increased c-myc expression drives the progression of cells 
through the cell cycle in the presence of genomic DNA damage. Thus, γ-radiation 
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induced functional loss of Per2 results in diminished p53-mediated apoptosis and in turn 
the accumulation of DNA damaged cells. Evidence further suggests that the 
overexpression of c-myc in DNA damaged cells may still result in the proceeding of 
these cells through the cell cycle which may result in elevated incidences of tumour 
development following γ-radiation.   
 
Increasing evidence suggests that Per2 also plays a critical role in tumour suppression. 
A recent study, comparing a mouse mammary carcinoma (EMT6) cell line to non-
tumorigenic (NIH3T3) cell line revealed diminished cellular proliferation and significantly 
increased apoptosis in EMT6 cells where Per2 was overexpressed. This may be 
explained by the fact that Per2 overexpression results in down-regulation of anti-
apoptotic c-myc, Bcl-XL, and Bcl-2 in addition to the up-regulation of pro-apoptotic p53 
and bax expression (Rana et al., 2010). Although significant evidence suggests a 
Figure 1.8: Schematic representation of the two proposed models involved in the coupling of the 
circadian clock system to the cell cycle. Serial coupling involves the regulation of the circadian and 
cell cycle via protein regulators of the other cycle. Whereas, direct coupling involves the regulation of 
both cycles by proteins such as timeless which play a part in the molecular machinery of both cycles. 
Adapted from: Ünsal-kaçmaz et al., 2005. 
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tumour suppressive role for Per2, further research is required to illuminate whether a 
specific mutation of Per2 results in oncogenic properties or if Per2 is in fact a tumour 
suppressor gene. 
Additionally, the cell cycle gene, Cyclin D1 (CCND1), is controlled by the circadian clock 
system and its overexpression leads to mammary tumourigenesis. Furthermore, CCND1 
overexpression in estrogen receptor α (ERα) – positive breast cancer is associated with 
poor patient prognosis (Rana et al., 2010).  
Essential cellular stress response pathways are activated in response to DNA damage; 
these pathways in turn result in the activation of the tumour suppressor p53, and 
subsequent apoptosis or cell cycle arrest. Thus, circadian proteins play a critical role in 
circadian controlled cellular response to DNA damage and cell proliferation. Recent 
evidence has also shown that human BMAL1-deficient cells activate p53 and p21 in 
response to DNA damage; however these cells are unable to undergo growth arrest 
(Antoch et al., 2010).  
It has also been proposed that Per1 plays a tumour suppressive role via its regulation of 
genes controlling cell cycle progression, as well as its ability to interact with crucial 
checkpoint proteins activated in response to DNA damage. Ionising radiation induced 
apoptosis increased in cancer cells where Per1 was overexpressed, however, apoptosis 
was blunted in cells where Per1 was inhibited. In addition, ionising radiation resulted in 
nuclear translocation of Per1 and the induction of c-myc expression. Thus, Per1 acts as 
a tumour suppressor through its ability to activate a wide range of signalling pathways 
including that involved in the DNA damage response.  
A recent study conducted by Filipski and colleagues, showed that a severe disruption in 
the central circadian clock of tumour-bearing mice resulted in accelerated tumour 
growth, confirming known clinical results where patients with maintained 24 hour 
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circadian rhythms generally have an improved prognosis compared to those with 
disrupted circadian rhythms (Filipski et al., 2006). It is evident that further investigations 
into the effects of circadian clock disruption on the cellular DNA damage response and 
cancer susceptibility are warranted, specifically with regards to elucidating the 
mechanisms behind this circadian clock disruption. 
Mammalian circadian rhythms play a pivotal role in a wide range of physiological 
processes, including those involved with energy and nutrient metabolism (Green et al., 
2008). Based on the knowledge that peripheral circadian clocks are known to be 
entrained by nutrient availability, and autophagy is highly dependent on intracellular 
nutrient status, autophagy itself may be subject to circadian regulation in accordance 
with rest and activity patterns (Sachdeva et al., 2008). 
 
1.11. Autophagy 
 
In order for physiological homeostasis to be maintained, the temporal organization of 
energy and nutrient metabolism (Ma et al., 2012) as well as a balance between cellular 
degradative and biosynthetic pathways is essential (Rubinsztein et al., 2007). Autophagy 
serves as one of the predominant cellular degradative pathways, whereby faulty or 
redundant cellular constituents are degraded (Levine, 2007). However, unlike other 
degradative pathways, like the ubiquitin proteasome pathway, responsible for the 
degradation of sterically hindered, ubiquitin tagged proteins (Mathew et al., 2011), 
autophagy is capable of degrading all folded proteins and protein complexes as well as 
whole intracellular organelles (Rubinsztein et al., 2007). 
Autophagy, derived from the Greek “auto” meaning oneself and “phagy” to eat, is 
classically defined as a dynamic, evolutionary conserved degradative process occurring 
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within all eukaryotic cells (Kondo et al., 2005).  Broadly classified as several intracellular 
pathways that all converge with the delivery of cytoplasmic cargo into lysosomes, 
autophagy typically refers to chaperone-mediated, micro- and macroautophagy (Morselli 
et al., 2009). Macroautophagy (hereafter referred to as autophagy) constitutes the most 
abundant form of autophagy and involves the delivery of cytosolic cargo to lysosomes by 
means of double membrane bound vesicles, called autophagosomes (Rabinowitz et al., 
2010).  
A low basal level of autophagy occurs under normal physiological conditions, which 
serves a beneficial “housekeeping” function, whereby old or redundant cellular 
constituents are degraded, and used as an additional energy source for various 
metabolic processes (Levine, 2007). Basal autophagy serves a particularly 
indispensable role in quiescent and terminally differentiated cells where the aggregation 
of defective components may become cytotoxic, as they are not diluted through the 
process of cell division (Rabinowitz et al., 2010).  
Under conditions where autophagy is activated in response to cellular stressors, such as 
nutrient deprivation and hypoxia, the process of autophagy becomes somewhat of a 
“double-edged sword” (Shintani et al., 2004) as increased levels of autophagy, serve as 
a protective mechanism, whereby non-essential cellular constituents may be broken 
down to refuel essential cellular processes (Hippert et al., 2006). However, unregulated 
autophagy in these conditions may result in the excessive “self-cannibalization” of 
intracellular organelles thereby resulting in cell death (Mizushima et al., 2008). 
The induction of autophagy occurs through the initiation of specific autophagy execution 
proteins eliciting a cascade of reactions that ultimately results in the formation of a 
phagophore, the initial isolation membrane. The newly formed phagophore then 
surrounds the cellular constituents to be degraded, where it matures to form a double 
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membrane bound vesicle called an autophagosome. Autophagosome formation is 
mediated by a group of autophagy-specific genes (ATG) whose products are 
categorized  into four classes, namely; (i) an upstream autophagy regulatory complex, 
which responds to nutrient availability, (ii) a vesicle nucleation lipid kinase group, (iii) two 
ubiquitin-like protein systems, responsible for the production of modified autophagy 
regulatory complexes (Atg8-PE and Atg5-Atg12-Atg16) essential for autophagosome 
assembly and size determination (Hanada et al., 2007), and (iv) a group of complexes 
responsible for the degradation of ATG complexes (Hippert et al., 2006).  
The autophagy receptor p62/SQSTM1 recognises and binds to proteins tagged by 
ubiquitin, targeting them for degradation (Komatsu et al., 2007). During the process of 
autophagosome formation, LC3 I is converted to LC3 II via a lipidation step. LC3 II is 
then sequestered to the inner surface of the phagophore, where it associates with p62 
(Mizushima et al., 2008). Autophagosomal cargo is subsequently delivered to lysosomes 
(Rabinowitz et al., 2010) where the release of lysosomal digestive enzymes into the 
lumen of the autophagolysosome results in the degradation of p62 as well as 
sequestered cellular constituents, ultimately resulting in the release of free fatty acids, 
amino acids, nucleotides and sugars (Figure 1.9) (Levine, 2007).  
The pharmacological inhibition of autophagy is achieved with the use of Bafilomycin A1. 
Bafilomycin A1 binds to essential vacuolar ATPase subunits located on lysosomal 
membranes inhibiting proton translocation. This inhibition results in an elevation in 
lysosomal pH, and thus blocks the fusion of autophagosomes to lysosome (Rubinsztein 
et al., 2007).  
As mentioned previously, autophagy undergoes diurnal (circadian) regulation based on 
nutrient availability. In fact, autophagy has been shown to display a robust circadian 
rhythm in the liver of mice (Ma et al., 2011), the main site of nutrient metabolism. In 
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mammals, nutritional status is dependent on daily feeding/fasting periods. During the 
active daytime periods, where food intake is highest plasma insulin levels peak, resulting 
in the inhibition of autophagy via the PI3K/Akt pathway. However, during nightly rest 
periods where food intake is minimal, plasma glucagon levels are highest, resulting in 
cellular ATP depletion and AMPK- induced autophagic activation (Figure 1.9).   
C/EBPβ has been shown to mediate the temporal orchestration of autophagy rhythms, 
as its rhythmic expression is tightly controlled by both nutritional status and circadian 
regulation. Additionally, C/EBPβ is known to be a potent activator of autophagy, through 
the induction of various genes involved in autophagy, such as Ulk1, and LC3B.  
Interestingly, an increased level of LC3 II caused by the induction of autophagy by 
C/EBPβ occurs independently of the protein kinase mammalian Target of Rapamycin 
(mTOR) activity (Ma et al., 2011). 
mTOR the predominant regulator of the autophagic process, is a sensor of intracellular 
nutrient status and master regulator of cell growth. mTOR serves as a negative regulator 
of autophagy through its ability to phosphorylate and thus inactivate Unc-51-like kinase 
(ULK1) and Atg13, two of the main ULK1 components, thus inhibiting the initiation of 
phagophore synthesis (Mathew et al., 2011). mTOR exists in two biologically functional 
signalling complexes namely, mTORC1 and mTORC2. Pharmacological administration 
of Rapamycin results in the detachment of RAPTOR from mTOR. RAPTOR acts as a 
scaffold for the recruitment and activation of mTOR substrates and thus the inhibition of 
mTORC1. Additionally, the mTORC1 substrates S6-kinase and eIF4E-binding protein 
(4E-BP1) interact with various mRNAs regulating the initiation of translation, and 
controlling protein synthesis rates (Belda-Iniesta et al., 2011). Furthermore, mTORC1 
governs the translation of regulators of cell growth, such as cyclin-D1, HIF1α and c-myc, 
thus promoting cellular processes such as cell cycle progression, cell growth and 
angiogenesis all of which become deregulated during tumourigenesis.  
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Figure 1.9: Schematic representation of the molecular pathways involved in the regulation of autophagy in mammalian cells. Adapted from: Mathew et al., 2011. 
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1.12. The Role of Autophagy in Cancer  
 
As stated previously, a failure in autophagy regulation has been implicated in a variety of 
diseases, including that of cancer (Chen et al., 2010). Within the solid tumour cell 
microenvironment, limited angiogenesis results in a state of nutrient deprivation and 
hypoxia. The up-regulation of autophagy in these conditions is expected to result in an 
increase in tumour cell growth, whereas autophagic down-regulation may limit growth, 
through the rapid induction of apoptosis (Hippert et al., 2006).  
Autophagy is known to play a paradoxical role in both cell survival and cell death in 
response to various intracellular stressors however, the mechanism behind this dual role 
in cancer cells remains to be fully elucidated. The increased signalling of the Ras 
pathway in certain cancer types is thought to trigger autophagy as survival mechanism 
within the hypoxic tumour interior until neoangiogenesis allows for revascularization 
(Singletary et al., 2008). 
Additionally, 50% of breast cancers are known to have deletions in the beclin-1 (BECN1) 
gene (Morselli et al., 2009), a mammalian homologue of the yeast autophagy-specific 
gene Atg6. BECN1 is involved in autophagosome formation (Kondo et al., 2005) as well 
as the activation of autophagy by binding to class III phosphatidylinositol 3-kinase (PI3K) 
(Hait et al., 2006). Single allele deletions of BECN1 have been shown to result in 
increased tumourigenesis (Karantza-Wadsworth et al., 2007) whereas its 
overexpression results in an inhibition of tumourigenesis, suggestive of defective 
autophagy playing a role in cancer malignancy (Dalby et al., 2010). Initially, BECN1 
mutations were suggestive of autophagy being a cell death pathway, nevertheless, 
BECN1 null embryonic stem cells do not display any changes in sensitivity to cell death 
and tumours of haploinsufficient mice do not show a reduction in BECN1 protein levels.  
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Under normal cellular conditions the binding of BECN1 to Bcl-2 results in diminished 
autophagic cell death (Hippert et al., 2006), however, a failure in beclin-1:bcl-2 complex 
formation, results in excessive levels of autophagy and cell death, signifying the role of 
bcl-2 in the regulation of both autophagy and apoptosis (Levine et al., 2008).  
 
1.13. AMPK and Breast Cancer 
 
AMP-activated protein kinase (AMPK), the master intracellular energy regulator, serves 
as a crucial mediator of metabolic signals (Lamia et al., 2009) where its activation in 
response to energy deprivation results in the stimulation of energy producing pathways 
concomitantly to an inhibition of energy consuming processes (Brown et al., 2013).  
AMPK is a heterotrimeric protein kinase (Jordan et al., 2013) consisting two catalytic α-
subunits, two regulatory β-subunits and three γ-subunits with multiple isoforms of each 
subunit existing. Various subunits of AMPK have been found to be constitutively 
expressed and activated in a tissue-specific manner. Expression patterns of AMPK have 
been extensively studied and are well characterized in animal models, however very little 
is currently known about its tissue distribution in humans with specific regards to human 
cancer cell types (Brown et al., 2013). 
AMPK activation leads to suppression of various ATP-dependent cellular processes, 
including that of gluconeogenesis, fatty acid and protein synthesis as well as promoting 
catabolic processes such as glycolysis and fatty acid β-oxidation (Goodwin et al., 2009). 
Additionally, AMPK activation has been also been shown to play a central role in 
mediating the effects of metformin.  
The biguanide, metformin is a common first line pharmacological drug used in the 
treatment of type II diabetes. Various studies, including that conducted by Chlebowski 
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and colleagues, comparing incidences of breast cancer in diabetic women with that of 
non-diabetic women, have demonstrated a definite reduction in the incidence of breast 
cancer in diabetics using metformin (Chlebowski et al., 2013). It is also widely accepted 
that patients suffering from type II diabetes have an increased risk for the development 
of cancer as well as a reduced prognosis following the onset of breast cancer when 
compared to that of non-diabetic cancer patients (Belda-Iniesta et al., 2011). 
The molecular effects of metformin and its role in cancer malignancy has gained 
increased interest, as both clinical and epidemiological evidence show that insulin 
resistance, hyperglycaemia and diabetes results in poor breast cancer prognoses. 
Furthermore, metformin has been shown to influence cancer cells directly by affecting 
cell proliferation and apoptosis as well as indirectly via insulin-mediated signalling 
(Goodwin et al., 2009).  
Evidence suggests that metformin’s mechanism of action involves increased insulin 
receptor mediated signalling leading to a reduction in insulin levels (Zakikhani et al., 
2006). However, recent evidence suggests that metformin-induced AMPK activation 
results in a decrease in circulating blood glucose levels through the down-regulation of 
hepatic gluconeogenesis and the stimulation of muscular glucose uptake (Belda-Iniesta 
et al., 2011) independently of insulin signalling (Zakikhani et al., 2006). This mechanism 
has also been shown to involve that activation of liver kinase B1 (LKB1), a serine-
threonine kinase (Dowling et al., 2007).  
LKB1 has recently been found to act as a tumour suppressor as mutations leading to a 
loss of AMPK signalling and mTOR inhibition are tumorigenic. There is currently 
increased interest in determining whether or not AMPK agonists like metformin lead to a 
coupling of growth and energy signalling within cancer cells in order to inhibit their 
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growth. Currently evidence shows metformin inhibits the growth of breast cancer cells 
through the activation of AMPK  (Rocha et al., 2011). 
LKB1 and calcium/calmodulin-dependent protein kinase kinase β (CaMKKβ) act as 
upstream AMPK kinases that respond to depleted intracellular ATP and calcium signals 
respectively. However, evidence suggests that the majority of AMPK signals in the liver, 
and muscle are mediated via LKB1. Furthermore it is believed that LKB1 is essential in 
the maintenance of normal adipocyte AMPK signalling.  
LKB1 loss of function is associated with the development of Peutz-Jeghers syndrome, 
typically characterized by the presence of by multiple gastrointestinal polyps as well as a 
significantly increased (>80%) risk for the development of a variety of epithelial cancers, 
including that of breast cancer (Zakikhani et al., 2006). AMPK is a direct substrate for 
LKB1 and the phosphorylation of the α-subunits of AMPK at Thr172 results in its 
enhanced activity (Figure 1.10) (Belda-Iniesta et al., 2011).  
AMPK has also been shown to act as a crucial regulator in many of the characteristic 
hallmarks of the malignant phenotype of cancer cells, including that of increased DNA 
and protein synthesis, proliferation, lipid production and migration, further solidifying its 
role in cancer (Brown et al., 2013). 
Due to the critical role that AMPK plays in homeostatic energy control, increased interest 
is currently placed towards the understanding of how alterations in AMPK may be 
associated with increased cancer cell tumourigenicity via both direct cellular metabolic 
and protein synthetic effects, and indirect endocrine-mediated activities (Brown et al., 
2013). In addition to the role that AMPK plays in energy homeostasis, it has also 
recently been shown to play a critical role in the regulation of p53, a potent tumour 
suppressor. Activation of AMPK results in the up-regulation of p53 and its subsequent 
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phosphorylation at Ser
15
. Conversely, p53 activation leads to an increased expression of 
the β1-subunit of AMPK.  
 
1.14. AMPK Regulation of the Circadian Clock System 
 
Increased interest in AMPK and its effect on circadian rhythms has gained much interest 
due to the fact that both energy metabolism and food intake are synchronised to daily 
light/dark cycles. In addition, AMPK has been shown to phosphorylate Ser
389
 of casein 
kinase Iε, leading to the degradation of Per2 leading to a phase advance and a 
shortening of period length (Figure 1.10). Thus, AMPK is a central key regulator in 
energy metabolism as well as circadian length. High intracellular AMP:ATP ratio’s results 
in the activation of AMPK by LKB1 mediated phosphorylation (Lamia et al., 2009). 
The suprachiasmatic nucleus (SCN) is entrained by light, whereas peripheral circadian 
clocks are predominantly entrained by food availability, although the mechanisms behind 
these entrainment signals remain to a large extent a mystery. The mammalian SCN 
serves as the master clock, coordinating both physiological and behavioural rhythms to 
daily light/dark cycles. Non-light sensitive peripheral clocks are entrained by daily 
feeding activities, theoretically allowing for anticipation of food consumption and 
optimized timing of metabolic process within these peripheral tissues (Lamia et al., 2009) 
Mammalian circadian clocks are dependent on cyclical activation and repression of 
transcription, wherein, CLOCK and BMAL1 result in the transcription of period and 
cryptochrome genes. The products of which feedback to inhibit Clock and BMAL1 thus 
resulting in their rhythmic expression. Posttranslational modifications, such as the 
ubiquitination of cryptochromes by F-box and leucine-rich repeat protein 3 (FBXL3), 
result in degradation and subsequent resetting of the intrinsic clock mechanism. Several 
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biochemical analyses suggest that modifications of Ser
71
 and Ser
280
 residues on Cry1 
alter the stability of these proteins. In addition both Ser
71
 and Ser
280
 residues conform to 
the optimal sequence AMPK phosphorylates, where mutations in a phosphomimetic 
amino acid, such as aspartic acid, is sufficient to destabilize Cry1, and mutations 
resulting in a non-phosphorylatable amino acid, such as alanine, is sufficient to stabilize 
Cry1 (Lamia et al., 2009).  
Lamia and colleagues demonstrated that AMPK is activated in response to glucose 
deprivation, resulting in a reduction in Cry1 stability and an increase in Clock: BMAL1 
target signalling in fibroblasts (Figure 1.10). Furthermore, fibroblasts which stably 
expressed luciferase under the control of a BMAL1 promoter (BMAL1-luciferase), result 
in a high amplitude circadian rhythm with a periodicity of ±25.3 hours under high glucose 
conditions. An increase in periodicity to ±30.7 hours as well as a decrease in BMAL1-
luciferase amplitude was seen after a reduction in glucose levels (Lamia et al., 2009).  
 
Thus, it is therefore reasonable to assume that expression, activation and/or localization 
of AMPK is dependent on diurnal regulation, due to the fact that AMPK directed 
phosphorylation of cryptochromes regulates peripheral clock phase (Lamia et al., 2009). 
Additionally, a wide range of evidence shows that efficient energy utilization and storage 
as well as the optimization of metabolic process timing are under the control of 
peripheral mammalian clocks. The majority of metabolism regulating receptors, enzymes 
and transporters display robust fluctuations throughout the course of the day (Jordan et 
al., 2013).  
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Figure 1.10: Proposed mechanism of the signalling pathways involved in the regulation of autophagy 
and the circadian clock system by AMPK. The activation of AMPK, either by p53, a LKB1-dependent 
mechanism, or alterations in glucose availability, leads to the inhibition of mTOR and the subsequent induction 
of the autophagy. Additionally, AMPK activation phosphorylates Cryptochrome proteins, and indirectly, via 
CKIε, the phosphorylation of Period 2. The phosphorylation of both Cryptochrome and Period, tags these 
proteins for degradation by the 26S proteasome and thus a resetting of the circadian clock system. 
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1.15. Problem Statement  
 
Doxorubicin an anthracycline antibiotic is extensively used in the treatment of breast 
cancer. Although effective to a large extent there are severe problems associated with 
this line of therapy, the main one being that cancer cells have become increasingly 
resistant to Dox therapy. There is therefore a critical need for effective adjuvant 
therapies aimed at improving cancer cell susceptibility to lower doses of doxorubicin. 
 
1.15.1. Hypothesis 
 
We hypothesize that the manipulation of the circadian Per2 protein in conjunction with 
Dox may provide a more effective chemotherapeutic strategy for the treatment breast 
cancer.  
 
1.15.2. Aims 
 
1. Characterize the role of Per2 in normal breast epithelial cells as well as in ER+ 
and ER- breast epithelial cells 
2. Determine the role of Per2 in doxorubicin-induced cell death  
3. Determine the role of Per2 in autophagy  
4. To evaluate the role of metformin, a modulator of Per2 expression, as a potential 
adjuvant chemotherapeutic agent. 
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Chapter 2: Materials and Methods 
 
2.1. Cell Culture 
Three different cell lines were used, namely, MCF-12A human derived breast epithelial 
cells, MCF-7 estrogen receptor positive (ER
+
) human breast adenocarcinoma cells and 
MDA-MB-231 estrogen receptor negative (ER
-
) human breast adenocarcinoma cells 
(Figure 2.1). Both MCF-7 and MDA-MB-231 breast cancer cells were cultured in 
Dulbecco’s Modified Eagles Medium (DMEM) (Life Technologies) that was 
supplemented with 10% Foetal Calf Serum (Scientific Group) and 1% Penicillin 
Streptomycin (PenStrep) (Life Technologies) collectively known as growth medium. The 
MCF-12A non-cancerous cells were cultured in a 1:1 ratio of Dulbecco’s Modified Eagles 
Medium (DMEM) (Life Technologies) and Ham’s F-12 nutrient mixture (Life 
Technologies) supplemented with 10% Foetal Calf Serum and 1% Penicillin 
Streptomycin (PenStrep), 10 µg/ml Insulin (Humalin 30/70), 20 ng/ml Epidermal Growth 
Factor (EGF), 500 ng/ml Hydrocortisone and 100 ng/ml Cholera toxin (Sigma Aldrich, 
#C8052). Cells were cultured in T75 flasks (75 cm
2
 flasks, NEST) and maintained in an 
incubator (C01901R, Snijders Scientific) set at an atmosphere of 37ºC and 5% CO2 
humidity. Growth media was refreshed every 2
nd
 day and were regularly sub-cultured 
once a confluency of 70-80% was reached.  Upon reaching 80% confluency, cells were 
split and seeded with fresh media for experiments. Seeding was accomplished by 
washing the cell monolayer with warmed Phosphate Buffered Saline (PBS) before 
incubation in 4 ml 0.25% Trypsin EDTA (1X) (Life Technologies) until all cells loosened 
from the surface of the flask. Detailed step-by-step protocols for all breast epithelial cell 
culture procedures have been included in Appendix A (Protocol 1). 
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2.2. Treatments 
 
Prior to treatment, media was aspirated and cell monolayer was washed twice with warm 
PBS to ensure all cell debris was removed. In order to determine optimal concentrations, 
concentration curves were done for a treatment period of 24 hours for doxorubicin 
(Sigma-Aldrich, # D1515) with the following concentrations: 0.1, 1.0, 2.5, 5.0 and 10.0 
µM. The selected concentration of doxorubicin based on cell viability, with the highest 
concentration that produces the least toxic effect in normal (MCF-12A) cells while still 
increasing cell death in the cancer (MDA-MB-231 and MCF-7) cells used. A 
concentration of Bafilomycin A1 from Streptomyces griseus (Sigma-Aldrich, #B1793) 
which is known to inhibit autophagy was chosen based on previous findings by our 
group (Thomas, PhD thesis, 2012. Available: http://hdl.handle.net/10019.1/19912). Once 
Figure 2.11: Images of the normal MCF-12A breast epithelial, the estrogen receptor negative (ER
-
) 
MDA-MB-231 adenocarcinoma and the estrogen receptor positive (ER
+
) MCF-7 adenocarcinoma 
cell lines obtained with an inverted microscope. (A) 100x and (B) 400x magnification. 
100X 
MCF-7 
400X 
100X 
MCF-12A 
400X 
100X 
MDA-MB-231 
400X 
A 
B 
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concentrations were established, cells were arbitrarily divided into treatment groups as 
described in table 2.1 below. Complete treatment protocols are provided in Appendix A 
(Protocol 2). 
Table 2.1: This study was divided into three main experiments which consist of the following groups: 
Experimental 
Group 1 
Control Doxorubicin Per2 
Per2 
+ 
Doxorubicin 
(C) (D) (P) (PD) 
 2.5 μM 30 nM 30 nM + 2.5 μM 
Experimental 
Group 2 
Control Bafilomycin Per2 
Per2 
+ 
Bafilomycin 
(C) (B) (P) (PB) 
 10 nM 30 nM 30 nM + 10 nM 
Experimental 
Group 3 
Control Doxorubicin Metformin 
Metformin 
+ 
Doxorubicin 
(C) (D) (M) (MD) 
 2.5 μM 40 mM 40 mM + 2.5 μM 
 
 
2.3. Per2 Silencing 
Cells were transfected in 6-well plates (Whitehead Scientific, #S00023) using a forward 
transfection protocol (Protocol 3). 100 000 cells were plated into the culture dishes 24 
hours prior to transfection. 30 nM of an endoribonuclease-prepared siRNA (esiRNA) 
targeted against Per2 (Sigma-Aldrich, Mission
®
 esiRNA human Per2 (esiRNA1) 
#EHU070571) was diluted into 100 µl serum free growth media. 12 μl of HiPerfect 
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transfection reagent (Qiagen, #301705) was added to the esiRNA mixture and allowed 
to incubate at room temperature for 20 minutes in order for esiRNA:HiPerfect complexes 
to form. Antibiotic free growth media was then added to produce a final volume of 2 ml 
which was added drop-wise onto cells. Plates were gently swirled and incubated at an 
atmosphere of 37ºC and 5% CO2 humidity for 48 hours before subsequent treatment. 
esiRNA against enhanced green fluorescent protein (eGFP) (Sigma-Aldrich, Mission 
esiRNA eGFP #EHU019931) was used as a negative control. Detailed step-by-step 
protocols for Per2 silencing procedures are included in Appendix A (Protocol 3). 
 
2.4. Western Blot Analysis  
 
In order to carry out western blot analysis cells were arbitrarily subdivided into above 
mentioned treatment groups (Protocol 2) and seeded accordingly into T25 flasks (25 cm
2
 
flasks, NEST) with 4 ml of growth media per flask. Flasks were all incubated in a 37ºC, 
5% CO2 environment for 24 hours to allow cells to attach and proliferate.  
 
2.4.1. Protein Extraction and Quantification 
 
Media was aspirated from T25 flasks and cells were immediately placed on ice. The cell 
monolayer was washed with 1 ml cold PBS, which was repeated twice more. 100 µl 
modified radio-immunoprecipitation assay (RIPA) buffer comprising of 2.5 mM Tris-HCL, 
1 mM EDTA, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM 
benzamidine, 50 mM NaF, 4 mg/ml SBTI, 10 mg/ml leupeptin, 0.1% SDS 0.5%, Na 
deoxycholate and 1% NP40, calibrated to pH 7.4, was added to each petri dish and 
allowed to stand for 5 min on ice in order to extract total cell protein. Cells were then 
detached from the flask surface with the use of a cell scraper which was rinsed in EtOH 
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between different samples. Whole cell lysates were sonicated on ice at 3 Hz for 8 
seconds and centrifuged at 8000 RPM for 30 seconds. The supernatant was then 
decanted into eppendorf tubes and stored at -80ºC. A Bradford protein determination 
assay was conducted to determine the protein content of each sample. A detailed step-
by-step protocol for protein extraction and determination is included in Appendix A 
(Protocol 4). 
 
2.4.2. Sample Preparation 
 
Samples used for western blots were prepared following protein determination. Aliquots 
were prepared containing 50 µg protein content and diluted with sample buffer. Prepared 
samples were then stored at -80ºC for further western blot analysis. A detailed step-by-
step protocol for sample preparation is included in Appendix A (Protocol 5). 
 
 
2.4.3. SDS-PAGE and Western Blot Analysis 
 
 
Cell lysates were subsequently separated on 4-15% polyacrylamide precast gels (mini-
PROTEAN® TGX™ Gels, Bio-Rad) by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). 5 µl of a protein marker ladder (PeqGold) was loaded into 
the first well of each gel run; this was used for orientation of gels as well as for 
determination of molecular weights of separated proteins.  Prepared cell lysates were 
heated to a temperature of 95ºC for 5 minutes in order to denature proteins and pulse 
centrifuged, after which 50 µg of protein was added to each lane. 
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Gels were run at 100 V (constant) and 400 mA for a period of ± 90 minutes (Power Pac 
300, BioRad). On completion of SDS-PAGE, proteins were transferred to prepared 
polyvinylidine fluoride (PVDF) membranes using a semi-dry electrotransfer system 
(TransBlot® Turbo™ v1.02, BioRad) for 30 minutes at 25 V and 1.0 A. Membranes were 
placed in PoncheauS staining solution in order to visualize that proteins transferred 
correctly. Membranes were subsequently washed in 0.1 % Tris Buffered Saline-
Tween20 (TBS-T) and blocked for 1 hour in 5 % (w/v) fat-free milk and TBS-T, whilst 
being gently agitated at room temperature, this prevents non-specific binding of the 
antibody. Membranes were then incubated at 4ºC overnight in TBS-T diluted primary 
antibodies (1:1000). The following day membranes were removed from the primary 
antibody and washed with TBS-T before being incubated in anti-rabbit IgG horseradish 
peroxidase conjugated secondary antibody (1:10000) (from donkey) (Cell Signalling 
Technologies) with gently agitation at room temperature for 1 hour. Subsequent to the 
incubation period membranes were washed in TBS-T before antibodies were detected 
with the use of an ECL western blotting substrate detection kit  (Pierce®, Thermo 
Scientific) and protein bands visualised with the use of ImageLab 4.0 software on a 
Chemi-Doc™ MP (BioRad) imaging system. Exposed bands were visualized and 
quantification was done using densitometry with the use of QuantityOne densitometry 
software. Bands for each specific protein were quantified as density readings 
comparative to the control sample present on the same blot. A complete step by step 
protocol for SDS-PAGE and Western blot analysis is included in Appendix A (Protocol 
6). 
 
2.5. Immunocytochemistry – Per2 and Hoechst 
MCF-12A and MDA-MB-231 cells were grown in 8-well chamber slides (Lab-Tek, 
Thermoscientific) at a density of 12 000 cells/well. After the treatment period, growth 
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medium was removed and cells were washed twice with warm PBS. Cells were fixed 
with ice-cold methanol and acetone (1:1) and left to incubate on ice for 10 min. The 
fixative mixture was then removed and cells were allowed to air-dry for 20 min. After 
being rinsed twice with PBS, non-specific binding was prevented by incubating cells in a 
1% BSA/PBS blocking solution for 30 min at RT. After this time period, the blocking 
solution was drained off and a primary antibody against Per2 diluted in PBS (1:50) was 
added to cells and allowed to incubate overnight at 4°C. Cells were then rinsed three 
times with PBS and allowed to incubate with the appropriate secondary antibody for 30 
min at room temperature. In this case an Alexa Fluor 488 conjugated donkey anti-rabbit 
secondary antibody (Life Technologies, #A-21206) was used. After incubation, Hoechst 
33342 dye (1:200) was additionally added and kept in contact with cells for a further 10 
min incubation period. Next, cells were rinsed and mounted with DAKO fluorescent 
mounting medium (DAKO Inc., CA, USA). Chambers were kept wrapped in foil at -20°C 
until analysis. Detailed step-by-step protocols for immunocytochemistry procedures 
using confocal microscopy have been included in Appendix A (Protocol 7). 
 
2.6. MTT Assay 
A MTT cell viability assay was conducted to assess the percentage of metabolically 
viable cells. The principle of this assay is based on the reduction of MTT to yield purple 
formazan crystals by various reduction enzymes present within the mitochondria. Cells 
from each cell line where arbitrarily divided into treatment groups (Table 2.1) and seeded 
at a cell density of 50 000 cells per well into 24 well plates (Cellstar, Greiner bio-one). 
Cells where left for 24 hours to attach and proliferate in 1 ml of growth media after which 
media was refreshed and treatments administered as described above. Subsequent to 
treatments, all media was aspirated (Mini-vac power, PeqLab biotechnologie GmbH) and 
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500 µl of MTT working solution (0.001 g MTT/ml PBS) was added to each well. As MTT 
is a light sensitive compound, this experiment was conducted in the dark and 24 well 
plates were covered in tin foil. After the addition of MTT working solution to wells, cells 
were incubated for 1.5 hours at a 37ºC, 5% CO2 humidified environment (C01901R, 
Snijders Scientific). Subsequent to incubation, 500 µl Isopropanol:HCl/Triton-X-100 
solution was added to each well, and the tinfoil wrapped plate was placed on a heated 
shaker (37ºC, 200 RPM) for a period of ±5 min until formazan crystals generated by 
healthy cells had dissolved. Plates were then analysed using KCjunior software on a 
universal micro plate reader (EL800, Bio-Tek Instruments Inc.) where absorbance values 
were determined at a wavelength of 595 nm. All groups were analysed in triplicate and 
three independent experiments were conducted. Absorbance values were all expressed 
as a percentage of MTT reduction versus the untreated control. Detailed step-by-step 
protocols for all MTT assay procedures have been included in Appendix A (Protocol 8). 
 
2.7. Flow Cytometry – Hoechst and PI Staining  
MCF-12A and MDA-MB-231 cells were grown in T25 flasks at a seeding density of 700 
000 cells/flask. After the treatment period, 2 ml 0.25% Trypsin EDTA (Life Technologies) 
was added to each flask for 3-4 min until all cells had detached. The cell suspension 
was then added to 15 ml Falcon tubes (BD Biosciences) and centrifuged at 1500 RPM 
for 3 min. The supernatant was removed and the pellet washed with 0.1 M PBS. The 
cells were centrifuged again at the same specifications and the supernatant was 
removed. Propidium Iodide (PI) (Sigma-Aldrich) and Hoechst 33342 was added to the 
unfixed cells to obtain a final concentration of 1 mg/ml and incubated for 10 min where 
after it was analysed on the flow cytometer (BD FACSAria I). A minimum of 10 000 
events were collected and analysed using a 488 nm laser and 610LP, 616/23BP 
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emission filters. PI inclusion signified loss in membrane integrity and cell death. Values 
were represented as a percentage of the control and mean percentages from three 
separate experiments were used to perform statistical comparisons. Detailed step-by-
step protocols for cell death analysis procedures using flow cytometry have been 
included in Appendix A (Protocol 9). 
 
2.8. Flow Cytometry – Cell Cycle Analysis  
Cell cycle analysis was performed by flow cytometry using the CycleTEST
TM
 PLUS DNA 
reagent kit (Becton Dickinson, California, USA). Prior to treatments MCF-12A and MDA-
MB-231 cells were seeded into T25 flasks at a density of 300 000 and 400 000 cells 
respectively. Media was discarded and the cell monolayer was washed twice with warm 
PBS where after cells were trypsinized and centrifuged at room temperature for 5 min at 
300 x g. The supernatant was discarded and the pellet gently re-suspended in 1 ml of 
the provided buffer solution (a mixture of sodium citrate, dimethylsulfoxide (DMSO) and 
sucrose). This procedure was then repeated twice more. Cells were then counted using 
a haemocytometer using standard counting procedures and concentrations were 
adjusted to 1x10
6
 cells / ml using buffer solution. In order to stain prepared cells, cell 
suspensions were centrifuged at 400 x g for 5 min at room temperature. 250 µl of 
solution A (trypsin buffer) was added to each tube, and allowed to react for 10 min at 
room temperature. Thereafter, 200 μl of solution B (trypsin inhibitor and RNase buffer) 
was added to each tube and allowed to react at room temperature for 10 minutes. 
Finally, 200 μl of ice cold solution C (propidium iodide (PI) stain solution) was added to 
each tube, which was incubated for a further 10 minutes in the dark at 4ºC. Samples 
were analysed on the flow cytometer (BD FACSAria I) within 3 hours of adding the PI 
staining solution. At least 30 000 list-mode data events were acquired for each sample. 
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As PI has an emission spectrum of 550 – 720 nm a bandpass filter of 585/42 was 
employed to detect light emitted between 564 and 606 nm by stained cells. ModFit LT 
software (Verity software house, Inc., ME, USA) was used to determine the percentage 
of cells in the G0/G1, S and G2/M phases.  The percentage of apoptotic cells was also 
determined using ModFit LT software. Mean percentages from three independent 
experiments were used to perform statistical comparisons. Detailed step-by-step 
protocols for cell cycle analysis procedures using flow cytometry have been included in 
Appendix A (Protocol 10). 
 
2.9. Flow Cytometry – G2/M Analysis 
MCF-12A and MDA-MB-231 cells were seeded into T25 flasks at a density of 300 000 
and 400 000 cells respectively. After the treatment period, 2 ml 0.25% Trypsin EDTA 
(Life Technologies) was added to each flask for 3-4 min until all cells had detached. The 
cell suspension was then added to 15 ml Falcon tubes (BD Biosciences) and centrifuged 
at 1500 RPM for 3 min. The supernatant was removed and the pellet re-suspended in 1 
ml PBS. Formaldehyde at a final concentration of 4% was added and cells were fixed at 
37ºC for 10 min, after which cells were placed on ice. Fixative was then removed and 
cells were centrifuged and the supernatant removed as previously. Permeabilization was 
achieved by adding ice cold methanol (90%) and incubating cells on ice for 30 min. 2-3 
ml incubation buffer (0.5 g BSA dissolved in 100 ml PBS) was added to cells and rinsed 
twice by centrifugation. Phospho-Aurora A (Thr
288
)/Aurora B (Thr
232
)/Aurora C (Thr
198
), 
Alexa Fluor 488 conjugated (Cell Signalling Technologies, #8525) and Phospho-Histone 
H3 (Ser
10
), Alexa Fluor 647 conjugated (Cell Signalling Technologies, #3458) primary 
antibodies were added to cells (1:50 dilution in incubation buffer) and incubated for 1 
hour at room temperature. Cells were washed by centrifugation in incubation buffer 
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before being re-suspended in 0.5 ml PBS and analysed on the flow cytometer (BD 
FACSAria I). A minimum of 30 000 events were collected and analysed using a 488 nm 
laser and 502LP, 520/30BP emission filters. Mean percentages from three independent 
experiments were used to perform statistical comparisons. Detailed step-by-step 
protocols for G2/M analysis procedures using flow cytometry have been included in 
Appendix A (Protocol 11). 
 
2.10. Statistical Analysis 
All statistical analysis was carried out using GraphPad Prism 5. All data was assessed 
using mean ± SEM. One-way analysis of variance (ANOVA) with Bonferroni post hoc 
corrections as well as Mann-Witney U t-tests were conducted where appropriate. A p-
value <0.05 was considered statistically significant. 
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Chapter 3: Results 
 
3.1. Characterizing the role of Per2 in normal breast epithelial cells 
as well as in ER+ and ER- breast epithelial cells  
 
3.1.1. Baseline Circadian Rhythms 
 
To determine the presence of a circadian expression pattern in the protein levels of 
Per2, all three cell lines were cultured under standard cell culture conditions and protein 
extractions were carried out hourly for a period of 25 hours commencing at 07h00 and 
terminating the following day at 08h00. Western blot analysis was carried out to 
determine the relative Per2 protein concentrations at each time point.    
 
MCF-12A cells show a clear circadian pattern in Per2 protein expression with a 
significant increase in Per2 protein levels seen at 20 hours (03h00) when compared to 
baseline (0 hours = 07h00) (745.9 ± 28.23% vs 100%, p < 0.0001). The MDA-MB-231 
cells showed the same rhythmic expression pattern for Per2, with levels significantly 
increasing at 20 hours (03h00) when compared to baseline (0 hours = 07h00) (537.8 ± 
64.91% vs 100%, p < 0.0001) however, to a  much lesser extent than that observed in 
the MCF-12A cells. Although the MCF-7 cells do express the Per2 protein, they do not 
display a distinct rhythmic expression pattern with protein levels remaining fairly constant 
over time (Figure 3.1).  
 
As no rhythmic pattern of Per2 protein expression was observed in the MCF-7 cancer 
cell line, further analyses using this cell line were terminated and only the normal MCF-
12A and ER
-
 MDA-MB-231 cancer cells were further utilized. 
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Figure 3.1: Rhythmic expression of the mammalian circadian protein period 2 (Per2) in non-tumourigenic 
breast epithelial MCF-12A cells (A), MDA-MB-231 estrogen receptor negative human breast 
adenocarcinoma cells (B) and MCF-7 estrogen receptor positive human breast adenocarcinoma cells (C). 
MCF-12A, MDA-MB-231 and MCF-7 cells were harvested hourly for a period of 25 hours (T0=Baseline). Western 
blot analysis was employed to assess relative Per2 protein levels. Values (normalized to GAPDH) are expressed 
as a percentage of baseline and presented as mean ± SEM (n=3). *** = P<0.0001 vs baseline. 
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3.1.2. Per2 Localization  
In order to determine the cellular localization of Per2 both MCF-12A and MDA-MB-231 
cells were cultured under standard cellular conditions until reaching confluency, after 
which they were immunostained with Per2:AlexaFluor 488 and Hoechst 33342 and 
visualized using confocal fluorescent microscopy.  
 
 
 
 
 
 
 
 
 
 
 
 
In the MCF-12A breast epithelial cells Per2 was seen to be localized predominantly 
within the cytoplasm, with only slight co-localization in the nucleus (Figure 3.2). In the 
MDA-MB-231 cancer cells Per2 also localized mainly in the cytoplasm of the cell 
however; nuclear co-localization was more prominent (Figure 3.3).  
Hoechst 33342 Per2 Merge 
A 
B 
   
   
Figure 3.2: Determination of Per2 localization in MCF-12A breast epithelial cells. MCF-12A cells were 
cultured under standard control cellular conditions in 8-well chamber plates for a period of 24 hours. Cells were 
immunostained for Per2 (Green) and Hoechst 33342 (Blue) and visualized using fluorescent confocal 
microscopy. White arrows indicate nuclear localization of Per2. (A) 63x and (B) 63x magnification. 
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In both cell lines two distinct populations of Per2 fluorescent intense cells were seen, a 
dim population (Figures 3.2A and 3.3A) as well as a brighter more fluorescently intense 
population (Figures 3.2B and 3.3B). In both cell lines it was noted that Per2 nuclear 
localization was limited to the fluorescently dimmer subpopulation of cells. 
 
3.1.3. Doxorubicin Dose Response  
In order to establish a clinically relevant dose of doxorubicin that is still able to produce a 
significant amount of cell death in the resistant MDA-MB-231 cancer cells, both cell lines 
were treated with various concentrations of doxorubicin for a period of 24 hours. MTT 
cell viability assays were carried out to determine the relative percentage cell death in 
each cell line. 
A 
B 
   
   
Hoechst 33342 Per2 Merge 
Figure 3.3: Determination of Per2 localization in MDA-MB-231 triple negative breast cancer cells. MDA-
MB-231 cells were cultured under standard control cellular conditions in 8-well chamber plates or a period of 24 
hours. Cells were immunostained for Per2 (Green) and Hoechst 33342 (Blue) and visualized using fluorescent 
confocal microscopy. White arrows indicate nuclear localization of Per2. (A) 63x and (B) 63x magnification. 
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When compared to control, 0.1 μM doxorubicin did not result in a decrease in the MTT 
reductive capacity of normal MCF-12A cells (96.14 ± 1.979% vs 100%) (Figure 3.4A), 
however when subjected to either 1.0, 2.5, 5.0, or 10.0 μM of doxorubicin for a period of 
24 hours a significant reduction in MTT reductive capacity was observed when 
compared to control (1.0 μM: 82.38 ± 3.464% vs 100%, p<0.005. 2.5 μM: 55.41 ± 
3.133% vs 100%, p<0.0001. 5.0 μM: 44.20 ± 5.302% vs 100%, p<0.0001 and 10.0 μM: 
32.62 ± 3.861% vs 100%, p<0.0001).  
No significant reduction in the ability of doxorubicin to reduced MTT was seen when 
MDA-MB-231 cancer cells were treated with either 0.1 or 1.0 μM of doxorubicin over 24 
hours (Figure 3.4B) However, a significant decrease in MTT reductive capacity was 
seen in the MDA-MB-231 cancer cells following 2.5 μM doxorubicin treatment after 24 
hours when compared to control (82.04 ± 2.959% vs 100%, p<0.0001). A further 
reduction in the MTT reductive capacity of doxorubicin in these cells was seen after 
treatment with 5.0 μM (58.27 ± 1.609% vs 100%, p<0.0001) and 10.0 μM (51.20 ± 
2.378% vs 100%, p<0.0001) of doxorubicin when compared to control. 
*** 
A 
*** 
B 
Figure 3.4: The effect of various concentrations of Doxorubicin on the viability of non-tumourigenic breast 
epithelial MCF-12A cells (A) and triple negative breast cancer cells MDA-MB-231 (B). MCF-12A and MDA-
MB-231 cells were incubated in 0 (Control), 0.1, 2.5, 5.0 and 10.0 µM doxorubicin for 24 hours. Cell viability was 
assessed using the MTT assay. Values are expressed as a percentage of the control and presented as mean ± 
SEM (n=3). *** = P<0.0001 vs control. 
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Clinically the administration of doxorubicin involves the intravenous bolus infusion of 
doses ranging between 15 and 90 mg/m
2
, which results in plasma concentrations 
ranging from 0.3 – 5 µM (Gewirtz, 1999). Our results demonstrated that 24 hour 
treatment with 5 µM of doxorubicin resulted in a significant reduction in the cell viability 
of the chemo-resistant MDA-MB-231 cancer cells, but as this concentration falls at the 
extreme limit of the clinically relevant dose range, we aimed to use a lower dose which 
still falls within this clinically relevant range. Based on these results as well as the fact 
that 2.5 µM falls within the range of clinically relevant dosages for doxorubicin, for this 
study we used 2.5 µM for all subsequent doxorubicin treatments. 
 
3.2. The Role of Per2 in Doxorubicin Induced Cell Death 
Gene silencing with the use of small interfering RNA (siRNA) sequences has become a 
popular model widely used in breast cancer research, as it allows for the accurate 
determination of the role that specific proteins play in disease pathology.   Therefore, for 
the initial part of this study we made use of an endoribonuclease-prepared siRNA 
(esiRNA) targeted specifically against Per2, to effectively silence its expression prior to 
treatment with doxorubicin in order to determine whether Per2 inhibition can sensitize 
chemo-resistant MDA-MB-231 cancer cells to doxorubicin treatment, esiRNA against 
Per2 was utilized in combination with doxorubicin. 
 
3.2.1. Verification of Per2 Silencing 
 
Per2 silencing was confirmed with the use of western blotting, after both MCF-12A and 
MDA-MB-231 cells were treated with 30 nM of esiRNA targeted against Per2 for a period 
of 48 hours.  
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The MCF-12A breast epithelial cells showed a significant reduction in Per2 protein 
expression levels following 48 hours of 30 nM esiRNA treatment when compared to both 
control (22.05 ± 6.064% vs 100%, p<0.0001), and the negative esiRNA control cells 
(22.05 ± 6.064% vs 86.68 ± 4.790%, p<0.0001), indicating a 77.95% silencing efficiency 
in the MCF-12A cells (Figure 3.5A). A significant reduction in Per2 protein expression 
was also seen following 30 nM esiRNA treatment in the MDA-MB-231 cancer cells when 
compared to control (1.501 ± 0.761% vs 100%, p<0.0001) as well as when compared to 
the negative eGFP control (1.501 ± 0.761% vs 64.89 ± 12.27%, p<0.001), indicating a 
98.5% silencing efficiency in the MDA-MB-231 cancer cells (Figure 3.5B).  
 
*** 
*** 
GAPDH 
37 kDa 
Period 2 
45 kDa 
*** 
** 
Figure 3.5: Verification of the silencing of Per2 in non-tumourigenic breast epithelial MCF-12A cells (A) 
and triple negative breast cancer cells MDA-MB-231 (B). MCF-12A and MDA-MB-231 cells were incubated 
under Control, 12 µl HiPerfect transfection reagent (Mock), 30 nM negative esiRNA control (eGFP), or 30 nM 
Per2 esiRNA conditions for 48 hours. Western blotting analysis was carried out to determine Per2 protein 
expression levels. Values are expressed as a percentage of the control and presented as mean ± SEM (n=3). 
*** = p<0.0001 vs control, ** = p<0.001 vs negative (eGFP) control. 
A B 
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3.2.2. Cell Viability (Mitochondrial Reductive Capacity) 
 
MTT cell viability assays were carried out to assess the effects of Per2 on doxorubicin 
induced cell death (Figure 3.6). MCF-12A cells showed a significant decrease in MTT 
reductive capacity following Per2 silencing when compared to control (61.58 ± 6.414% 
vs 100%, p<0.0001). Doxorubicin treatment alone resulted in a significant reduction in 
MTT reductive capacity when compared to control (55.37 ± 5.554% vs 100%, p<0.0001), 
which was further reduced following Per2 silencing prior to doxorubicin treatment (20.11 
± 1.898% vs 55.37 ± 5.554%, p<0.0001) in comparison to doxorubicin treatment alone.  
In the MDA-MB-231 cancer cells a significant reduction in MTT reductive capacity was 
seen following doxorubicin treatment alone when compared to control (81.99 ± 3.212% 
vs 100%, p<0.0001). However, an even greater reduction was seen when Per2 was 
silenced prior to doxorubicin treatment (53.26 ± 3.057% vs 81.99 ± 3.212%, p<0.001) 
when compared to doxorubicin alone.  
### 
*** 
### 
*** 
Figure 3.6: Determining the effect of Per2 silencing on the viability of non-tumorigenic breast epithelial MCF-
12A cells (A) and ER
-
 MDA-MB-231 breast cancer cells (B). MCF-12A and MDA-MB-231 cells were subjected to 
(1) Control conditions (C), (2) 2.5 µM Doxorubicin (D), (3) 30 nM Per2 and (P) and (4) 30 nM Per2 for 48 hours + 2.5 
µM Doxorubicin for 24 hours (PD). Cell viability was assessed using the MTT assay. Values are expressed as a 
percentage of the control and presented as mean ± SEM (n=3). *** = p<0.0001 vs control and 
###
 = p<0.0001 vs 
doxorubicin. Abbreviations: Per2 + Dox = Period 2 + Doxorubicin. 
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3.2.3. Western Blot Analysis 
 
Per2 Protein Expression 
 
Per2 protein levels were analysed prior to western blot analysis of apoptotic markers in 
order to verify the effects seen are due to the silencing of Per2 (Figure 3.7). A significant 
reduction in Per2 protein expression levels was seen following Per2 silencing alone as 
well as in combination with doxorubicin treatment in comparison to control (Per2: 16.68 ± 
5.029% vs 100%, p<0.0001 and Per2 + Dox: 17.76 ± 5.862% vs 100%, p<0.0001). 
 
Apoptosis was further evaluated with the use of western blotting for common markers of 
apoptotic cell death, namely; p-p53 (Ser
15
) and its negative regulator p-MDM2 (Ser
166
), 
cleaved Caspase-3 as well as cleaved PARP.  
*** **
GAPDH 37 kDa 
Per2  45 kDa 
Figure 3.7: Western Blot analysis of Per2 in MDA-MB-231 breast cancer cells following Per2 silencing 
and doxorubicin treatment. MDA-MB-231 cells were subjected to (1) Control conditions (C), (2) 2.5 µM 
Doxorubicin (D), (3) 30 nM Per2 esiRNA (P) and (4) 30 nM Per2 for 48 hours + 2.5 µM Dox for 24 hours (PD). 
Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± 
SEM (n=3). ** = p<0.001 vs control and *** = p<0.0001. Abbreviations: Per2 + Dox = Period 2 + Doxorubicin.   
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p-MDM2 (Ser166) and p-p53 (Ser15) Activity  
 
The MDA-MB-231 breast cancer cells showed a significant increase in p-MDM2 (Ser
166
) 
protein levels following Per2 silencing alone in comparison to control (1351 ± 287.5% vs 
200%, p<0.05) (Figure 3.8). Although p-MDM2 (Ser
166
) levels were increased following 
Per2 silencing in combination with doxorubicin when compared to control, they were not 
significant (820.6 ± 173.6% vs 200%).  
A significant increase in p-p53 (Ser
15
) protein levels was seen following doxorubicin 
treatment alone when compared to control (987.1 ± 92.20% vs 200%, p<0.0001) whilst 
Per2 silencing alone and in combination with doxorubicin had no significant effect on p-
p53 (Ser
15
) expression when compared to control (Figure 3.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p-MDM2  
90 kDa 
GAPDH  
37 kDa 
 
* 
p-p53  
53 kDa 
GAPDH  
37 kDa 
*** 
Figure 3.8: Western Blot analysis of p-MDM2 (Ser
166
) and p-p53 (Ser
15
) in MDA-MB-231 breast 
cancer cells following Per2 silencing and doxorubicin treatment. MDA-MB-231 cells were subjected 
to (1) Control conditions (C), (2) 2.5 µM Doxorubicin (D), (3) 30 nM Per2 esiRNA (P) and (4) 30 nM Per2 
for 48 hours + 2.5 µM Dox for 24 hours (PD). Statistical analysis: One way ANOVA with Bonferroni post 
hoc correction. All results are presented as mean ± SEM (n=3). * = p<0.05 vs control and *** = p<0.0001 
vs control. Abbreviations: Per2 + Dox = Period 2 + Doxorubicin.   
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Caspase-3 Cleavage 
Once Caspase-3 is cleaved and activated by upstream caspases in the caspase 
cascade apoptotic cell death ensues. A significant increase in cleaved caspase-3 was 
seen following Per2 silencing alone as well as in combination with doxorubicin treatment 
when compared to control (Per2: 588.6 ± 105.7% vs 100%, p<0.05 and Per2 + Dox: 
619.0 ± 111.0% vs 100%, p<0.05) (Figure 3.9).   
 
 
 
 
 
 
 
 
 
 
 
PARP - Cleavage 
The MDA-MB-231 cancer cells show a significant increase in cleaved PARP levels 
following doxorubicin treatment (680.8 ± 43.45% vs 100%, p<0.0001), Per2 silencing 
(713.7 ± 64.57% vs 100%, p<0.0001), as well as the combination of Per2 silencing prior 
to doxorubicin treatment when compared to control (644.1 ± 39.18% vs 100%, 
p<0.0001) (Figure 3.10).  
* 
* 
Cleaved 
Caspase 3 
17/19 kDa 
GAPDH 37 kDa 
Figure 3.9: Western Blot analysis of cleaved Caspase-3 in MDA-MB-231 breast cancer cells following 
Per2 silencing and doxorubicin treatment. MDA-MB-231 cells were subjected to (1) Control conditions (C), 
(2) 2.5 µM Doxorubicin (D), (3) 30 nM Per2 esiRNA (P) and 30 nM Per2 for 48 hours + 2.5 µM Dox for 24 
hours (PD). Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented 
as mean ± SEM (n=3). * = p<0.05 vs control. Abbreviations: Per2 + Dox = Period 2 + Doxorubicin.   
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3.2.4. Flow Cytometry – Hoechst and PI  
 
Cell death was further assessed by means of flow cytometry, in order to fully elucidate 
the role of Per2 in doxorubicin induced cell death in MDA-MB-231 breast cancer cells.  
 
Doxorubicin treatment alone resulted in an increase in the percentage of cell death when 
compared to control (9.733 ± 0.5548% vs 7.850 ± 0.2598%, p<0.05) however, no 
significant reduction was seen in the percentage of the live cell population (Figure 3.11). 
Per2 silencing resulted in a significant reduction in the percentage of live cells (67.80 ± 
7.448% vs 90.10 ± 1.484%, p<0.05) with a concomitant increase in the percentage of 
dead cells in comparison to control (31.80 ± 7.275% vs 7.850 ± 0.2598%, p<0.05). The 
combination of Per2 silencing and doxorubicin treatment resulted in a significant 
increase in the dead cell population (35.90 ± 0.8660% vs 7.850 ± 0.2598%, p<0.0001) 
Figure 3.10: Western Blot analysis of cleaved PARP in MDA-MB-231 breast cancer cells following 
Per2 silencing and doxorubicin treatment. MDA-MB-231 cells were subjected to (1) Control conditions 
(C), (2) 2.5 µM Doxorubicin (D), (3) 30 nM Per2 esiRNA (P) and 30 nM Per2 for 48 hours + 2.5 µM Dox 
for 24 hours (PD). Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results 
are presented as mean ± SEM (n=3). *** = p<0.0001 vs control. Abbreviations: Per2 + Dox = Period 2 + 
Doxorubicin.   
*** 
*** 
*** 
Cleaved 
PARP 
89 kDa 
GAPDH 37 kDa 
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0and significantly decreased the live cell population when compared to control (63.70 ± 
0.9238% vs 90.10 ± 1.484%, p<0.0001). 
C D 
PD P 
* 
*** 
* 
*** ** 
Figure 3.11: The effects of Per2 silencing in doxorubicin induced cell death of MDA-MB-231 breast 
cancer cells. MDA-MB-231 cells were subjected to (1) Control conditions (C), (2) 2.5 µM Doxorubicin (D) (3) 30 
nM Per2 esiRNA (P) and (4) 30 nM Per2 for 48 hours + 2.5 µM Dox treatment for 24 hours (PD). G2/M transition 
analysis was assessed by flow cytometry. Statistical analysis: One way ANOVA with Bonferroni post hoc 
correction. All results are presented as mean ± SEM (n=3). * = p<0.05 vs control ** = p<0.001 vs control and *** 
= p<0.001 vs control. Abbreviations: Per2 + Dox = Period 2 + Doxorubicin. 
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3.2.5. Cell cycle progression following Per2 silencing in MDA-MB-
231 breast cancer cells 
 
As cell cycle regulation is thought to be under the control of circadian genes, cell cycle 
analysis using flow cytometry was assessed to determine the effects of Per2 silencing 
on cell cycle progression in the MDA-MB-231 cancer cells.  
Silencing of Per2 in the MDA-MB-231 cancer cells resulted in a significant increase in 
the percentage of cells in the G0/G1 phase of the cell cycle (68.77 ± 4.901% vs 52.42 ± 
0.5762%, p<0.05), with a concomitant decrease in the G2/M phase (5.520 ± 1.201% vs 
13.88 ± 0.5505%, p<0.001) and significant increase in apoptosis when compared to 
control (16.97 ± 5.260% vs 0.070 ± 0.070%, p<0.05) (Figure 3.12). A significant 
increase in the percentage of cells in the G2/M phase of the cell cycle was seen 
following doxorubicin treatment alone in comparison to control (37.38 ± 7.341% vs 13.88 
± 0.5505%, p<0.05) with significantly increased levels of apoptosis (13.58 ± 4.252% vs 
0.070 ± 0.070%, p<0.05). The combination of Per2 silencing prior to doxorubicin 
treatment resulted in S phase cell cycle arrest (50.84 ± 2.439% vs 33.70 ± 0.6445%, 
p<0.001), and a significant decrease in G2/M (2.200 ± 1.270% vs 13.88 ± 0.5505%, 
p<0.001). A significantly greater level of apoptosis was also seen with the silencing of 
Per2 prior to doxorubicin treatment when compared to control (24.68 ± 3.513% vs 0.070 
± 0.070%, p<0.001). 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
66 
 
 
Channels (PE-Texas Red-A)
0 50 100 150 200
N
u
m
b
e
r
0
4
0
0
8
0
0
1
2
0
0
1
6
0
0
Debris
Aggregates
Apoptosis
Dip G1
Dip G2
Dip S
C 
Channels (PE-Texas Red-A)
0 30 60 90 120 150
N
u
m
b
e
r
0
2
0
0
4
0
0
6
0
0
8
0
0
1
0
0
0
Debris
Aggregates
Apoptosis
Dip G1
Dip G2
Dip S
D 
Channels (PE-Texas Red-A)
0 50 100 150 200 250
N
u
m
b
e
r
0
4
0
0
8
0
0
1
2
0
0
1
6
0
0
Debris
Aggregates
Apoptosis
Dip G1
Dip G2
Dip S
P 
Channels (PE-Texas Red-A)
0 50 100 150 200 250
N
u
m
b
e
r
0
4
0
0
8
0
0
1
2
0
0
1
6
0
0
Debris
Aggregates
Apoptosis
Dip G1
Dip G2
Dip S
PD 
* 
** 
* 
* 
** 
** 
** 
* 
Figure 3.12: Analysis of cell cycle progression in MDA-MB-231 breast cancer cells following Per2 
silencing and doxorubicin treatment. MDA-MB-231 cells were subjected to (1) Control conditions (C), 
(2) 2.5 µM Doxorubicin (D) (3) 30 nM Per2 esiRNA (P), and (4) 30 nM Per2 for 48 hours + 2.5 µM Dox for 
24 hours (PD). Cell cycle analysis was assessed following propidium iodide staining by flow cytometry. 
Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented as 
mean ± SEM (n=3). * = p<0.05 vs control and ** = p<0.001 vs control. Abbreviations: Per2 + Dox = Period 
2 + Doxorubicin. 
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3.2.6. Modulation of G2/M cell cycle transition following Per2 
silencing in MDA-MB-231 breast cancer cells 
 
G2/M transition was analysed by means of flow cytometry using conjugated primary 
antibodies against phosphorylated Histone H3 (Ser
10
) and phosphorylated Aurora A 
(Thr
288
) / Aurora B (Thr
232
) / Aurora C (Thr
198
), in order to distinguish between cells in 
interphase, early mitosis and late mitosis. A significant increase in the interphase cell 
population was seen following doxorubicin treatment (98.70 ± 0.500% vs 36.30 ± 
7.600%, p<0.0001), as well as a shift from mitosis as is evident from a significant 
decrease in p-Aurora levels in comparison to control (1.200 ± 0.400% vs 61.25 ± 
6.850%, p<0.0001) (Figure 3.13). Treatment of MDA-MB-231 cells with doxorubicin 
resulted in a complete inhibition of the mitotic process when compared to control (0.000 
± 0.000% vs 2.350 ± 0.6500%, p<0.001). Per2 silencing resulted in a shift in cells from 
early mitosis evident by a decrease in p-Aurora (6.567 ± 2.484% vs 61.25 ± 6.850%, 
p<0.0001) and an increase in interphase when compared to control (92.77 ± 2.657% vs 
36.30 ± 7.600%, p<0.0001). A significant decrease in mitosis was also seen following 
Per2 silencing in the MDA-MB-231breast cancer cells in comparison to control cells 
(0.3333 ± 0.2082 % vs 2.350 ± 0.6500%, p<0.05). The silencing of Per2 prior to 
doxorubicin treatment appears to have a profoundly negative effect on the MDA-MD-231 
cells, as a significant reduction was seen in the both p-Aurora and mitotic cell 
populations in comparison to control (p-Aurora: 1.333 ± 0.5696%  vs 61.25 ± 6.850%, 
p<0.0001 and mitosis: 0.0667 ± 0.0667% vs 2.350 ± 0.6500, p<0.001). However, a 
significant increase in the interphase population can be seen when compared to control 
(98.50 ± 0.5132% vs 36.30 ± 7.600%, p<0.0001). 
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Figure 3.13: Determination of G2/M cell cycle transition in MDA-MB-231 breast cancer cells following 
Per2 silencing and doxorubicin treatment. MDA-MB-231 cells were subjected to (1) Control conditions (C), 
(2) 2.5 µM Doxorubicin (D) (3) 30 nM Per2 esiRNA (P) and (4) 30 nM Per2 for 48 hours + 2.5 µM Doxorubicin 
for 24 hours (PD). G2/M transition analysis was assessed by flow cytometry. Statistical analysis: One way 
ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). * = p<0.05 vs 
control ** = p<0.001 vs control and *** = p<0.0001 vs control. Abbreviations: Per2 + Dox = Period 2 + 
Doxorubicin. 
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3.3. The Role of Per2 in Autophagy 
In order to determine the role of Per2 in autophagy, Per2 was silenced using an 
esiRNA targeted against Per2 prior to treatment with Bafilomycin A1, a known inhibitor 
of autophagy. 
 
3.3.1. Cell Viability (Mitochondrial Reductive Capacity) 
 
 
 
 
 
 
 
 
 
 
 
 
To gain a better understanding of Per2 and its role in cell death as well as the 
mechanisms involved, autophagic cell death was also assessed. MTT cell viability 
assays were initially carried out in order to determine the effects of Per2 silencing and 
bafilomycin treatment (Figure 3.14). MCF-12A cells showed no significant decrease in 
MTT reductive capacity following bafilomycin A1 treatment alone when compared to 
control (90.88 ± 4.121% vs 100%). Per2 silencing alone resulted in a significant 
reduction in MCF-12A reductive capacity (61.58 ± 6.414% vs 100%, p<0.0001), which 
### ### 
*** 
Figure 3.14: Determining the effect of Per2 silencing on the viability of non-tumorigenic breast epithelial 
MCF-12A cells and the ER
-
 MDA-MB-231 breast cancer cells. MCF-12A and MDA-MB-231 cells were subjected 
to (1) Control conditions (C), (2) 10 nM Bafilomycin (B), (3) 30 nM Per2 esiRNA (P) and (4) 30 nM Per2 for 48 hours 
+ 10 nM Bafilomycin for 8 hours (PB). Cell viability was assessed using the MTT assay. Values are expressed as a 
percentage of the control and presented as mean ± SEM (n=3). *** = p<0.0001 vs control and 
###
 = p<0.0001 vs 
Bafilomycin. Abbreviations: Per2 + Baf = Period 2 + Bafilomycin. 
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was further reduced with the addition of bafilomycin treatment in conjunction with Per2 
silencing in comparison to bafilomycin treatment alone (35.71 ± 4.543% vs 90.88 ± 
4.121%, p<0.0001). The MDA-MB-231 breast cancer cells showed a significant 
reduction in MTT reductive capacity following Per2 silencing when compared to control 
(65.64 ± 3.225% vs 100%, p<0.0001). A significant reduction in MTT reductive capacity 
was also seen following bafilomycin treatment alone in comparison to control cells 
(81.04 ± 2.645% vs 100%, p<0.0001). When compared to bafilomycin, a further 
reduction in MTT reductive capacity was seen following Per2 silencing prior to 
bafilomycin treatment (62.19 ± 3.098% vs 81.04 ± 2.645%, p<0.0001).  
 
3.3.2. Western Blot Analysis 
To provide further insight into the effect of Per2 silencing on the autophagic process, 
western blot analysis was carried out on MDA-MB-231 breast cancer cells using 
recognised markers of autophagy, namely; AMPK, mTOR and LC3. 
 
Per2 and AMPK 
Prior to the analysis of autophagic markers, Per2 silencing was again confirmed in order 
to ensure the effects seen are as a result of the absence of Per2 protein expression. A 
significant reduction in Per2 protein expression (Figure 3.15) was seen following Per2 
silencing alone (17.77 ± 5.931% vs 100%, p<0.0001) as well as in combination with 
bafilomycin A1 treatment when compared to control (11.53 ± 5.593% vs 100%, 
p<0.0001). A significant increase in AMPKα protein expression was seen with Per2 
silencing (857.5 ± 213.2% vs 100%, p<0.001). Although AMPKα protein expression was 
increased with the silencing of Per2 in combination with bafilomycin treatment, results 
were not statistically significant (413.8 ± 93.18% vs 100%) (Figure 3.15). 
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mTOR (Ser2448) Phosphorylation 
 
mTOR (Ser
2448
) phosphorylation was significantly higher following Per2 silencing alone 
in comparison to the control (1053 ± 70.95% vs 100%, p<0.0001). Per2 silencing in 
combination with bafilomycin resulted in a significant increase in mTOR (Ser
2448
) 
phosphorylation when compared to control (467.7 ± 92.66% vs 100%, p<0.001) 
however, to a much lesser extent than seen with Per2 silencing alone (Figure 3.16). 
 
 
 
 
 
GAPDH 37 kDa 
Per2  45 kDa 
*** *** 
AMPKα  60 kDa 
GAPDH 37 kDa 
** 
Figure 3.15: Western Blot analysis of Per2 and AMPKα in MDA-MB-231 breast cancer cells following Per2 
silencing and bafilomycin A1 treatment. MDA-MB-231 cells were subjected to (1) Control conditions (C), (2) 10 nM 
Bafilomycin (B), (3) 30 nM Per2 esiRNA (P) and (4) 30 nM Per2 for 48 hours + 10 nM Baf for 8 hours (PB). Statistical 
analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). ** = 
p<0.001 vs control and *** = p<0.0001. Abbreviations: Per2 + Baf = Period 2 + Bafilomycin.   
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LC3 
Examination of LC3 II expression revealed a significant increase in protein levels with 
bafilomycin treatment (1181 ± 164.4% vs 100%, p<0.05). An increase in both LC3 I and 
LC3 II expression was seen when Per2 was silenced however, LC3 II expression was 
not significant in comparison to the control (718.3 ± 83.96% vs 100%). Silencing of Per2 
in combination with bafilomycin lead to a significantly greater accumulation of LC3 II in 
comparison to control (2164 ± 365.3% vs 100%, p<0.0001) (Figure 3.17). 
 
 
mTOR 289 kDa 
p-mTOR 289 kDa 
GAPDH 37 kDa 
*** 
** 
Figure 3.16: Western Blot analysis of p-mTOR (Ser
2448
) in MDA-MB-231 breast cancer cells following Per2 
silencing and bafilomycin A1 treatment. MDA-MB-231 cells were subjected to (1) Control conditions (C), (2) 10 nM 
Bafilomycin (B), (3) 30 nM Per2 esiRNA (P) and (4) 30 nM Per2 for 48 hours + 10 nM Baf for 8 hours (PB). Statistical 
analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). ** = 
p<0.001 vs control and *** = p<0.0001. Abbreviations: Per2 + Baf = Period 2 + Bafilomycin.   
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3.3.3. Flow Cytometry – Hoechst and PI  
 
Cell death was also assessed by staining cells with Hoechst 33342 and propidium iodide 
analysed with flow cytometry. A significant increase in cell death (31.80 ± 7.275% vs 
7.850 ± 0.2598%, p<0.001) and reciprocal decrease in the live cell population (67.80 ± 
7.448% vs 90.10 ± 1.484%, p<0.05) was seen with Per2 silencing alone when compared 
to the control (Figure 3.18). The silencing of Per2 in combination with bafilomycin 
treatment in the MDA-MB-231 breast cancer cells resulted in an even greater 
percentage of cell death (60.40 ± 2.021% vs 7.850 ± 0.2598%, p<0.0001) and less live 
cells in comparison to control (39.00 ± 1.848% vs 90.10 ± 1.484%, p<0.0001). 
LC3 II 
LC3 I 
14 kDa 
16 kDa 
GAPDH 37 kDa 
* 
*** 
Figure 3.17: Western Blot analysis of LC3 II in MDA-MB-231 breast cancer cells following Per2 silencing 
and bafilomycin A1 treatment. MDA-MB-231 cells were subjected to (1) Control conditions (C), (2) 10 nM 
Bafilomycin (B), (3) 30 nM Per2 esiRNA (P) and (4) 30 nM Per2 for 48 hours + 10 nM Baf for 8 hours (PB). 
Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM 
(n=3). * = p<0.05 vs control and *** = p<0.0001. Abbreviations: Per2 + Baf = Period 2 + Bafilomycin.   
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Figure 3.18: The effects of Per2 silencing on cell death in MDA-MB-231 breast cancer cells. MDA-MB-231 
cells were subjected to (1) Control conditions (C), (2) 10 nM Bafilomycin (B) (3) 30 nM Per2 esiRNA (P), and (4) 
30 nM Per2 for 48 hours + 10 nM Baf for 8 hours (PB). Cell death was assessed by flow cytometry. Statistical 
analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). 
* = p<0.05 vs control ** = p<0.001 vs control and *** = p<0.001 vs control. Abbreviations: Per2 + Dox = Period 2 
+ Doxorubicin. 
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3.3.4. Flow Cytometry – Cell Cycle Analysis  
 
Cell cycle analysis demonstrated a significant increase in G0/G1 cell cycle arrest 
following individual treatments with bafilomycin and Per2 silencing as well as the 
combination of Per2 silencing prior to bafilomycin treatment when compared to control 
(baf: 72.30 ± 3.567% vs 52.42 ± 0.5762%, p<0.001. Per2: 68.77 ± 4.901% vs 52.42 ± 
0.5762%, p<0.05 and Per2 + baf: 77.03 ± 5.886% vs 52.42 ± 0.5762%, p<0.05).  A 
significant decrease in the G2/M cell cycle phase was seen across all treatment groups 
when compared to control (baf: 4.035 ± 2.042% vs 13.88 ± 0.5505%, p<0.001. Per2: 
3.680 ± 2.197% vs 13.88 ± 0.5505%, p<0.05 and Per2 + baf: 3.273 ± 0.9184% vs 13.88 
± 0.5505%, p<0.0001). Additionally, a concomitant increase in apoptosis was seen for all 
treatments in comparison to control cells (baf: 20.66 ± 0.6784% vs 0.0700 ± 0.0700%, 
p<0.05. Per2: 21.43 ± 2.797% vs 0.0700 ± 0.0700%, p<0.05 and Per2 + baf: 23.26 ± 
3.279% vs 0.0700 ± 0.0700%, p<0.05) (Figure 3.19). 
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Figure 3.19: Analysis of cell cycle progression in MDA-MB-231 breast cancer cells following 
Per2 silencing and bafilomycin treatment. MDA-MB-231 cells were subjected to (1) Control 
conditions (C), (2) 10 nM Bafilomycin (B) (3) 30 nM Per2 esiRNA (P), and (4) 30 nM Per2 for 48 hours 
+ 10 nM Baf for 8 hours (PB). Cell cycle analysis was assessed following propidium iodide staining by 
flow cytometry. Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results 
are presented as mean ± SEM (n=3). * = p<0.05 vs control and ** = p<0.001 vs control. Abbreviations: 
Per2 + Baf = Period 2 + Bafilomycin 
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3.3.5. Flow Cytometry – G2/M Analysis  
* ** ** 
* * 
* 
** 
** 
C B 
P PB 
Figure 3.20: Determination of G2/M cell cycle transition in MDA-MB-231 breast cancer cells 
following Per2 silencing and bafilomycin treatment. MDA-MB-231 cells were subjected to (1) Control 
conditions (C), (2) 10 nM Bafilomycin (B), (3) 30 nM Per2 esiRNA (P), and (4) 30 nM Per2 for 48 hours + 
10 nM Baf for 8 hours (PB). G2/M transition analysis was assessed by flow cytometry. Statistical 
analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented as mean ± SEM 
(n=3). * = p<0.05 vs control and ** = p<0.001 vs control. Abbreviations: Per2 + Baf = Period 2 + 
Bafilomycin. 
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G2/M transition analysis of the MDA-MB-231 breast cancer cells following Per2 silencing 
and bafilomycin A1 treatment revealed a significant increase in the interphase cell 
population following bafilomycin treatment alone (85.07 ± 10.83% vs 36.30 ± 7.600%, 
p<0.05) with a shift from early mitosis seen by a decrease in p-Aurora when compared 
to control (14.03 ± 10.56% vs 61.25 ± 6.850%, p<0.05) (Figure 3.20). Per2 silencing 
alone resulted in a significant increase in interphase (92.77 ± 2.657% vs 36.30 ± 
7.600%, p<0.001), and a decrease in p-Aurora in comparison to control (6.567 ± 2.484% 
vs 61.25 ± 6.850%, p<0.001). A significant decrease in mitosis was also seen following 
Per2 silencing when compared to control (0.3333 ± 0.2082 % vs 2.350 ± 0.6500%, 
p<0.05). The combination of Per2 silencing prior to bafilomycin treatment resulted in an 
almost complete inhibition of mitosis in comparison to control (0.133 ± 0.133% vs 2.350 
± 0.6500%, p<0.001) which resulted in virtually the entire population of cells in 
interphase (97.67 ± 1.184% vs 36.30 vs 7.600%, p<0.001). A significant shift from early 
mitosis was also seen following Per2 silencing in combination with bafilomycin treatment 
when compared to control (1.867 ± 1.189% vs 61.25 ± 6.850%, p<0.001). 
  
 
3.4. Metformin - A modulator of circadian Per2 expression and a 
potential adjuvant chemotherapeutic agent. 
 
3.4.1. MTT Cell Viability Assay 
 
MTT cell viability assays were carried out to assess the cell viability of the MDA-MB-231 
cancer cells following treatment with metformin and doxorubicin. The MDA-MB-231 
cancer cells, which are known to be resistant to doxorubicin treatment showed a slight 
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although significant reduction in MTT reductive capacity when treated with 2.5 µM of 
doxorubicin in comparison to the control (86.82 ± 2.478% vs 100%, p<0.0001). The 
combination treatment of metformin and doxorubicin resulted in a statistically greater 
reduction in cell viability when compared to control (79.05 ± 2.398% vs 100%, 
p<0.0001), however when compared to doxorubicin alone only a slight reduction in cell 
viability was seen with the combination treatment (79.05 ± 2.398% vs 86.82 ± 2.478%, 
p<0.05) (Figure 3.21). 
 
 
MD C    D M 
*** 
# 
Figure 3.21: Effects of metformin on the viability and morphology of the MDA-MB-231 cancer cells.  MDA-MB-
231 cells were subjected to (1) Control conditions (C), (2) 2.5 µM Doxorubicin (D), (3) 40 mM Metformin (M) and (4) 
2.5 µM Dox for 24 hours + 40 mM Dox for 24 hours (MD). Cell viability was assessed using the MTT assay and 
inverted microscope images were obtained at 100x magnification. Statistical analysis: One way ANOVA with 
Bonferroni post hoc correction. All results are presented as mean ± SEM (n=3). *** = p<0.0001 vs control and
 #
 = 
p<0.05 vs Doxorubicin. Abbreviations: C = Control, D = Doxorubicin, M = Metformin and MD = Metformin + 
Doxorubicin 
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3.4.2. Cell Cycle Analysis 
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Figure 3.22: Analysis of cell cycle progression of the MDA-MB-231 cancer cells following metformin and 
doxorubicin treatment. MDA-MB-231 cells were subjected to (1) Control conditions (C), (2) 2.5 µM Doxorubicin (D) 
(3) 40 mM Metformin (M), and (4) 40 mM Metformin for 24 hours + 2.5 µM Dox for 24 hours. Cell cycle analysis was 
assessed following propidium iodide staining by flow cytometry. Statistical analysis: One way ANOVA with Bonferroni 
post hoc correction. All results are presented as mean ± SEM (n=3). * = p<0.05 vs control. Abbreviations: Met + Dox 
= Metformin + Doxorubicin. 
* 
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Cell cycle regulation was assessed using flow cytometry to determine the effects of 
metformin on the cell cycle in the MDA-MB-231 cancer cells. The MDA-MB-231 cancer 
cells showed a significant increase in the percentage of cells in the G2/M phase of the 
cell cycle (21.91 ± 1.614% vs 7.407 ± 1.309%, p<0.001) with a slight non-significant 
increase in apoptosis (3.407 ± 2.656% vs 0.5233 ± 0.2621%) following doxorubicin 
treatment in comparison to the control. However, no significant changes were seen with 
either metformin treatment alone or in combination with doxorubicin when compared to 
the control (Figure 3.22). 
 
3.4.3. Western Blot Analysis 
Per2 
Figure 3.23: Western Blot analysis of Per2 in the MDA-MB-231 breast cancer cells following metformin 
and doxorubicin treatment. MDA-MB-231 cells were subjected to (1) Control conditions (C), (2) 2.5 µM 
Doxorubicin (D), (3) 40 mM Metformin (M) and (4) 40 mM Metformin for 24 hours + 2.5 µM Doxorubicin for 24 
hours (MD). Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented 
as mean ± SEM (n=3). * = p<0.05 vs control, ** = p<0.001 vs control and *** = p<0.0001 vs control. 
Abbreviations: Met + Dox = Metformin + Doxorubicin.   
Per2 
45 kDa 
GAPDH 
37 kDa 
*** 
** 
* 
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Western blot analysis of Per2 protein levels was analysed prior treatment with metformin 
treatment in order to determine the effects of metformin on its protein expression in the 
MDA-MB-231 breast cancer cells. The MDA-MB-231 cancer cells showed a significant 
reduction in Per2 protein levels with metformin treatment alone (36.39 ± 8.495% vs 
100%, p<0.0001) as well as with the combination of metformin and doxorubicin 
treatment in comparison to the control (55.47 ± 8.144% vs 100%, p<0.001) (Figure 
3.23). 
 
AMPKα (Thr172) Phosphorylation 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24: Western Blot analysis of p-AMPKα (Thr
172
) in the MDA-MB-231 (B) breast cancer cells 
following metformin and doxorubicin treatment. MDA-MB-231 cells were subjected to (1) Control conditions 
(C), (2) 2.5 µM Doxorubicin (D), (3) 40 mM Metformin (M) and (4) 40 mM Metformin for 24 hours + 2.5 µM 
Doxorubicin for 24 hours (MD). Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All 
results are presented as mean ± SEM (n=3). ** = p<0.001 vs control and *** = p<0.0001 vs control. Abbreviations: 
Met + Dox = Metformin + Doxorubicin.   
** *** 
p-AMPKα 
60 kDa 
GAPDH 
37 kDa 
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The MDA-MB-231 cancer cells showed a significant reduction in the phosphorylation of 
AMPKα following metformin treatment alone (40.21 ± 11.54% vs 100%, p<0.0001), and 
in combination with doxorubicin treatment when compared to the control (47.67 ± 
6.865% vs 100%, p<0.001) (Figure 3.24). 
 
p53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The MDA-MB-231 cancer cells showed a significant reduction in p53 activity following 
treatment with doxorubicin alone (41.32 ± 4.255% vs 100%, p<0.0001) as well as with 
the combination of metformin and doxorubicin treatment in comparison to the control 
(40.52 ± 7.703% vs 100%, p<0.0001). No significant change in p53 activity was seen in 
the MDA-MB-231 cancer cells following treatment with metformin alone (91.78 ± 3.242% 
vs 100%) (Figure 3.25). 
*** *** 
p53 
53 kDa 
GAPDH 
37 kDa 
Figure 3.25:  Western Blot analysis of p53 in the MDA-MB-231 breast cancer cells following metformin 
and doxorubicin treatment. MDA-MB-231 cells were subjected to (1) Control conditions (C), (2) 2.5 µM 
Doxorubicin (D), (3) 40 mM Metformin (M) and (4) 40 mM Metformin for 24 hours + 2.5 µM Dox for 24 hours 
(MD). Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented as 
mean ± SEM (n=3). *** = p<0.0001 vs control. Abbreviations: Met + Dox = Metformin + Doxorubicin.   
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Caspase-3 
 
Caspase-3, an executioner caspase leads to the induction of apoptosis upon its 
cleavage by upstream initiator caspases. Western blot analysis for caspase-3 was used 
to assess apoptotic activity in the MDA-MB-231 cells. The MDA-MB-231 cancer cells 
showed a significant reduction in caspase-3 activity with metformin treatment alone 
(67.58 ± 3.702% vs 100%, p<0.001) which was further reduced with the combination of 
metformin and doxorubicin treatment in comparison to the control (55.27 ± 6.857% vs 
100%, p<0.0001) (Figure 3.26). 
 
 
** 
*** 
Caspase-3 
35 kDa 
GAPDH 
37 kDa 
Figure 3.26: Western Blot analysis of Caspase-3 in the MDA-MB-231 breast cancer cells following 
metformin and doxorubicin treatment. MDA-MB-231 cells were subjected to (1) Control conditions (C), (2) 2.5 
µM Doxorubicin (D), (3) 40 mM Metformin (M) and (4) 40 mM Metformin for 24 hours + 2.5 µM Dox for 24 hours 
(MD). Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented as 
mean ± SEM (n=3). ** = p<0.001 vs control and *** = p<0.0001 vs control. Abbreviations: Met + Dox = Metformin 
+ Doxorubicin.   
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PARP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PARP protein expression was assessed as a marker of nuclear damage and apoptosis 
induction in both the MDA-MB-231 cancer cells. The MDA-MB-231 cancer cells showed 
a significant reduction in PARP levels following doxorubicin (36.89 ± 10.02% vs 100%, 
p<0.0001), and metformin treatments alone when compared to the control (50.20 
±6.088% vs 100%, p<0.001). A significant reduction in PARP was also seen following 
the combination of metformin and doxorubicin treatment in comparison to control (49.40 
± 11.02% vs 100%, p<0.001) (Figure 3.27). 
 
 
 
 
Figure 3.27: Western Blot analysis of PARP in the MDA-MB-231 breast cancer cells following metformin 
and doxorubicin treatment. MDA-MB-231 cells were subjected to (1) Control conditions (C), (2) 2.5 µM 
Doxorubicin (D), (3) 40 mM Metformin (M) and (4) 40 mM Metformin for 24 hours + 2.5 µM Doxorubicin for 24 
hours (MD). Statistical analysis: One way ANOVA with Bonferroni post hoc correction. All results are presented 
as mean ± SEM (n=3). *** = p<0.0001 vs control. Abbreviations: Met + Dox = Metformin + Doxorubicin.   
** 
PARP 
118 kDa 
GAPDH 
37 kDa 
** 
*** 
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Table 3.1: A summary of the significant changes in markers of cell death following Per2 silencing in 
combination with doxorubicin treatment, in the MDA-MB-231 breast cancer cell line. ↑ / ↓ = p<0.05, ↑↑ / ↓↓ = 
p<0.001 and ↑↑↑ / ↓↓↓ = p<0.0001. Treatment groups: Dox = Doxorubicin, esiPer2 = Per2 silencing, esiPer2 + 
Dox = Per2 silencing + Doxorubicin. 
vs Control 
The Role of Per2 in Doxorubicin-induced Cell 
Death 
Dox esiPer2 esiPer2 + Dox 
MTT Viability ↓↓↓ ↓↓↓ ↓↓↓ 
 
Western 
Blotting 
Per2 NS ↓↓↓ ↓↓↓ 
p-MDM2 (Ser166) NS ↑ NS 
p-p53 (Ser15) ↑↑↑ NS NS 
CC3 NS ↑ ↑ 
CP ↑↑↑ ↑↑↑ ↑↑↑ 
 
Hoechst + PI 
Live cells NS ↓ ↓↓↓ 
Dead cells ↑ ↑↑ ↑↑↑ 
 
Cell Cycle 
Analysis 
G0/G1 NS ↑ NS 
S  NS NS ↑↑ 
G2/M ↑ ↓↓ ↓↓ 
Apoptosis ↑ ↑ ↑↑ 
 
G2/M 
Transition 
Interphase ↑↑↑ ↑↑↑ ↑↑↑ 
p-Aurora ↓↓↓ ↓↓↓ ↓↓↓ 
Mitosis ↓↓ ↓ ↓↓ 
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Table 3.2: A summary of the significant changes in markers of cell death and autophagy following Per2 
silencing in combination with autophagy inhibition using bafilomycin A1 in the MDA-MB-231 breast 
cancer cell line. ↑ / ↓ = p<0.05, ↑↑ / ↓↓ = p<0.001 and ↑↑↑ / ↓↓↓ = p<0.0001. Treatment groups: Baf = Bafilomycin 
A1, esiPer2 = Per2 silencing, esiPer2 + Baf = Per2 silencing + Bafilomycin. 
vs Control 
The Role of Per2 in Autophagy 
Baf esiPer2 esiPer2 + Baf 
MTT Viability ↓↓↓ ↓↓↓ ↓↓↓ 
 
Western 
Blotting 
Per2 NS ↓↓↓ ↓↓↓ 
AMPKα NS ↑↑ NS 
p-mTOR (Ser2448) NS ↑↑↑ ↑↑ 
LC3 II ↑↑ NS ↑↑↑ 
 
Hoechst + PI 
Live cells NS ↓ ↓↓↓ 
Dead cells NS ↑↑ ↑↑↑ 
 
Cell Cycle 
Analysis 
G0/G1 ↑↑ ↑ ↑ 
S  NS NS NS 
G2/M ↓↓ ↓ ↓↓ 
Apoptosis ↑ ↑ ↑ 
 
G2/M 
Transition 
Interphase ↑ ↑↑ ↑↑ 
p-Aurora ↓ ↓↓ ↓↓ 
Mitosis NS ↓ ↓ 
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Table 3.3: A summary of the significant changes in markers of cell viability, markers of cell death and cell 
cycle analysis following treatment with metformin and doxorubicin in the MDA-MB-231 breast cancer cell 
line. ↑↑ / ↓↓ = p<0.001 and ↑↑↑ / ↓↓↓ = p<0.0001. Treatment groups: Dox = Doxorubicin, Met = Metformin, Met + 
Dox = Metformin + Doxorubicin. 
vs Control 
Metformin: A modulator of Per2 expression and  
possible adjuvant chemotherapeutic agent 
Dox Met Met + Dox 
MTT Viability ↓↓↓ ↓↓↓ ↓↓↓ 
 
Western 
Blotting 
Per2 ↓ ↓↓↓ ↓↓ 
p-AMPKα (Thr172) NS ↓↓↓ ↓↓ 
p53 ↓↓↓ NS ↓↓↓ 
Caspase-3 NS ↓↓ ↓↓↓ 
PARP ↓↓↓ ↓↓ ↓↓ 
 
Cell Cycle 
Analysis 
G0/G1 NS NS NS 
S  NS NS NS 
G2/M ↑ NS NS 
Apoptosis NS NS NS 
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Chapter 4: Discussion 
 
4.1. Introduction 
 
Most peripheral organ and tissue clocks have been shown to express internal circadian 
oscillations which operate independently of central hypothalamic inputs. Increased 
reliance on incandescent light and rotating night shift work, associated with modern day 
living has resulted in a de-synchronization of these intrinsic oscillations giving rise to 
severe circadian disruptions which have been implicated in the pathogenesis of various 
diseases including that of breast cancer.  
Breast cancer has become a global concern, as the burden of this disease is rapidly on 
the rise in both developed and developing countries. In South Africa it was estimated 
that in 2004 alone one in 29 women were newly diagnosed with breast cancer, with 
numbers set to rise each year (National Cancer Registry., 2004). Furthermore, breast 
cancer cells have become increasingly resistant to the anti-carcinogenic effects of 
chemotherapeutic agents like doxorubicin, and as such a critical need for more effective 
adjuvant therapies aimed at improving cancer cell susceptibility to chemotherapy-
induced cell death has arisen. 
Therefore this study was designed to provide insight into the molecular nature behind 
intrinsic peripheral circadian clocks, as well as to assess whether the manipulation of 
these clocks through the silencing of Per2, a key regulator involved in the resetting of 
the circadian clock, could sensitize resistant breast cancer cells to the anti-carcinogenic 
effects of doxorubicin. Prior to the assessment of the role of Per2 in both doxorubicin-
induced cell death and autophagy, this study set out to characterize Per2 in a normal 
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MCF-12A breast epithelial cell line, as well as in the estrogen receptor positive MCF-7 
and estrogen receptor negative MDA-MB-231 breast adenocarcinoma cell lines. 
Western blotting analysis was employed to assess the rhythmic changes in Per2 protein 
expression over a period of 25 hours. Additionally, fluorescent confocal microscopy was 
used to determine the cellular localization of Per2 under basal cellular conditions. An in 
vitro experimental model was subsequently employed, which made use of the MDA-MB-
231 estrogen receptor negative adenocarcinoma cell line, as they are known to be 
resistant to doxorubicin-induced cell death (Smith et al., 2006). Doxorubicin dose 
responses were carried out and a concentration, which falls within a clinically relevant 
range, was chosen based on the ability of doxorubicin to elicit a differential response in 
MTT reductive capacity of the normal MCF-12A and MDA-MB-231 cancer cells. Per2 
was silenced by making use of an esiRNA targeted against the Per2 gene, and silencing 
was confirmed with western blotting. With the use of various molecular techniques (MTT 
assay, western blotting and flow cytometry) the role of Per2 in doxorubicin-induced cell 
death and autophagy was assessed. Additionally, metformin was employed in this study 
as a pharmacological inhibitor of Per2, in order to substantiate the findings seen with 
Per2 gene silencing in the context of doxorubicin-induced cell death. The following aims 
were thus formulated:    
 To characterize the role of Per2 in normal breast epithelial cells as well as in ER+ 
and ER- breast epithelial cells.  
 To determine the role of Per2 in doxorubicin-induced cell death.  
 To determine the role of Per2 in autophagy.  
 To evaluate the role of metformin, a modulator of Per2 expression, as a potential 
adjuvant chemotherapeutic agent. 
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4.2. Characterizing the Role of Per2 in Normal, ER+ and ER- Breast 
Epithelial Cells.  
 
All nucleated cells have been shown to possess intrinsic circadian clocks, which are 
thought to function in a cell-autonomous fashion, evident by the self-sustained rhythmic 
oscillations in detached cell culture models (Balsalobre et al., 1998). Therefore, in this 
part of the study we aimed to elucidate the presence of a rhythmic expression pattern of 
the circadian Per2 protein in a normal breast epithelial (MCF-12A) cell line, an estrogen 
receptor positive (ER
+
) breast adenocarcinoma cell line (MCF-7) as well as in an 
estrogen receptor negative (ER
-
) cell line (MDA-MB-231). We have demonstrated for the 
first time that a clear circadian pattern in Per2 protein expression in the normal MCF-
12A cells as well as in the ER- MDA-MB-231 cancer cells exists. However, the ER+ 
MCF-7 breast cancer cells showed no rhythmic Per2 protein expression, as protein 
levels remained fairly constant over 25 hours (Figure 3.1). These results are in 
accordance with other studies where differential Per2 expression was observed on an 
mRNA level in human breast cancer tissue samples (Chen et al., 2005). Additionally, 
Rossetti and colleagues failed to see rhythmic changes in Per2 when assessing mRNA 
expression in the MCF-7 cell line (Rossetti et al., 2012).   
Two distinct subpopulations of cells expressing the Per2 protein were observed in both 
the normal MCF-12A breast epithelial cells and the MDA-MB-231 breast 
adenocarcinoma cells. In both the fluorescently dimmer and brighter subpopulations, 
Per2 was seen to be located predominantly within the cytoplasm. Co-localization of Per2 
in the nucleus was only seen in the fluorescently dimmer subpopulations of both cell 
lines. These results are in agreement with known literature where both cytoplasmic and 
nuclear localization of Per2 is seen in the kidney fibroblast-like COS7 cell line (Yagita et 
al., 2002). Additionally, the differences in Per2 protein expression patterns seen in 
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different populations of the MDA-MB-231 cancer cells, highlights the a-synchronous 
nature of peripheral circadian clocks as well as the heterogeneity of cancer cell 
populations (Chen et al., 2005). The fact that nuclear localization of Per2 was associated 
only with diminished cytoplasmic protein expression, may be explained by the fact that  
Per2 protein levels begin to accumulate within the cytoplasm after its translation at the 
start of a circadian day (Albrecht, 2002). Per2 protein levels reach threshold levels at the 
end of a circadian day (Figure 3.2A and Figure 3.3A), where they heterodimerize with 
accumulated Cry proteins and CKIε - this complex then translocates into the nucleus 
resulting in the repression of Per2 gene transcription. Once repressed, unbound 
cytoplasmic Per2 is phosphorylated by CKIε, leading to its degradation by the 26S 
proteasome pathway thus causing a decrease in cytoplasmic Per2 protein levels (Figure 
3.2B and Figure 3.3B) and a resetting of the circadian clock (Lefta et al., 2011). 
 
4.3. The Role of Per2 in Doxorubicin-Induced Cell Death  
 
The Per2 gene is an essential regulator of the mammalian circadian clock system, and 
mutations arising in this gene have been identified in a wide range of human cancers 
including, colorectal and breast cancer (Yang et al., 2009). Furthermore, circadian Per2 
disruption has been implicated in cell cycle dysfunction and apoptosis, evident by the 
aberrant rhythmic expression of the cell cycle gene, cyclin D1, as well as the negative 
p53 regulator, MDM2, in Per2 deficient mice (Canaple et al., 2003). Based on this 
knowledge, we focussed on Per2 as a molecular target for the sensitization of resistant 
breast cancer cells to doxorubicin treatment. In order to determine the role of Per2 in 
doxorubicin induced cell death, we made use of an endoribonuclease-prepared siRNA 
against the mammalian Per2 gene to effectively silence Per2 protein expression. Results 
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obtained following western blot analysis show that we were able to achieve a silencing 
efficiency of ±78% in the normal MCF-12A cells and an efficiency of ±99% in the MDA-
MB-231 breast cancer cells using 30 nM Per2 esiRNA for a period of 48 hours (Figure 
3.4), we therefore used this concentration and time point for all subsequent 
transfections. 
Per2 was silenced in both the normal MCF-12A and MDA-MB-231 breast cancer cells 
prior to their treatment with 2.5 µM of doxorubicin for 24 hours, in order to determine 
whether the resistant MDA-MB-231 cancer cells could be sensitized to a lower, clinically 
relevant, dose of doxorubicin by Per2 circadian disruption. Our results show that 2.5 µM 
doxorubicin lead to a significant reduction in MTT reductive capacity of the normal MCF-
12A cells. Although treatment with 2.5 µM doxorubicin did lead to a significant reduction 
in the reductive capacity of the MDA-MB-231 cancer cells when compared to the normal 
MCF-12A cells, doxorubicin treatment was less effective in decreasing the reductive 
capacity of the MDA-MB-231 cells, demonstrating the resilient nature of these cancer 
cells to doxorubicin treatment (Figure 3.6). Our results also demonstrate that the 
silencing of Per2 prior to doxorubicin treatment does in fact sensitize the resistant MDA-
MB-231 cancer cells to doxorubicin treatment, as a significant decrease in the MTT 
reductive capacity of these cells was seen in comparison to doxorubicin treatment alone. 
These results are contradictory to other studies which show an increase in cell death 
with the overexpression of Per2 in MCF-7 breast cancer cells (Xiang et al., 2008). An 
explanation for the results we obtained may be due to the fact that the function of the 
140 kDa protein isoform of Per2 was assessed in these studies, whereas in our study 
the smaller 45 kDa protein isoform was assessed. We also observed a significant 
decrease in the MTT reductive capacity of the MCF-12A cells with Per2 silencing prior to 
doxorubicin when compared to doxorubicin treatment alone which demonstrates the 
essential role that Per2 plays in the normal cellular DNA-damage response pathway 
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(Albrecht et al., 2007). Although this combination therapy was more effective than Dox 
alone in the MDA-MB-231 cells, the normal MCF-12A cells were also severely affected. 
This treatment strategy should therefore be targeted specifically to the cancer cells via 
nanoparticles comprising polyethyleneimine (PEI) and poly(D,L-lactide-co-glycolide) 
(PLGA), to encapsulate a combination of siRNA and chemotherapeutic agent (Patil et 
al., 2011), in our case the combination of Per2 esiRNA and doxorubicin should be used. 
Oncogenic signalling and DNA damage are invariably associated with p53 mediated 
tumour suppression.  In response to DNA damage, the activation of p53 by ATM/ATR 
and Chk1/Chk2, a set of Ser/Thr kinases (Eymin et al., 2006),  results in the induction of 
apoptosis, senescence or cell cycle arrest (Reinhardt et al., 2014). Oncogenic signalling 
on the other hand is involved in tumour suppression, via the stabilization of p53 in an 
ARF-dependent mechanism. Activation of p53 by ARF leads to the activation of MDM2, 
and the subsequent inhibition of p53-ubiquitin ligase activity (Jin et al., 2001). Thus the 
stabilization of p53 by ARF, leads to an increase in p53 activity, and the induction of 
apoptosis or senescence (Efeyan et al., 2007). 
Mutations arising in p53 are seen in over 50% of all human cancers, with a large 
proportion of these mutations occurring as a result of missense mutations that give rise 
to protein products lacking p53-trancriptional activity (Wang et al., 2011). The loss of 
functional p53 may thus account for the ability of these cancer cells to evade cell death. 
Additionally, p53 aberrations have been associated with an increase in the resistance of 
cancer cells to chemotherapeutic treatment (Weller, 1998). 
Our results obtained from western blot analysis of the MDA-MB-231 breast cancer cells, 
showed a significant increase in p-MDM2 (Ser
166
) activity in response to Per2 silencing 
(Figure 3.8). A slight, non-significant increase in MDM2 (Ser
166
) phosphorylation was 
seen with doxorubicin treatment alone, which was associated with a significant increase 
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in p-p53 (Ser
15
) activity (Figure 3.8). An increase in MDM2 activity is usually associated 
with a decrease in functional p-p53 (Ser
15
) activity, as MDM2 phosphorylation leads to 
the stabilization and subsequent degradation of p53 (Malmlöf et al., 2007). However, our 
results showed that p-p53 (Ser
15
) activity remained unchanged following Per2 silencing 
and was concomitantly increased with doxorubicin treatment. This may be explained by 
the fact that the MDA-MB-231 breast cancer cells possess a p53 mutation (codon 280, 
AGA (arginine) to AAA (lysine)) which leads to the increased expression of dysfunctional 
p53 (Li et al., 1999).  
Our results also show a slight although non-significant increase in cleaved caspase-3 
(Figure 3.9) with a subsequent significant increase in cleaved PARP in the MDA-MB-
231 cancer cells following treatment with 2.5 µM doxorubicin (Figure 3.10). This was 
unexpected, as findings on human T-cell leukaemia show that doxorubicin leads to the 
induction of cell death in a caspase-3 dependent manner (Gamen et al., 1997). These 
results may be explained by the fact that once activated caspase-3 leads to the 
cleavage of PARP, thereby resulting in a rise in cleaved PARP levels (Earnshaw et al., 
1999). Additionally, findings in Hela cells shows that active caspase-3 is rapidly 
degraded (Tawa et al., 2004). Thus we may have seen a significantly greater increase 
after a shorter treatment period. Per2 silencing alone as well as in combination with 
doxorubicin treatment resulted in a significant increase in both cleaved caspase-3 and 
cleaved PARP levels which suggests that these cells are committed to cells death 
through apoptosis.  
In order to add to the cell death results obtained by western blotting, MDA-MB-231 
cancer cells were stained with Hoechst 33342 and propidium iodide and analysed by 
flow cytometry (Figure 3.11). Our results show a significant increase in the percentage 
of dead cells with the treatment of 2.5 µM doxorubicin. Per2 silencing resulted in a 
significant decrease in the percentage of live cells with a concomitant increase seen in 
Stellenbosch University  http://scholar.sun.ac.za
96 
 
the dead cell population. Our results also indicate that by silencing Per2 prior to 
treatment with doxorubicin, the resistant MDA-MB-231 cancer cells become more 
sensitive to the cytotoxic effects of doxorubicin. These results support the increase in 
caspase-3 and PARP cleavage seen with our western blotting data. Apoptotic cell death 
is classically defined by distinct morphological changes which are initiated by cleavage 
of caspase-3 and subsequent PARP cleavage, nuclear condensation and fragmentation 
ensues resulting in a loss of membrane integrity, thus allowing the propidium iodide stain 
to permeabilize the cell and causing an increase in fluorescence as measured by flow 
cytometry (Riccardi et al., 2006).  
Results obtained from cell cycle analysis of the MDA-MB-231 breast cancer cells, show 
a significant increase in the G2/M phase with a significant increase in apoptosis (Sub-
G1) with the treatment of 2.5 µM doxorubicin over 24 hours indicating G2/M cell cycle 
arrest (Figure 3.12). These results are in agreement with several other studies showing 
G2/M arrest in the MDA-MB-231 breast cancer cells following doxorubicin treatment 
(Bar-on et al., 2007 and Siu et al., 1999).  
A significant increase in the G0/G1 phase with a concomitant decrease in the G2/M cell 
cycle phase was seen with Per2 silencing, whereas the combination of Per2 silencing 
and doxorubicin treatment resulted in cells exiting the cell cycle during the S-phase, this 
resulted in a significant reduction in the G2/M phase with a concomitant increase in 
apoptosis. Our results show that Per2 may be involved in the regulation of cell cycle 
progression as suggested in literature, and this mechanism may be mediated by the 
effect of Per2 on cyclin D1 and c-myc expression (Filipski et al., 2006). However, as we 
did not assess expression of these key G0/G1 cell cycle regulators in response to Per2 
silencing, this still remains to be elucidated.  
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In order to shed further light on the cell cycle data obtained, particularly during mitosis, 
G2/M cell cycle transition was also assessed by means of flow cytometry. The 
phosphorylation of Histone H3 at the Ser
10
 residue is strongly associated with the 
condensation of chromosomes during mitosis (Goto, 1999), whereas the 
phosphorylation of the Aurora kinases (A, B and C) is associated with various functions 
during mitosis, which include but are not limited to mitotic spindle formation, 
chromosome segregation and cytokinesis (Andrews et al., 2003). The functional 
influences of these kinases thus span from the beginning of the G2 phase right to the 
end of mitosis. Additionally, during G2/M cell cycle transition the phosphorylation of 
Histone H3 is tightly coupled to the expression of the Aurora kinases (Crosio et al., 
2002). Therefore, cells staining positive for both p-Histone H3 (Ser
10
) and p-Aurora A 
(Thr
288
) / Aurora B (Thr
232
) / Aurora C (Thr
198
) indicate cells which are truly mitotic and 
have progressed through the entire cell cycle (late stage mitosis), whereas those 
staining positive for only the phosphorylated Aurora kinases are indicative of early 
mitotic cells.  
Our results show that treatment with 2.5 µM doxorubicin results in a severe blunting in 
mitosis of the MDA-MB-231 cancer cells as a significant reduction in both early and late 
stage mitosis was seen compared to control (Figure 3.13), this adds to the cell cycle 
analysis data showing a complete arrest in the G2-phase. Per2 silencing also resulted in 
a significant decrease in late stage mitosis as well as that of early mitosis; however the 
decrease in early mitosis was not as severe as that seen with doxorubicin treatment 
alone. The combination of Per2 silencing and doxorubicin also resulted in a complete 
inhibition of both early and late mitosis.  
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4.4. The Role of Per2 in Autophagy  
 
Autophagy or type II programmed cell death, is classically defined by the sequestration 
of redundant or faulty cellular constituents into double membrane bound vesicles which 
fuse with internal lysosomes, resulting in their degradation and removal from the cell 
(Gozuacik et al., 2004). Although autophagy serves an essential “housekeeping” role in 
normal cells through its ability to remove these faulty constituents, cells fated to die 
possess increased autophagic activity which results in their excessive destruction by 
“self-cannibalization” (Levine et al., 2005).  
In addition, autophagy has been shown to display circadian rhythmicity in accordance 
with daily feeding and rest / activity patterns. In rat hepatocytes, autophagy was shown 
to peak during the rest or fasting periods when plasma glucagon levels peak and 
intracellular ATP levels are depleted. However, during the active feeding period, plasma 
insulin levels peak, which results in the activation of the PI3K/Akt pathway, leading to the 
inhibition of autophagic activity (Sachdeva et al., 2008 and Ma et al., 2012). 
The hypoxic and nutrient deprived microenvironment that cancer cells in the centre of a 
tumour face, causes a shift in cellular metabolism allowing cancer cells to utilize large 
quantities of glucose for anabolic processes (Kroemer et al., 2008). Additionally, 
autophagy has been shown to be up-regulated in certain cancer cell types (Ogier-Denis 
et al., 2003), which confers a survival advantage to the cancer cells as intracellular 
constituents are broken down and fed into the tricarboxylic acid (TCA) cycle to yield ATP 
and other catabolites which can be utilized for energy metabolism (Hanahan et al., 
2011).  
Recently, modulation of the autophagic process has become an attractive therapeutic 
target against cancer, as it has been postulated that if autophagy does confer a 
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protective mechanism to cancer cells by allowing them to evade cell death, then it 
stands to reason that the inhibition of autophagy may force these cells to undergo 
programmed cell death (Hait et al., 2006). Therefore, for this part of the study we aimed 
to determine whether the silencing of Per2 could sensitize the chemo-resistant MDA-
MDB-231 cancer cells to the inhibition of autophagy, thereby forcing them to undergo 
programmed cell death. 
For this part of the study Per2 was silenced in both the normal MCF-12A and MDA-MB-
231 breast cancer cells prior to autophagy inhibition using 10 nM bafilomycin for 8 hours. 
Our results show that treatment of the normal MCF-12A with bafilomycin A1 had no 
significant effect on the MTT reductive capacity of these cells, whereas Per2 silencing 
prior to bafilomycin treatment in the MCF-12A cells resulted in a significant decrease in 
MTT reductive capacity (Figure 3.14). The resistant MDA-MB-231 breast cancer cells 
showed a significant decrease in MTT reductive capacity following treatment with 10 nM 
bafilomycin A1, suggesting that these cells do in fact appear to be sensitive to the 
inhibition of autophagy. Our results also show that when Per2 was silenced in the MDA-
MB-231 cells prior to treatment with bafilomycin, the sensitivity of these cells to 
autophagic inhibition is greatly enhanced.   These results were further supported by flow 
cytometry analysis by staining cells with Hoechst and propidium iodide (Figure 3.18), as 
a significant increase in cell death was seen following the silencing of Per2 prior to the 
inhibition of autophagy by bafilomycin A1. 
In order to gain insight into the mechanism whereby Per2 silencing appears to sensitize 
the MDA-MB-231 cancer cells to autophagy inhibition, western blot analysis was 
conducted assessing key markers of autophagic activity, namely; AMPKα, p-mTOR 
(Ser
2448
) and LC3. 
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Assessment of AMPKα showed a significant increase following Per2 silencing (Figure 
3.15), this result may be explained by the fact that the intrinsic circadian clock is 
additionally stabilized via the activation of CK1ε by AMPK, leading to the 
phosphorylation of Per2 and thus its degradation by the 26S proteasome (Eide et al., 
2005). This might result in a possible feedback mechanism leading to the rise in AMPKα 
activity which was observed in our results. Interesting to note is that although the 
silencing of Per2 prior to bafilomycin treatment did lead to an increase in AMPKα activity 
in comparison to control, the activity still remained lower than with Per2 silencing alone. 
This decrease could possibly be as a result of a negative feedback mechanism, whereby 
the inhibition of autophagy by bafilomycin leads to a decrease in the elevated AMPKα 
activity seen following Per2 silencing. 
The mammalian Target of Rapamycin (mTOR), a sensor of nutrient availability, serves 
as a potent regulator of autophagic activity with a decrease in its activity resulting in the 
activation of Unc-51-like kinase (ULK1) and Atg13, two of the main initiators of 
phagophore formation (Lozy et al., 2012). Bafilomycin A1 treatment resulted in a slight 
but not significant increase in the phosphorylation of mTOR (Figure 3.16) and when 
compared to the control this suggests that autophagy is inhibited (Easton et al., 2006). 
These results are further supported by the accumulation LC3 II following bafilomycin 
treatment (Figure 3.17). The increase in both LC3 I and LC3 II levels seen with the 
silencing of Per2 is suggestive of an increase in autophagic activity in these cells. 
However, the interpretation of the western blot data for LC3 II accumulation can often be 
misleading, as an increase in LC3 II can be as a result of impaired autophagy as seen 
with its accumulation following bafilomycin treatment. Basal autophagy flux can be 
determined by the change in relative LC3 II levels seen with the pharmacological 
inhibition or induction of autophagy (Castillo et al., 2013); in our study this was 
determined with bafilomycin treatment.  
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A significant increase in LC3 II accumulation was seen with the combination of Per2 
silencing and bafilomycin treatment when compared to bafilomycin treatment alone, 
suggestive of an increase in autophagy flux associated with Per2 silencing. The increase 
in LC3 I seen when Per2 was silenced was abolished when autophagy was inhibited 
with bafilomycin, suggesting that the increase in autophagy flux may be as a result of 
increased autophagosomal synthesis in the MDA-MB-231 cancer cells.  Traditionally, an 
increase in mTOR (Ser
2448
) phosphorylation, as seen when Per2 was silenced both 
alone and in combination with bafilomycin treatment (Figure 3.16), is associated with the 
inhibition of autophagy, however, recently it has been shown that autophagy is 
additionally regulated via mechanisms which are independent of mTOR (Williams et al., 
2008). Additionally, C/EBPβ has been shown to induce autophagy by increasing the 
lipidation of LC3 I into LC3 II, independently of mTOR activation (Ma et al., 2011). 
Therefore, our results suggest that Per2 is associated with the regulation of autophagy 
via an mTOR-independent mechanism.  
 
Cell cycle analysis by flow cytometry was assessed in order to determine the underlying 
mechanisms of how Per2 silencing sensitizes the resistant MDA-MB-231 cancer cells to 
autophagy inhibition. Our results show that the inhibition of autophagy with bafilomycin 
results in a significant increase in the G0/G1 phase of the cell cycle with a concomitant 
decrease in the G2/M phase (Figure 3.19). Therefore, bafilomycin results in G0/G1 cell 
cycle arrest leading to the apoptotic cell death of the MDA-MB-231 cancer cells. These 
results are in accordance with other studies which showed G0/G1 cell cycle arrest and 
the induction of apoptosis in HT-29 human colon cancer cells (Wu et al., 2009) as well 
as in PC12 rat pheochromocytoma cells (Kinoshita et al., 1996). Per2 silencing in 
combination with bafilomycin treatment resulted in the significant increase in cells in the 
G0/G1 phase with a decrease in the G2/M phase and a subsequent induction of 
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apoptosis of the MDA-MB-231 cancer cells, however, when compared to treatment with 
bafilomycin alone no significant changes were observed.  
These results may therefore support the notion that both the circadian clock system and 
autophagy (Young et al., 2009) are implicated in cellular senescence, wherein mitotic 
cells undergo cell cycle arrest (typically in the G0/G1 phase of the cell cycle) in response 
to genotoxic stress (Campisi et al., 2007). Evident by the fact that Per2 mutations result 
in increased senescence of vascular endothelial cells (Wang et al., 2008) and that Per2 
mutant mice exposed to low levels of γ-irradiation display distinct phenotypic changes 
associated with early aging in addition to an increase rate of mortality (Kondratov, 2007). 
Furthermore, cellular senescence has also been implicated in the induction of cell death 
possibly via mitotic catastrophe (Roninson et al., 2001). 
 
As previously mentioned, the increased phosphorylation of histone H3 (Ser
10
) 
accompanied by the increased phosphorylation of the aurora kinases (A (Thr
288
), B 
(Thr
232
) and C (Thr
198
)) is associated with cells in the mitotic phase of the cell cycle. 
Analysis of G2/M transition in the MDA-MB-231 cancer cells showed no significant 
changes in the percentage of mitotic cells when compared to control, however, a 
significant increase in resting cells with a shift from late to early mitosis was seen, as the 
percentage of p-Aurora positive cells was significantly lowered in response to autophagy 
inhibition (Figure 3.20). Treatment with bafilomycin subsequent to Per2 silencing 
resulted in an almost complete inhibition of late stage mitosis as well as a significant 
decrease in the percentage of p-Aurora only cells, confirming the significant decrease 
we observed in the G2/M phase with the analysis of the cell cycle. Furthermore, these 
results suggest that Per2 silencing in combination with bafilomycin treatment leads to 
increased cellular senescence and the induction of cell death via mitotic catastrophe. 
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4.5. Metformin - A modulator of circadian Per2 expression and a 
potential adjuvant chemotherapeutic agent. 
 
Since its approval by the food and drug administration (FDA) in 1995, Metformin (1,1-
Dimethylbiguanide hydrochloride) still remains the most widely used anti-diabetic drug 
for the treatment of type II diabetes (Alimova et al., 2009). Its effectiveness in the clinical 
management of diabetes is largely attributed to its ability in reducing serum blood 
glucose levels via the reduction in hepatic gluconeogenesis in addition to an increase in 
cellular glucose uptake (Zakikhani et al., 2006).  
It is widely accepted that metabolic disturbances associated with diabetes results in an 
increased risk for the development of breast cancer and adversely affects patient 
prognosis (Rocha et al., 2011). Additionally, alterations in substrate metabolism of 
nutrient deprived cancer cells confers pro-survival advantages (Warburg et al., 1927)  
which allow them to effectively evade cell death.  
The mechanism behind metformin’s efficacy as an anti-carcinogenic agent is attributed 
to its ability to inhibit mTOR via a liver kinase B1 (LKB1) / AMPK dependent mechanism. 
Additionally the activation of AMPK by metformin leads to an inhibition of protein 
synthesis and a rapid induction of cell cycle arrest and / or apoptosis (Goodwin et al., 
2009), resulting in the improved prognosis of diabetic cancer patient taking metformin 
(Hirsch et al., 2009). Furthermore, metformin was shown to inhibit tumour growth of triple 
negative (estrogen receptor negative, progesterone receptor negative and HER2 
negative) breast cancer cells both in vitro (Liu et al., 2009) as well an in tumour 
xenograft models in mice  (Iliopoulos et al., 2011).  
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The internal circadian rhythms of peripheral clocks have been shown to play a critical 
role in cellular metabolism allowing for the synchronization of these intrinsic oscillations 
to daily feeding activities. The activation of AMPK as a result of nutrient deprived cellular 
conditions results in the destabilization of the negative feedback loop of the circadian 
clock system via the degradation of Per2 (Barnea et al., 2012). Taking this into account, 
coupled with the fact that metformin is a potent inducer of intracellular AMPK, for this 
part of the study we aimed to determine whether the pharmacological inhibition of Per2 
with metformin could sensitize resistant MDA-MB-231 breast cancer cells to doxorubicin-
induced cell death. 
Therefore, in this section the estrogen receptor negative MDA-MB-231 breast cancer 
cells were treated with 40 mM metformin for 24 hours followed by 2.5 µM doxorubicin for 
24 hours. The MDA-MB-231 breast cancer cells showed a significant decrease in MTT 
reductive capacity with the treatment of doxorubicin treatment alone (Figure 3.21); this 
was further reduced with metformin pre-treatment prior to doxorubicin. No discernible 
changes in cell morphology were observed with either metformin treatment alone or in 
combination with doxorubicin. However, a slight reduction in cell viability was observed 
with metformin pre-treatment prior to doxorubicin in comparison to control cells.  
Our results demonstrated that treatment with 2.5 µM doxorubicin in the MDA-MB-231 
cells lead to cell cycle arrest at the G2 check point of the cell cycle, evident by the 
significant increase seen in the G2/M phase, although an increase in the sub-G1 phase 
(apoptosis), it was not significant in comparison to control (Figure 3.22). A greater 
increase may have been observed following a longer treatment time course. No 
significant effects to the cell cycle of the MDA-MB-231 cancer cells were observed 
following metformin treatment either alone or in combination with doxorubicin. These 
results are not in agreement with previous studies, which showed that metformin 
sensitizes both MCF-7 breast cancer and A549 lung cancer cells to paclitaxel treatment 
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(Rocha et al., 2011). An explanation for the differences seen in our results may be as a 
result of different glucose concentrations in the growth media. The MDA-MB-231 breast 
cancer cells are routinely sub-cultured in media containing 25 mM glucose (high glucose 
conditions) as per guidelines recommended by the ATCC. Research has shown that a 
significant increase in the clonogenic ability and proliferation of cancer cells is 
associated with glucose concentrations above that of 5 mM. Additionally, glucose 
concentrations above 10 mM have been shown to greatly abolish the anti-carcinogenic 
efficacy of metformin (Wahdan-Alaswad et al., 2013). Therefore in order for metformin to 
sensitize the MDA-MB-231 cancer cells to doxorubicin-induced cell death, cells should 
have been serum starved and media changed from that containing 25 mM glucose to 
one containing 5 mM glucose prior to experimentation.  
As AMPKα is upstream of CKIε and the degradation of Per2 is directly reliant on its 
hyper-phosphorylation by CKIε, it is expected that a decrease in Per2 protein expression 
is coupled to the activation of AMPKα by metformin. However, our results showed that 
when the MDA-MB-231 cancer cells were treated with metformin the decrease in Per2 
protein expression was not associated with an increase in p-AMPKα activity, but rather a 
reduction in AMPKα phosphorylation was seen (Figure 3.24). When apoptosis was 
assessed by western blotting for caspase-3 and PARP, a significant reduction in both 
total caspase-3 and total PARP was seen following metformin treatment alone and in 
combination with doxorubicin in the MDA-MB-231 cancer cells, indicative of the induction 
of apoptosis in these cells (Figure 3.26, Figure 3.27). Our results are thus suggestive 
that, in the estrogen receptor negative MDA-MB-231 cancer cells, metformin induces cell 
death independently of the activation of AMPKα. A study recently conducted by 
Kalender and colleagues demonstrated that metformin is able to inhibit mTOR, 
independently of AMPKα, via a Rag-GTPase dependent mechanism (Kalender et al., 
2010). 
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Chapter 5: Final Conclusions 
 
Due to its potent anti-carcinogenic properties, doxorubicin remains one of the most 
extensively used chemotherapeutic agents for the treatment of solid tumours, including 
that of breast cancer (Octavia et al., 2012). Although effective to a large extent, several 
problems are associated with this line of therapy. In addition to the severe cumulative 
dose-dependent side effects, such as that of cardiotoxicity, an increase in the resistance 
of metastatic breast cancer is an ongoing problem that many cancer patients are faced 
with (Coley, 2008).     
It is widely accepted that circadian disruptions are implicated in the pathogenesis of 
various diseases including that of cancer. In fact, a significant increase in the prevalence 
and lifetime risk for the development of breast cancer is seen in women who work 
prolonged periods of rotating night shift  (Innominato et al., 2010). As a result the world 
health organization recognizes that circadian disruption may be carcinogenic. 
Furthermore, aberrant Per2 expression, leading to circadian disruption, is seen in a wide 
variety of cancer cell types (Chen et al., 2005 and Fu et al., 2002) 
Therefore the initial part of this study was designed to characterize Per2 protein 
expression in a normal breast epithelial cell line as well as in two breast cancer cell lines 
differing in estrogen receptor status and malignancy. Our results demonstrated for the 
first time that Per2 protein expression fluctuates in a circadian dependent manner in the 
normal MCF-12A cells, as well as in the metastatic estrogen receptor negative MDA-MB-
231 cancer cells over the course of 25 hours. Whereas, the non-metastatic estrogen 
receptor positive MCF-7 cells, failed to demonstrate a circadian pattern in Per2 protein 
expression. Furthermore, nuclear Per2 localization was also demonstrated in cells where 
cytoplasmic localization was lower. These results demonstrate the heterogeneity of 
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cancer cells within a single population as well as the asynchronous nature of Per2 in 
different cancer cell types. 
Additionally, this study was aimed at determining whether the modulation of Per2 protein 
expression, via both a genetic (esiRNA transfection) and pharmacological (metformin) 
approach, could sensitize chemo-resistant breast cancer cells to doxorubicin-induced 
cell death and autophagy inhibition. Collectively, results obtained for both the 
pharmacological and genetic modulation of Per2 demonstrate that the resistant nature of 
the MDA-MB-231 breast cancer cells to doxorubicin treatment was effectively abrogated 
via the disruption of the intrinsic circadian clock system. The suppression of the 45 kDa 
Per2 protein by means of a targeted esiRNA approach, in the context of doxorubicin 
induced cell death, resulted in cell cycle arrest of the MDA-MB-231 breast cancer cells, 
with a concomitant increase in apoptosis. As both aberrant Per2 expression (Wang et 
al., 2008) and doxorubicin (Jackson et al., 2006) have been shown to induce cellular 
senescence in response to genotoxic stress, we propose that the induction of apoptosis 
seen following the sensitization of MDA-MB-231 breast cancer cells to the cytotoxic 
effects of doxorubicin, may in part be mediated by mitotic catastrophe following cellular 
senescence (Figure 5.1). However, the underlying mechanisms behind senescence 
induced cell death in resistant breast cancer cells warrants further investigation.  
In the presence of conditions resulting in intracellular stress, such as that of nutrient 
deprivation or hypoxia, cancer cells rely heavily on the process of autophagy as a 
cellular survival mechanism. The increased in basal autophagic flux seen in the chemo-
resistant MDA-MB-231 breast cancer cells is thought to confer a pro-survival 
mechanism, via its ability to fulfil the high metabolic demands of these cells (Tu et al., 
2011). The manipulation of the autophagic pathway in highly resistant cancer cells has 
therefore become an attractive target in overcoming resistance. Increased reliance of the 
MDA-MB-231 breast cancer cells on autophagy as a cell survival mechanism is evident 
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by results showing a significant reduction in mitochondrial reductive capacity seen with 
the inhibition of autophagy by bafilomycin A1. Moreover, it appears that with Per2 
silencing an increase in the synthesis of autophagosomes occurs, resulting in increased 
autophagic flux as a possible compensatory mechanism. We also provided evidence 
that increased autophagic activity due to Per2 silencing occurs via an mTOR-
independent mechanism, as increased AMPKα activity was not accompanied by a 
decrease in mTOR, instead increased mTOR activity was observed. The main objective 
of this part of the study was to elucidate whether the manipulation of Per2 protein 
expression by means of a targeted esiRNA approach would sensitize the MDA-MB-231 
cancer cells to autophagic inhibition with bafilomycin A1, thereby forcing cells to undergo 
cell death. This was satisfied when a significant increase cell death was observed in 
addition to G0/G1 cell cycle arrest following Per2 silencing prior to autophagic inhibition 
(Figure 5.1).   
Although morphologically distinct, autophagy as a mechanism of cell death and 
apoptosis are not mutually exclusive processes, instead both work in unison to induce 
cell death (Thorburn, 2008). AMPK, a known regulator of autophagy, also has the ability 
to phosphorylate p53 thereby resulting in the induction of apoptosis (Jalving et al., 
2010). Collectively, our results suggest that circadian disruption as a result of Per2 
silencing is involved in both apoptosis and autophagic cell death in the MDA-MB-231 
cancer cells. We therefore postulate that this mechanism may be mediated by crosstalk 
between AMPK and p53 activity (Figure 5.1), as Per2 silencing resulted in a significant 
increase in AMPK activity. Although p53 (Ser
15
) phosphorylation was elevated in 
response to Per2 silencing, this increase was not statistically significant. A significant 
increase may have been observed following a longer treatment period. These results 
demonstrate the clear need for more extensive research in order to fully elucidate the 
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mechanism whereby these two cell death pathways converge to promote cancer cell 
death following Per2 silencing.    
 
 
Figure 5.1: Proposed mechanism of action involved in sensitizing chemoresistant MDA-MB-231 
breast cancer cells to doxorubicin-induced cell death and autophagy inhibition following Per2 
manipulation. The reduction in Per2 protein expression following either genetic inhibition (esiRNA) or 
pharmacological (Metformin) leads to the phosphorylation and activation of AMPKα, an intracellular nutrient 
sensor. Increased AMPK activity is known to induce phagophore formation and thus results in an increase 
in basal autophagic flux. The pharmacological inhibition of autophagy using bafilomycin A1, leads to G0/G1 
cell cycle arrest, possibly by resulting in cellular senescence and mitotic catastrophe. Doxorubicin is known 
to induce cell death in the MDA-MB-231 breast cancer cells; however, these cells have become 
increasingly resistant to doxorubicin treatment. Silencing Per2 in the MDA-MB-231 breast cancer cells 
overcomes this resistance to doxorubicin, and as such greatly enhances caspase-3 and PARP cleavage, 
resulting in cell cycle arrest and increased cell death. Therefore, Per2 silencing in the MDA-MB-231 cancer 
cells prior to doxorubicin or bafilomycin A1 treatment effectively sensitizes these resistant cancer cells to 
both doxorubicin-induced cell death and autophagic inhibition. 
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Chapter 6: Limitations and Future Studies 
 
Increasing evidence shows a complex interplay between the circadian clock system and 
the regulation of metabolism exists, with the disruption of the circadian clock leading to 
severe metabolic derangements. Recently, Per2 has been shown to directly repress 
peroxisome proliferator activated receptor gamma (PPARγ), a key regulator of 
adipogenesis and insulin sensitivity, thus mutations arising in Per2 have been linked 
directly to alterations in lipid metabolism (Grimaldi et al., 2010). Therefore, metabolic 
profiling of the MDA-MB-231 cancer cells, both in the presence and absence of Per2, 
may provide further insight into the role of this protein in cancer cell metabolism. 
Furthermore, the induction of autophagy by PPARγ in cancer may result in the release of 
intracellular free fatty acids which can be fed into the TCA cycle, thereby conferring pro-
survival properties (Zhou et al., 2010). As such a worthy avenue of exploration would be 
to assess the ATP production and consumption in response to Per2 silencing alone as 
well as in conjunction with autophagic manipulation using bafilomycin A1 and 
Rapamycin.  
Post-translational modifications, including phosphorylation, play a critical role in 
regulating Per2 protein stability and cellular localization. Alterations in the 
phosphorylation state of Per2, specifically those arising from mutations in the Ser
662
 
residue, are responsible for shortened circadian periods (Xu et al., 2007). However, the 
exact role that altered Per2 phosphorylation states play in the metabolic signalling of 
circadian clocks remains to be elucidated. This may be achieved by means of 
phosphoamino acid analysis, which relies on the phosphorylation of proteins using 
32
P-
ATP and then separating both phosphorylated and dephosphorylated proteins using thin 
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layer chromatography, exposure to ninhydrin and autoradiography (Sickmann et al., 
2001).  
Additionally, as different isoforms of the Per2 protein exist, it would be of great 
importance to assess the function of these isoforms both in cancer cell death and 
metabolism in order to determine whether specific isoforms of Per2 play a role in cell 
death. Furthermore, to fully elucidate the role that Per2 plays in both apoptosis and 
autophagy the use of an in vitro overexpression model of the 45 kDa Per2 protein 
isoform in both the normal MCF-12A and MDA-MB-231 cancer cell lines should be 
conducted.  
Literature suggests that Per2 serves a critical mediator linking the estrogen receptor to 
the circadian clock system (Gery et al., 2007), it would therefore be interesting to 
determine the effects of both silencing and overexpression of Per2 in an estrogen 
receptor positive breast cancer cell line (MCF-7) in order to assess the effects of the 
estrogen signalling pathway on both doxorubicin-induced cell death and autophagic 
inhibition. 
The culturing of cells in a 3-dimensional in vitro setting instead of the traditional 2-
dimensional monolayer approach provides a more physiological representation of the in 
vivo tumour microenvironment. As cells cultured on a reconstructed basement 
membrane, lead to the formation of acini-like spheroids which respond differently to 
chemotherapeutic intervention (Pampaloni et al., 2007). Therefore, it would be of value 
to determine whether MDA-MB-231 cancer cells cultured in 3-dimension can also be 
sensitized to doxorubicin-induced cell death and autophagy inhibition. 
Finally, the efficacy of metformin is largely dependent on glucose concentrations, and 
hyperglycaemia (>10 mM glucose) severely blunts the anti-proliferative effects of 
metformin in highly resistant MDA-MB-231 breast cancer cells (Wahdan-Alaswad et al., 
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2013). Therefore, repeating these experiments under normoglycaemic (5 mM glucose) 
conditions would be beneficial in elucidating the mechanism of action of the anti-
carcinogenic properties of metformin.  
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Protocol 1: Cell Culture 
 
Before work was started in the laminar flow hood, hands were washed and gloves were 
worn. Hands were sprayed with 70% ethanol each time before putting inside the hood to 
maintain sterility. 
 
a) Cracking a vial  
 Carefully remove a vial of required cells (MCF-12A, MCF-7 or MDA-MB-231 cells) 
from the liquid nitrogen tank and gently immerse the vial in the water bath set at 37 
ºC (take extreme care not to get the lid of the cryovial wet, in order to ensure 
sterility). Allow cells to thaw until there is only a small frozen pellet of cells 
 Remove cells from the cryovial and place them into a sterile 15 ml falcon tube 
containing 2 ml warm growth media (see Appendix B) and centrifuge at 1500 RPM 
for 3 min. 
 Carefully aspirate the supernatant and re-suspend the pellet in 4 ml of warm growth 
media using a serological pipette. 
 Place cells into a sterile T25 flask and incubate at an atmosphere of 37 ºC and a 
humidity of 5% CO2. 
 Wash cells with warm sterile PBS (see Appendix B) and replace growth media every 
day until cells reach a confluency of 70 – 80%. 
 Once 70 - 80% confluency is reached cells are ready to be split. 
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b) Splitting and seeding 
 Cells are ready to be split when 70 - 80% confluency is reached. Cell confluency is 
subjectively measured by viewing cells under a 20x objective using an inverted 
microscope. 
 Place growth media, PBS and trypsin in a water bath set at 37 ºC and allow them to 
warm up. 
 Media was aspirated and the cell monolayer was washed twice with warm PBS (see 
Appendix B) in order to completely remove growth media and all cell debris 
 2ml of warm 0.25% trypsin-EDTA was added to lift adherent cells, by gently agitation 
in a 37 ºC shaking incubator set to low speed for ± 4 min. 
 Once all cells had loosened, trypsin was neutralized by adding double the amount of 
warm growth media to the cells to avoid trypsin from killing the cells. 
 Cells were then transferred to sterile 15 ml falcon tubes and centrifuged for 3 min at 
1500 RPM. 
 The supernatant (media and trypsin) was carefully removed so as not to disturb the 
pellet (cells). Cells were then re-suspended in fresh growth media using a serological 
pipette. 
 Cells were then either split into new flasks and allowed to proliferate or counted 
using a haemocytometer and standard counting techniques before seeding for 
experimentation was done.  
 For experimental procedures the normal MCF-12A breast epithelial cells, MCF-7 
breast cancer or MDA-MB-231 breast cancer cells, were seeded into either 6 well 
plates or T25 flasks at a density of ± 150 000 cells in 2 ml growth media or ± 400 000 
cells in 4 ml growth media per well / flask respectively. 
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c) Freezing down cells 
 Once cells reached a confluency of 70 – 80%, old media was aspirated and 
discarded using a sterile pipette 
 The cell monolayer was washed twice with warm PBS in order to completely remove 
growth media and all cell debris. 
 2 ml / 4 ml warm trypsin was added to T25 and T75 flasks respectively and cells 
were gently agitated by placing them in a 37 ºC shaking incubator set at low speed 
for ± 4 min, until all cells had detached from the bottom of the flask. 
  Double the amount of warm growth media was then added and cells were 
transferred to a sterile 15 ml falcon tube and centrifuged at 1500 RPM for 3 min. 
 Supernatant was hen decanted and the pellet re-suspended in freezing media (see 
Appendix B) that was freshly made up. 
 Cells were then placed at -20 ºC for 2 hours before being transferred to the -80 ºC 
freezer overnight. The next morning cells were transferred to the liquid nitrogen tank 
for storage. 
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Protocol 2: Treatments 
a) Doxorubicin  
 
 Under sterile conditions 10 mg of Doxorubicin Hydrochloride (Mr: 579.98 g/mol) was 
dissolve in exactly 5071 𝜇L growth medium to obtain a stock concentration of 3.4 mM 
 The solution was then vortex and filter-sterilized 
 100 µl aliquots were then prepared in order to avoid freeze-thaw cycles, and epi’s 
were wrapped individually in tinfoil before being stored at -20℃. 
 NB: Doxorubicin is light sensitive therefore when working with the solution care was 
taken to protect Dox from light by covering it with foil and ensuring the lights were 
switched off. 
 Day of use: An epi containing doxorubicin was removed from the freezer and 
allowed to thaw by placing it in the hood at room temperature. Appropriate dilutions 
were made by adding Dox to warm growth media to obtain a final working 
concentration of 2.5 µM.  
 Old media was aspirated and discarded from 70 – 80% confluent cells using a sterile 
pipette 
 The cell monolayer was washed twice with warm PBS in order to completely remove 
growth media and all cell debris, and the 2.5 µM doxorubicin solution was added to 
cells. 
 Flasks were then wrapped in tinfoil, labelled and allowed to incubate for 24 hours at 
an atmosphere of 37 ºC and a humidity of 5% CO2. 
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b) Bafilomycin A1 
 
 Under sterile conditions 10 µg of Bafilomycin A1 (Mr: 622.83 g/mol) was dissolve in 
exactly  5000 µl of sterile PBS to obtain a stock concentration of 3.2 µM 
 The solution was then vortex and filter-sterilized 
 160 µl aliquots were then prepared in order to avoid freeze-thaw cycles, and epis 
were stored at -20℃. 
 Day of use: An epi containing bafilomycin was removed from the freezer and 
allowed to thaw by placing it in the hood at room temperature. Appropriate dilutions 
were made by adding baf to warm growth media to obtain a final working 
concentration of 10 nM.  
 Old media was aspirated and discarded from 70 – 80% confluent cells using a sterile 
pipette 
 The cell monolayer was washed twice with warm PBS in order to completely remove 
growth media and all cell debris, and the 10 nM bafilomycin solution was added to 
cells. 
 Cells were then allowed to incubate for 8 hours at an atmosphere of 37 ºC and a 
humidity of 5% CO2. 
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c) Metformin - 1,1-Dimethylbiguanide hydrochloride 
 
 40 mM working concentrations of Metformin (Mr: 165.62 g/mol) were made up 
fresh on the day of treatment by weighing out the appropriate amount of 
metformin powder and dissolving it in warm sterile PBS. 
 Solution was then vortex to ensure even distribution.  
 Old media was aspirated and discarded from 70 – 80% confluent cells using a 
sterile pipette 
 The cell monolayer was washed twice with warm PBS in order to completely 
remove growth media and all cell debris, and the 40 mM metformin solution was 
added to cells. 
 Cells were then allowed to incubate for 24 hours at an atmosphere of 37 ºC and a 
humidity of 5% CO2. 
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Protocol 3: Forward Transfection 
 
Method: 
 Seed cells in 6 well culture dishes 24 hours prior to transfection. 
 Prepare master mix by diluting 30 nM of Per2 esiRNA into 100 μl of serum and 
antibiotic free medium per well. 
 Add 12 μl HiPerfect transfection reagent per 100 μl of mix prepared.  
 Allow to incubate for 20 minutes to ensure the formation of esiRNA: HiPerfect 
complexes.  
 Add antibiotic free growth media to produce a final volume of 2ml and add drop-
wise onto cells.  
 Gently swirl plates to distribute media evenly over cells 
 Incubate until cells are ready to treat 48 hours later.  
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Protocol 4: Protein Extraction 
 
In order to avoid protein de-phosphorylation and proteolysis, all protein extraction steps 
where carries out on ice in a 4ºC walk-in fridge. 
 All eppendorf tubes were labelled according to treatment group. 
 Once cells reached a confluency of 70 – 80%, old media was aspirated and 
discarded using a sterile pipette. 
 The cell monolayer was washed twice with ice cold PBS in order to completely 
remove growth media and all cell debris. 
 100 µl of ice cold RIPA buffer was added to each sample and cells were left on 
ice for 5 min, after which cells were gently detached from plastic ware using a 
plastic cell scraper which was rinsed in ethanol between different treatment 
groups. 
 Cells were broken up in order to release protein content by sonication for 8 
seconds at 3 Hz while sample was maintained on ice. Microtip™ was rinsed with 
ethanol between different samples, in order to prevent cross-contamination. 
 All samples were left on ice in a 4ºC fridge for ± 1 hour until all foam had settled. 
 All insoluble cellular debris was removed by micro-centrifugation at 8000 RPM for 
a period of 30 seconds. 
  Supernatant was decanted into new epppendorf tubes that were pre-chilled and 
labelled according to treatment group, cell line and date. 
 All lysate samples were stored at -80ºC until use. 
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Protocol 5: Protein Quantification and Sample Preparation 
 
 Prior to use, a 200 µg/ml BSA working solution was prepared by diluting a 1 mg/ml 
BSA stock solution in a 1:4 ration with dH2O as a solvent. 
 Eppendorf tubes were labelled according to each treatment group and dilution 
standard. 
 A standard curve was set up by means of a BSA dilution series as follows: 
Concentration (µg) BSA (µl) dH2O 
0 0 100 
2 10 90 
4 20 80 
8 40 60 
12 60 40 
16 80 20 
20 100 0 
 
 Each treatment sample to be tested was prepared by pipetting 5 µl of protein lysate 
into the labelled eppendorf tubes and diluting them in 95 µl of dH2O. Samples were 
briefly vortexed prior to pipetting. 
 900 µl of working Bradford solution was added into each Eppendorf tube and 
samples were vortexed briefly to distribute solutions. 
 Absorbance values of all standards and treatment samples were measured using a 
spectrophotometer set to a wavelength of 595 nm. 
 A standard curve was plotted using the BSA serial dilution absorbencies and protein 
content of treatment samples was quantified by means of interpolation. 
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Protocol 5: Sample Preparation 
 
 Desired number of eppendorf tubes for each experimental group, were labelled and 
appropriate volume of lysate to yield a protein content of 50 µg was pipetted into 
appropriate tubes. 
 Lammli sample buffer equal to a third of the final volume was added to in order to fix 
each aliquoted sample. 
 Samples were boiled for 5 min in a heating block set to a temperature of 95ºC . 
Ensure that all eppendorf tubes had pin-sized holes made into their lids in order to 
prevent a build-up of pressure. 
 If samples are not to be used immediately, store all samples upright in cryoboxes in 
the -80ºC freezer. 
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Protocol 6: SDS-PAGE and Western Blot Analysis 
 
a) Preparation of Polyacrylamide Gels 
 Thoroughly clean glass 1 mm spacer plates and short plates with 70% ethanol 
and rise with dH2O. 
 Assemble the glass spacer and short plates in the green casting frame. Ensuring 
that they are perfectly lined up at the bottom. Place the green casting frame by 
securing clips and placing the casting frame onto the rubber gasket in the casting 
stand. Press down onto the casting frame to ensure a tight seal so as to prevent 
leakages. 
 Make up a 10% or 12% stain free polyacrylamide resolving gel (see Appendix B), 
depending on the size range of proteins to be separated.  
 Using a plastic Pasteur pipette, gently pipette the resolving gel solution in 
between the glass plates, leaving enough space for the stacking gel. 
 Pipette isobutanol over the resolving gel, so create a barrier against the air and to 
prevent evaporation. 
 Allow the gel to set at room temperature. The gel is completely polymerized once 
a sharp interface between the resolving gel and the isobutanol appears. 
 Remove the isobutanol and gently rinse with dH2O 
 Make up a 4% stain free polyacrylamide stacking gel (see Appendix B) and add 
the solution gently on top of the resolving gel using a plastic Pasteur pipette. 
Gently insert a 10 or 12 well comb into the stacking solution ensuring it is aligned 
perfectly and that no bubbles have been trapped under the comb. 
 Allow the gel to completely polymerize before removing the comb. 
 Before the gel can be used, gently rinse the wells out with dH2O. 
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b) SDS - Polyacrylamide Gel Electrophoresis (PAGE) 
 Prepare a 1x Running buffer solution by diluting a 10x stock solution (see Appendix 
B) in dH2O. 
 Retrieve all samples to be run from the -80ºC freezer as well as protein molecular 
weight marker from the -20ºC freezer and allow to thaw on ice. 
 Boil samples for a second time in a heating block set to a temperature of 95ºC. Once 
boiled immediately place samples on ice to prevent protein form being denatured 
further. 
 Briefly pulse centrifuge samples to ensure that the sample is all at the bottom of the 
eppendorf tubes. 
 Assemble gels into the U-shaped adapter cassette, ensuring the short glass plates 
are facing into the centre.  
 Place the assembled cassette into the electrophoresis tank and fill the inner 
compartment with 1x running buffer. Make sure that no running buffer leaks form the 
inner compartment 
 Gently pipette 5 µl of molecular weight marker in the well of the first lane. This allows 
for the monitoring of the electrophoretic run. 
 Load 50 µg of protein samples into wells following the marker.  
 Gently fill the outer compartment of the electrophoresis tank with 1x running buffer. 
Attach the lid ensuring leads are not tangled and attached correctly. 
 An initial run of 100 V (constant) and 200 mA, until samples have migrated through 
the stacking gel. Thereafter, run gels at 200 V (constant) and 200 mA until the front 
reaches the bottom of the gel. 
 Migration efficiency is determined by activating the gel for 2.5 minutes using the 
ChemDoc
MP
 stain free gel protocol, and visualizing protein separation. 
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c) Transferring 
 Remove prepared transfer buffer from the 4ºC fridge at the time of use. 
 Cut PVDF membrane and blotting paper to the same size as the gel. Activate 
PVDF membrane by briefly placing the membrane in 100% methanol and rinse 
with dH2O before soaking in ice cold transfer buffer. Once activated the 
membrane turns slightly transparent.  
 Soak blotting paper and membrane in transfer buffer until use.  
 Allow gels with fractionated protein pattern to equilibrate in transfer buffer with 
gently agitation for 10 – 15 min. 
 Construct the horizontal semi-dry transfer sandwich by placing a soaked blotting 
pad onto the TransBlot® Turbo™ transfer cassette, place the activated 
membrane on top of the blotting pad followed by the polyacrylamide gel and a 
second blotting pad. Ensure that no air bubbles are trapped in the sandwich by 
gently rolling them out between each layer using a roller rinsed in transfer buffer. 
 Close the cassette, ensuring that the sandwich is not disturbed. Transfer proteins 
to the membrane for 30 minutes at 25 V and 1.0 A.  
 Protein transfer can be visualized using the stain free blot protocol on the Chemi-
Doc™ MP (BioRad) imaging system. 
 Wash membranes 3x in 1x TBS-Tween 20 solution for 5 min each. 
 
d) Immunodetection 
 In order to prevent non-specific binding of antibodies, membranes were blocked 
by incubation in 5% (w/v) fat free milk solution for 2 hours. If proteins detected 
are in their phosphorylated state a 3% BSA blocking solution was used as the 
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milk contains the phosphorylated protein casein which will bind non-specifically to 
antibodies. 
 Membranes were then washed 3x in TBS-T for 5 min each, before being placed 
into a 1:1000 primary antibody solution in TBS-T overnight on a rotator. 
 Prior to incubation in a 1:10000 solution of secondary antibody in TBS-T for 1 
hour at room temperature, membranes were washed 3x in TBS-T for 5 min each. 
 Protein detection was carried out with the use of the ECL western blotting 
substrate detection kit on the Chemi-Doc™ MP (BioRad) imaging system. 
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Protocol 7: Immunocytochemistry – Per2 and Hoechst 33342 
 
For this technique, cells were grown in 8 well chamber plates which were first UV 
sterilized by placing them face open in the hood under the UV light for a period of 4 
hours.  Cells were cultured as previously described (Protocol 1). All staining techniques 
were performed in the Histology lab where there is minimal light. 
 
Method 
 
 Medium was removed from cells and washed 3x with sterile PBS (0.1M) 
 100 µl fixative (1:1 methanol/acetone) per well was added and incubated for 10 
min at 4ºC. This process was carried out whilst cells were kept on ice. 
 The fixative was then removed and the coverslips were allowed to air dry for 20 
min at room temperature  
 The cells were then rinsed 3x with 200 µl ice cold sterile PBS.  
 200µl of a 5% donkey serum made in PBS (see Appendix B) was added to each 
well and incubated for 20 min at room temp 
 After the time had elapsed, the serum was drained (NOT washed) and 200µl 
primary antibody solution in a 1:50 dilution (in this case a Per2 primary antibody 
was used) was added to each well and incubated overnight at 4ºC.  
 The cells were then rinsed once with PBS, only 200µl was used for each well and 
200µl secondary antibody solution in a 1:200 dilution (in this case an anti-rabbit 
AlexaFluor488 conjugated secondary antibody) was added. Incubation continued 
for 30 min at room temp. The secondary used was tagged with a fluorophore and 
was not grown in the same animal as the primary antibody. 
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 REMEMBER TO VORTEX THE SECONDARY ANTIBODY SOLUTION TO 
AVOID THE FORMATION OF CRYSTALS 
 In addition, 100µl Hoechst 33342 solution was added on top of the secondary 
antibody solution and incubated or another 10 min at room temp. 
 The coverslips were lastly rinsed 3x with sterile PBS and a small drop of 
fluorescent mounting medium was added to each well to mount cells. 
 8-well chamber plates can now be used or stored wrapped in foil to avoid light for 
up to 2 weeks at -20ºC 
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Protocol 8: MTT Assay 
 
Method: 
Three independent experiments were conducted in triplicate. 
 An Isopropanol solution (1%): containing 1 ml concentrated HCl and 99 ml 
Isopropanol was made.  
 Triton solution (0.1 %) containing 0.1 ml Triton-X-100 was made up to 100 ml 
with distilled water.  
 An Isopropanol / Triton solution was made in a 50:1 ratio, where 50 ml of 1% 
Isopropanol was added to 1 ml of 0.1% Triton. 1%  
 MTT (0.01 g/1 ml PBS) solution was made up just before use. MTT is 
photosensitive, thus the solution was covered in foil. 
 Medium was removed from treated cells. 
 PBS (1.5 ml) and MTT (500 μl) was added and allowed to incubate, in 6 well 
plates covered with foil for 1 to 2 hours at 37ºC. 
 After incubation time, MTT solution was removed and 2ml of the Isopropanol / 
Triton solution was added to each well and plates covered in foil were placed on 
a shaker for 5 minutes. 
 The contents of each wells was transferred to 2 ml eppendorf tubes, centrifuged 
for 2mins at RPM 1500. 
 The absorbance values of the supernatant were read at 540 nm using a 
spectrophotometer with Isopropanol / Triton solution was used as a blank. 
 If absorbance was greater than one the supernatant was diluted with the 
Isopropanol / Triton solution and read at 540 nm again. 
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Protocol 9: Hoechst and Propidium Iodide (PI) staining technique 
 
Method 
 Medium was removed from cells and washed 3x with sterile PBS (0.1M) 
 100µl of PI solution (see appendix B) was added to each coverslip and incubated 
for 20 minutes at 4ºC 
 PI solution was then removed and cells were rinsed 2x with sterile PBS 
 A cold fixative (1:1 methanol/acetone), enough to cover the monolayer of cells, 
was added to each coverslip and incubated for 10 min at 4ºC 
 The fixative was removed and the coverslips were left to air dry  completely for a 
further 10 min 
 After the time had elapsed, 150µl of Hoechst solution (see Appendix B) was 
added to each coverslip and incubated for 10 min at 4ºC 
 Hoechst solution was removed and cells were rinsed 5x with sterile PBS to avoid 
or minimize background noise 
 The coverslips were allowed to dry before being mounted on a microscope slide 
using a small drop of fluorescent mounting medium 
 The slides were now placed ace down on tissue paper and covered in foil to 
protect them from light  
 The slides can now be stored at -20ºC for up to 2 weeks 
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Protocol 10: Cell Cycle Analysis 
 
Method 
 Add 3 ml Trypsin/EDTA (0.25%) to each flask and place on the cell shaker for 5 
minutes or until the cells have detached from the surface of the flask.  
 Add 6 ml of appropriate culture medium to each flask.  
 Transfer each resulting cell suspension to a separate, sterile 15 ml falcon tube.  
 Centrifuge at 400 x g for 5 minutes at room temperature.  
 Carefully decant all the supernatant, and tap off the last drop onto a tissue.  
 Wash the pellet with sterile room temperature PBS.  
 Centrifuge at 400 x g for 5 minutes at room temperature.  
 Add 250 μl of trypsin buffer (Solution A) to each tube and mix by tapping. (Do not 
vortex).  
 Allow solution A to react for 10 minutes at room temperature.  
 Do not remove solution A.  
 Add 200 μl of trypsin inhibitor and RNase buffer was added to each tube and mix 
gently by hand tapping. (Do not vortex).  
 Incubate for 10 minutes at room temperature.  
 Add 200 μl of ice cold propidium iodide stain solution was added to each tube 
and incubated on ice in the dark for a further 10 minutes.  
Stellenbosch University  http://scholar.sun.ac.za
151 
 
 Filter samples through a 50 μm nylon mesh into 12x75 mm tubes.  
 Analyse using flow cytometry  
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Protocol 11: G2/M Transition Analysis – Flow Cytometry 
 
Method 
 Add 3 ml Trypsin/EDTA (0.25%) to each flask and place on the cell shaker for 5 
minutes or until the cells have detached from the surface of the flask.  
 Add 6 ml of appropriate culture medium to each flask.  
 Transfer each resulting cell suspension to a separate, sterile 15 ml falcon tube.  
 Centrifuge at 1500 RPM for 3 minutes at room temperature.  
 Carefully decant all the supernatant, and re-suspended in 1 ml PBS.  
 Add formaldehyde to a final concentration of 4% and fix cells at 37ºC for 10 min.  
 Place cells on ice and chill for 1min  
 Remove fixative by centrifugation and permeabilize cells by adding 90% ice cold 
methanol to cells and incubate cells on ice for 30 min 
 Add 2-3 ml incubation buffer (0.5g BSA dissolved in 100 ml PBS) to cells and 
rinsed twice by centrifugation.  
 Dilute conjugated primary antibodies in incubation buffer (1:50) and incubate for 1 
hour at room temperature. 
  Wash cells by centrifugation in incubation buffer before re-suspending in 0.5 ml 
PBS and analysing on the flow cytometer.  
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Appendix B: Recipes 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
154 
 
Growth Medium 
a) MCF-7 and MDA-MB-231 cancer cells  
 500ml Dulbecco’s Modified Eagles  Medium (DMEM) 
 56ml Fetal Bovine Serum (FBS) 
 5.6ml PenStrep  
 
b) MCF-12A normal breast epithelial cells  
 250 ml MCF-7 / MDA-MB-231 growth media  
 250 ml Hams F12 nutrient mixture containing 10% FBS and 1% Penstrep 
 1110 µl Insulin (30 / 70 Humalin) 
 50 µl Cholera toxin 
 25 µl Hydrocortisone   
 
1X Phosphate Buffered Saline (PBS) – 0.1M 
Dissolve the following in 1L of water 
 16g NaCl 
 0.4g KCl 
 2.88g Na2HPO4  (di Sodium hydrogen phosphate) 
 0.48g KH2PO4  (Potassium dihydrogen phosphate) 
Adjust pH to 7.4, fill up to the 2L mark with distilled water and sterilize by autoclaving. 
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Propidium Iodide and Hoechst 33342 stain 
 Dissolve 5µl PI in 1000µl sterile PBS 
 Dissolve 5µl Hoechst 33342 in 1000µl sterile PBS 
 These solutions are made fresh and must be kept on ice away from light 
 
BSA (Bovine serum albumin) – 1mg/ml 
 For 1ml BSA, weigh out 1mg BSA and add 1000µl distilled water  
 Or use during Western blotting, this BSA needs to be diluted. Pipette 100µl  from 
1mg/ml stock solution in a new eppendorf tube and add 400µl distilled water  
 Mix well 
 
Bradford Reagent (1L) 
 Weigh out 500mg Coomassie Brilliant Blue G and add it to 25ml 95% ethanol 
 Add 500ml phosphoric acid and mix well 
 Fill up to 1L mark with distilled water and store at 4ºC 
 For use during Western Blotting, this solution needs to be filtered 2x and then a 
1:5 dilution needs to be made. 
 
3X Sample Buffer 
 Measure 33.3ml stacking Tris (0.5M) and place in a beaker  
 Weigh out 8.8g SDS and 20g glycerol and place in the beaker  
 Add a pinch of bromo-phenol blue to the mixture 
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 Add and make up to 75.47ml with distilled water  
 
Tris pH 8.8 (500ml) 
 Weigh out 68.1g Tris (1.124M) and 1.5g SDS (0.3%) and place in a beaker 
 Add 400ml distilled water, stir and then adjust pH to 8.8  using HCl 
 Add 100ml distilled water to make the final volume of 500ml 
 
Tris pH 6.8 (500ml) 
 Weigh out 30.3g Tris (0.5M) and 2g SDS (0.4%) and place in a beaker  
 Add 400ml distilled water, stir and then adjust pH to 6.8 using HCl 
 Add 100ml distilled water to make up final volume of 500ml 
 
Tris pH 6.8 (100ml) for Sample Buffer 
 Weigh out 6.06g Tris (0.5M) and add 4ml 10% SDS and place in a beaker 
 Add 80ml distilled water, stir and adjust pH to 6.8 using HCl 
 Add 20ml distilled water to make up the final volume of 100ml 
 
10% Sodium Dodecyl Sulphate (SDS) – 500ml 
 Weigh out 50g SDS and add 500ml distilled water 
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10% Ammonium Persulphate (APS) - 1000µl 
 Weigh out 0.1g APS into an eppendorf tube and add 1000µl distilled water 
 
10% Acrylamide separating gel  
 Distilled water – 3.85ml 
 1.5M Tris- HCl (pH 8.8) – 2.5ml 
 10% SDS - 100µl 
 Acrylamide – 2.5ml 
 10% APS - 50µl 
 Temed - 5µl 
 
12% Acrylamide separating gel  
 Distilled water – 3.35ml 
 1.5M Tris- HCl (pH 8.8) – 2.5ml 
 10% SDS - 100µl 
 Acrylamide – 3.0ml 
 10% APS - 50µl 
 Temed - 5µl 
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4% Acrylamide stacking gel  
 Distilled water – 6.1ml 
 0.5M Tris- HCl (pH 6.8) – 2.5ml 
 10% SDS - 100µl 
 Acrylamide – 1.0ml 
 10% APS - 100µl 
 Temed - 20µl 
 
Running Buffer -1L 
 Weigh out 3.03g Tris, 1.44g Glycine and 1g SDS into a beaker 
 Add 500ml distilled water and stir until dissolved 
 Fill up to 1L mark with distilled water  
 
10X TBS – 5L 
 Weigh out 121g Tris and 80g NaCl into a 5L beaker  
 Add 2.5L distilled water and stir until dissolved  
 Adjust to pH 7.6 using HCl and then fill up to 5L with distilled water  
 For use in Western blotting, take 1L measuring cylinder and add 100ml 10x TBS 
and dilute with 900ml distilled water  
 To make TBS-T – add 1ml Tween-20 to 1L diluted solution of TBS 
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RIPA buffer – 100ml 
 
Add the reagents in the following order. Protect the solution from light and prepare while 
stirring on ice.  
 
 Tris-HCl pH 7.4 (790 mg Tris + 900 mg NaCl) (50 mM)  
 10 ml of 10% NP-40  
 2.5 ml Na-deoxycholate (0.25%)  
 1 ml of 100 mM EDTA pH 7.4 (1 mM)  
 100 μl of 1 mg/ml Leupeptin (1 μg/ml)  
 80 μl of 5 mg/ml SBT1 (4 μg/ml)  
 100 μl of 1M Benzamadine (1 mM)  
 500 μl of 200 mM NaF (1 mM) Toxic!  
 500 ul of 200 mM Na3VO4 (1 mM)  
 Mix briefly.  
 Allow to incubate until the cells are ready to treat and assay.  
 Add 1 ml of Triton X-100. Viscous!  
 Aliquot into practical amounts to avoid freeze thawing 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
